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Abstract 
 
Background: The omega-3 fatty acid eicosapentaenoic acid (EPA) has been 
demonstrated to be incorporated into tumours and inhibit tumour growth in pre-
clinical models of colorectal cancer liver metastases (CRCLM). 
Aims:  To test the safety, tolerability and effect on tumour biomarkers of growth and 
vascularity of orally administered EPA in patients awaiting liver resection surgery for 
CRCLM. 
Methods:  In a Phase II randomised, double-blind, placebo-controlled trial, patients 
with CRCLM received EPA 2g daily (n=43) or placebo (n=45) prior to surgery. 
CRCLM tissue was analysed for fatty acid content, PGE2 content, proliferation 
index (Ki-67), apoptosis index and vascularity. Blood was collected for platelet 
function and monocyte NFkB binding studies, and urine for measurement of PGE-
M.  Supplementary in vitro endothelial cell studies investigated the effects of EPA 
on angiogenesis. 
Results:  The two treatment groups were well matched for burden of disease and 
previous chemotherapy exposure.  Mean duration of EPA treatment was 30 days 
(range 12-65 days).  EPA was safe and well tolerated, with a small excess of 
diarrhoea (p=0.09), and no excess of post-operative complications. Tumours from 
the EPA group had a 40% higher EPA content (p<0.01), no difference in 
proliferation or apoptosis, and a trend to reduced vascularity.  EPA treatment was 
associated with a 36% reduction in urinary PGE-M (p=0.03) compared to placebo, 
and reduced monocyte NFкB DNA binding compared to baseline (p=0.03).  EPA 
inhibited angiogenesis in vitro. 
Conclusions:  EPA 2g daily is safe and well-tolerated in patients with CRCLM 
before liver resection. EPA incorporates into CRCLMs, exhibits systemic anti-
inflammatory effects, and may have anti-angiogenic activity. Phase III clinical 
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evaluation of prolonged EPA treatment is warranted in patients with, or at risk of, 
CRCLM. 
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Chapter 1: Introduction 
1.1 Colorectal cancer (CRC) and colorectal cancer liver metastasis (CRCLM) 
Colorectal cancer (CRC) remains a major cause of morbidity and mortality in the 
western world, responsible for approximately 10% of all UK cancer deaths (1).  In 
2008, there were 31,846 new CRC cases in the UK with an incidence of 57 cases 
per 100,000 in men and 37 per 100,000 in women.(1)  Approximately 5% of CRCs 
are clearly linked to hereditary syndromes, such as familial adenomatous polyposis 
(FAP) and hereditary non-polyposis colorectal cancer (HNPCC), with studies 
suggesting that a further 15-25% of CRCs have a familial link.(2-4)  Other CRCs 
arise on a background of chronic intestinal inflammation such as ulcerative colitis.  
The majority, however, are believed to be caused by a complex interaction of 
environmental exposures and non-Mendelian genetic predisposition. These are 
known as “sporadic” CRCs.  Smoking, alcohol, obesity, dietary patterns and 
exercise levels have all been linked to the development of CRC.(5)  The impact of 
dietary patterns on the development of cancer has been extensively reviewed by 
the World Cancer Research Fund and the American Institute for Cancer 
Research.(6)  In their Second Expert Report into Food, Nutrition, Physical Activity 
and the Prevention of Cancer they conclude that there is convincing evidence that 
the consumption of red meat and processed meats increases the risk of CRC, that 
the consumption of dietary fibre, garlic and calcium probably reduces the risk of 
CRC,  and that the consumption of fish may also reduce the risk of CRC.(6)    
Most deaths from CRC are due to metastatic disease.  Metastasis is the spread of 
cancer from one part of the body to another, with the most common site of 
metastasis from CRC being the liver.  Around 50% of all CRC patients will 
eventually develop metastatic disease of the liver.  Liver metastases are present at 
the time of diagnosis of CRC in 15-20% of patients (known as synchronous 
metastases),(7-9) and a further 6-20% of patients with CRC will develop CRCLM at 
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a later date (known as metachronous metastases).(7, 10)  The metastatic process 
is complex (Figure 1.1).  Not all cells that break away from a cancer develop into 
metastatic tumours.  Only subpopulations of cells with particular combinations of 
genetic mutations and gene expression patterns will have the necessary 
characteristics to proceed through each sequential step of the metastatic process to 
form metastatic colonies.  This involves the acquisition of a mesenchymal as 
opposed to an epithelial phenotype, the so called epithelial-mesenchymal transition.  
Several reviews are available which provide a detailed overview of epithelial-
mesenchymal transition (11, 12) and the metastatic pathway.(13, 14)  Briefly, to 
metastasise cells must first escape their normal structural constraints, acquire 
motile behaviour, and invade and traverse the basement membrane and 
extracellular matrix to enter the circulation.  Cells must survive within the circulation 
then arrest in the capillary bed of a distant organ such as the liver.  Here they must 
escape from the circulation (extravasate) by adherence to and migration through 
the subendothelial basement membrane into the liver parenchyma.  Once in the 
liver parenchyma, cells must respond to growth factors in the liver 
microenvironment to proliferate, evade the signalling pathways that promote 
apoptosis, and stimulate the growth of new blood vessels (angiogenesis) to sustain 
the growth of the metastatic colony.   
The growth of any tissue beyond a size of 1-2 mm3, being the threshold for nutrient 
diffusion across cells, is dependent on angiogenesis to deliver oxygen and 
nutrients, and this occurs in both physiological and pathological processes.    The 
critical role of angiogenesis in the development of tumours has long been 
recognised,(15) with extensive research into understanding the mechanism of 
tumour angiogenesis and its manipulation as a potential therapeutic target.(16-18)  
Of the many pro-angiogenic factors and signalling pathways identified, vascular 
endothelial growth factor (VEGF) has been the most intensely studied.(17, 19, 20)  
It is expressed in approximately 50% of CRC and CRCLM,(21-23) and has been 
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shown to stimulate endothelial cell proliferation, migration and invasion and 
increase vascular permeability.(20) 
It is increasingly apparent that this overview of metastasis is simplistic, and that 
cancer cells interact with cells in both the tumour microenvironment and in the 
circulation to facilitate this process.  For example, macrophages at the tumour 
periphery can be activated and facilitate invasion by the secretion of matrix 
metalloproteinases (MMP) to degrade extracellular matrix.(24, 25)  An interaction 
between cancer cells and platelets has also been shown.  Platelets aggregate with 
circulating tumour cells and may act to shield cancer cells from immune responses 
as well as protecting cells from physical shear forces, thereby promoting survival 
within the circulation.(26)  These aggregations may also promote arrest of cancer 
cells in capillary beds both by physical plugging, and through platelet adhesion to 
the endothelium.(26)  More recently, a direct interaction between platelets and 
cancer cells has been shown in which platelet-derived transforming growth factor β 
(TGFβ) activates epithelial-mesenchymal transition related genes in the cancer cell, 
promoting extravasation and metastasis formation.(27)  Different types of cancers 
have a predisposition to metastasise to different sites.  This is affected by 
circulatory patterns, differences in capillary wall structural features or the 
endothelial cell surface expression of molecules such as integrins and adhesins, 
the favourability of tissue microenvironments to support the growth of different 
cancer cell types, as well intrinsic properties of the circulating cancer cell itself.(28, 
29)  In the case of CRC, venous blood from the colon drains directly to the liver via 
the portal vein, and CRC cells are likely to become trapped in the narrow hepatic 
sinusoids (approximately 7µm diameter).(30)  This, together with the rich 
vascularity, nutrient supply and growth factor production of the liver which makes it 
an amenable microenvironment for the establishment of metastatic colonies, 
probably explains why CRC typically form metastatic colonies in the liver.     
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Figure 1.1.  The carcinogenesis, epithelial-mesenchymal transition and metastasis 
pathway.  Adapted from Thiery JP, Epithelial-mesenchymal transitions in tumour 
progression. Nat Rev Cancer, 2002. 2(6): p. 442-54.   
 
The accumulation of genetic mutations by a normal epithelial cell, each conferring a 
growth advantage, results in uncontrolled proliferation of that cell to become a focus of 
disordered epithelial proliferation (dysplasia).  Dysplasia is identified by characteristic 
cellular and architectural features, with the loss of normal morphological appearance and 
disordered tissue architecture.  In colorectal carcinogenesis, the earliest dysplastic feature 
may be an aberrant crypt focus, a cluster of abnormal tube like glands in the colonic 
epithelium.  As dysplasia progresses, a discrete lump or polyp (adenoma) may form on the 
lining of the colon.   The severity of dysplasia is often classified as low-grade or high-grade 
dysplasia.  High grade dysplasia is often referred to as carcinoma-in-situ in certain cancer 
types, although high grade dysplasia is the preferred terminology in CRC.  These cells have 
all the features of cancer, but have not yet breached the basement membrane.  Once cells 
have escaped their normal structural constraints and acquired motile and invasive 
characteristics (the epithelial to mesenchymal transition) they can invade through the 
basement membrane.  At this stage the tumour is an invasive carcinoma.  The next steps 
on the metastatic pathway involve invasion into an adjacent blood or lymphatic vessel 
(intravasation) and then extravasation from the circulation at a distant site.  Cells may 
then establish a metastatic colony at a distant site.  This may involve reversion back to an 
epithelial phenotype (mesenchymal to epithelial transition).   
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1.2 The molecular basis of colorectal carcinogenesis  
1.2.1 The Wnt/β-catenin pathway, APC, and other genetic mutations 
Activation of the Wnt/β-catenin signaling pathway is believed to be key in the 
initiation of colorectal carcinogenesis.(31)  Cytoplasmic β-catenin levels are 
ordinarily regulated by a multi-protein complex containing the adenomatous 
polyposi coli (APC) protein, Axin and glycogen synthase kinase.(32)  This complex 
binds to β-catenin and promotes proteosomal degradation.  Mutations in the tumour 
suppressor gene APC occur in 60-80% of sporadic CRCs.(33-35) APC mutations 
typically cause truncation of the APC protein with loss of the β-catenin binding site, 
and result in cytoplasmic accumulation of β-catenin.(32)  Similarly, activation of the 
proto-oncogene Wnt which leads to inhibition of the APC-protein complex, mutation 
in the Axin tumour suppressor gene, or a mutation in the β-catenin gene can all 
lead to cytoplasmic accumulation of β-catenin.(32)  With increasing cytoplasmic 
levels of β-catenin, there is the potential for translocation of β-catenin into the 
nucleus where it acts as a co-factor for the transcription of genes associated with 
cell-cycle regulation, such as c-MYC (36) and CCND1,(37) and other genes 
involved in carcinogenesis such as MMP-7 (38) and VEGF.(39)   However, whilst 
APC loss contributes initially to adenoma formation, further mutations are required 
for progression from adenoma to carcinoma.(40)  These typically include 
inactivation of the p53 tumour suppressor pathway as a subsequent step in 
colorectal carcinogenesis, inactivation of tumour-suppressing TGF-β signaling, and 
activation of the oncogenes KRAS, BRAF and PI3K.(31)   The mutations in these 
pathways are described in more detail in the review by Markowitz and 
Bertagnolli.(31)  
 
 
 
 
6 
 
1.2.2 Cyclooxygenase and prostaglandins 
Upregulated cyclooxygenase (COX) expression and the COX-dependent synthesis 
of prostaglandins (PG)s and thromboxanes are also believed to play a critical role in 
the early stages of colorectal carcinogenesis.(41, 42)  Arachidonic acid is the 
principle substrate for COX.  It is a polyunsaturated fatty acid (PUFA) found in cell 
phospholipid membranes.  Fatty acids are carbon chains with a methyl group at one 
end and a carboxyl group at the other.  Saturated fatty acids contain only carbon-
carbon single bonds, whereas unsaturated fatty acids contain one 
(monounsaturated) or more (polyunsaturated) carbon-carbon double bonds.  
Arachidonic acid is a 20-carbon chain with 4 carbon-carbon double bonds.  It is an 
omega (ω)-6 PUFA, so named by the position of the first double bond at the 6th 
carbon from the methyl (omega) end.  Arachidonic acid can therefore be 
represented by the notation "20:4 ω-6 " (Figure 1.2).  Arachidonic acid is liberated 
from phospholipid membranes by phospholipase A2 and catalysed by COX to 
produce PGH2, via the unstable intermediate PGG2.  PGH2 is further catalysed by 
prostaglandin synthases to produce a range of prostaglandins, including PGE2 
(Figure 1.3), and thromboxane (Tx) A2.  AA can also be metabolised by the 
lipoxygenase (LOX) pathway to leukotrienes (LT) such as LTB4.  COX exists as two 
isozymes.  COX-1 is constitutively expressed in most human tissues, including 
platelets, and is responsible for the basal level of PG synthesis required for normal 
tissue homeostasis.  Meanwhile, COX-2 is not normally expressed in most tissues 
but is induced in response to inflammation and carcinogenesis.(43, 44)  Increased 
COX-2 expression has been found in 50-77% of adenomas,(45, 46)  61-84% of 
adenocarcinomas,(45, 47-49) and 100% of CRCLM.(50, 51) 
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Figure 1.2.  Structure and nomenclature of polyunsaturated fatty acids (PUFAs). Cx:y 
ω-z refers to the chemical structure where x is the number of carbon atoms, y is the number 
of carbon-carbon double bonds and z is the position of the first carbon-carbon double bond 
away from the methyl (ω) end of the hydrocarbon chain.  Note that position of the first 
carbon-carbon double bond which defines arachidonic acid as an ω-6 PUFA, in contrast to 
the position of the first carbon-carbon double bond in eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) which defines them as ω-3 PUFAs.  EPA and DHA are 
discussed further in section 1.6.   
 
 
 
 
 
Figure 1.3.  Metabolism of arachidonic acid by the COX, LOX and CYP450 pathways. 
COX=cyclooxygenase, LOX=lipoxgenase, CYP450=cytochrome P450, 
EET=eicosatetraenoic acid, HETE=hydroxyeicosatetraenoic acid, PG=prostaglandin, 
TX=thromjboxane, HPETE=hydroperoxyeicosatetraenoic acid, LT=leukotriene, LX=lipoxin  
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Prostaglandins mediate their effects through specific cell-surface G-protein coupled 
receptors, with PGE2 acting through the receptors EP1-EP4.(52)  EP1 signals via 
phospolipase C / inositol triphosphate signalling, EP2 and EP4 signal predominantly 
through an increase in intracellular cyclic adenosine monophosphate (cAMP), 
whereas EP3 is regarded as an inhibitory receptor, signaling via a reduction in 
cAMP.(52)  Prostaglandins may also exert an effect by acting as direct ligands for 
peroxisome proliferator-activated receptors (PPARs).  Prostaglandin catabolism is 
regulated by 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a nicotinamide 
adenine dinucleotide (NAD)+ linked dehydrogenase that oxidizes the 15-hydroxy 
group of a prostaglandin to a ketone group, rendering it inactive.(53)  Suppressed 
15-PGDH has been demonstrated in up to 80% of colorectal adenomas and 
carcinomas.(54, 55)     
Prostaglandins and thromboxanes have wide-ranging roles in inflammation, platelet 
aggregation and tissue homeostasis, and can act in an autocrine or paracrine 
manner to effect changes in their immediate environment.  Increased PG signaling, 
through an upregulation of the COX-2/PGE2 pathway is believed to play a key role 
in colorectal carcinogenesis, with PGE2 having been shown to promote CRC cell 
proliferation in vitro (56, 57) and stimulate intestinal adenoma formation in vivo.(58, 
59)  Elevated PGE2 levels have been demonstrated in human CRC and adenomas 
(60).  The pro-tumourgenic effects of PGE2 are mediated through a number of 
signaling pathways involved in tumour proliferation, apoptosis, migration, invasion 
and angiogenesis, which have not been clearly elucidated but which may be 
interlinked.(41, 44)  These include promotion of tumour proliferation through the 
activation of the β-catenin/Wnt pathway (61, 62) and promotion of cell proliferation, 
migration and survival through the activation of epidermal growth factor receptor 
(EGFR) signaling.(63-65)  PGE2 has been shown to suppress apoptosis by 
increasing BCL-2 expression (66, 67), activating EGFR and nuclear PPARδ 
signaling,(59, 64) and activating the Ras-MAPK/ERK and PI3K/AKT pathways.(59, 
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65, 68)  PGE2 has also been associated with inactivation of E-cadherin and 
increased expression of MMPs, thereby promoting cell migration and invasion.(66, 
69)  Finally, PGE2 has been shown to stimulate the production of pro-angiogenic 
factors including VEGF and basic fibroblast growth factor (bFGF).(70-73).  PGE2 
has been demonstrated to promote tumour angiogenesis in pre-clinical models of 
CRC, (74, 75) whilst the expression of COX-2 and PGE2 has been shown to 
correlate with VEGF expression and tumour vascularity in human CRC,(71, 76, 77) 
CRCLM (78) and gastric cancer.(79) 
Whilst PGE2 levels can easily be measured in vitro, measurement of systemic PGE2 
production in humans is more challenging.  Sampling techniques, such as 
venepuncture, can cause platelet activation and prostaglandin release, and 
prostaglandin production and metabolism can continue in samples ex vivo.  
Measurement of PGE2 in the urine is similarly unreliable as this primarily reflects 
local production of PGE2 in the kidney.(80)  It is widely accepted that the most 
accurate index of systemic PGE2 production is the measurement of PGE-M, a 
stable metabolite of PGE2 that is excreted in the urine.(81)  Elevated levels of 
urinary PGE-M have been associated with colorectal adenomas and carcinomas in 
humans,(82-84) suggesting PGE-M as a potential biomarker for the detection of 
CRC and other cancers.(85)    
 
1.3  Surgery for CRCLM 
Untreated, the prognosis from CRCLM is poor, with a median survival of 6-12 
months.(86)  Current chemotherapy regimens for inoperable disease extend 
median survival up to almost 24 months in those that respond to treatment,(87) but 
this remains a palliative treatment.  Surgery is the only potentially curative treatment 
for patients with CRCLM, with 5 year survival rates after surgery ranging from 30-
60%.(88-92)  Of all patients who undergo liver resection surgery for CRCLM, 40-
60% will develop disease recurrence, at a median of 13.8-16.3 months.(91, 93)  
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Just under half of all recurrences will be in the liver alone, one-third extra-hepatic 
alone, and the remaining one-fifth will be both hepatic and extra-hepatic 
recurrences.(91)  Patients with recurrent hepatic metastases may be offered repeat 
liver resection, so long as the disease is technically resectable.  This is true for first, 
second, and even third recurrences of CRCLMs.  Such a strategy of aggressive 
redo-resections of recurrent CRCLMs is justified by a 5-year overall survival rate 
after repeat resections of almost 30%.(93)      
1.3.1 Liver anatomy 
The liver is the largest solid organ in the body, situated in the right upper quadrant 
of the abdomen and weighing approximately 1.5kg.  The liver has a dual blood 
supply, with approximately 75% of blood flow from the portal vein and 25% from the 
hepatic artery.  The portal vein delivers venous blood from the small intestine to the 
liver, ensuring that substances absorbed from the gut are metabolised and 
detoxified by the liver before entering the systemic circulation.  The portal 
circulation provides a direct route for the haematogenous spread of CRC cells to 
the liver, and explains why the liver is the most common site of CRC metastases.  It 
is the first capillary bed in which CRC cells escaping into the circulation will arrest 
and "plug". 
Whilst the liver might be divided on external anatomic appearances by the falciform 
ligament into a right and left lobe, it is more common to divide the liver based on its 
functional anatomy into two lobes and eight functionally independent segments 
(Figure 1.4), as described by Couinaud in 1957.(94)  The middle hepatic vein 
divides the liver into a larger right lobe (segments 5-8) and a smaller left lobe 
(segments 2-4).  This plane runs in an approximate plane between the gallbladder 
fossa and the inferior vena cava (IVC).  The right hepatic vein divides the right lobe 
into an anterior section (segments 5&8) and posterior section (segments 6&7), 
whilst the left hepatic vein divides the left lobe into a lateral section (segments 2&3) 
11 
 
and medial section (segment 4a and 4b).  All three hepatic veins meet to drain into 
the IVC at the postero-superior aspect of the liver.  The liver is then further divided 
by the right and left portal veins into superior and inferior sections.  The right portal 
vein separates segments 7&8 superiorly from segments 5&6 inferiorly, and the left 
portal vein separates segments 4a&2 superiorly from segments 4b&3 inferiorly.  
Segment 1, also known as the caudate lobe, lies posteriorly adjacent to the IVC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Anatomy of the liver, and its anatomical relations. (Adapted from a Leeds 
Teaching Hospitals NHS Trust patient education leaflet).  The liver is divided into eight 
segments (numbered).  Segments 1-4 form the left lobe of the liver, and segments 5-8 form 
the right lobe of the liver.  The hepatic artery (red) and portal vein (blue) can be seen 
immediately below segments 3 and 4, where they are branching into their respective left 
and right branches before entering the liver.  The inferior vena cava lies behind segment 1 
and is not shown.   
Falciform ligament 
Stomach 
Spleen 
Gallbladder 
Duodenum 
Pancreas 
Superior mesenteric artery (red) 
Superior mesenteric vein (blue) 
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1.3.2 Liver resection and other surgical adjuncts 
Because each segment of the liver has its own branch of the hepatic artery and 
portal vein (vascular inflow), its own branch of the hepatic vein (vascular outflow), 
and its own branch of the bile duct, each segment can be individually resected 
without compromising the viability of the remaining segments.  Following liver 
resection hyperplasia of hepatocytes in the remaining segments occurs,(95) and 
the remaining liver begins to grow within days of surgery.(96, 97)  Liver functional 
capacity is restored within days to weeks of surgery,(98) and growth will continue 
over a period of weeks and months until the original liver volume is restored.  The 
liver may recover 75% of its original volume within 1-3 months (98, 99) and 100% of 
its original volume within 12 months after a major resection.(96) 
Resectability of CRCLMs is dependent on the ability to obtain a complete 
macroscopic clearance of tumour, preserve at least 2 contiguous segments of liver 
with adequate vascular inflow and outflow, and preserve sufficient liver volume 
(known as the liver remnant) to be able to continue all of the liver functions.  Up to 
75-80% of the liver can be resected whilst still preserving sufficient liver function in 
the liver remnant for the patient not to develop liver failure.(100)  However, the 
extent of resection that is feasible depends not only on the residual volume, but 
also the functional capacity of the predicted remnant.  Functional capacity may be 
impaired in patients with steatotic or cirrhotic livers, such as in chronic liver 
diseases or following chemotherapy,(100) and their rate of liver regeneration may 
be slower.(101, 102)  This may mean that a larger remnant of diseased liver would 
be required to achieve the same function as a smaller remnant of healthy liver.  
Concerns about the functional capacity of the liver remnant may limit the extent of 
resection that can safely be performed in patients with underlying liver disease.  
Historically, only 20-25% of patients with CRCLM presented with resectable 
CRCLMs.(103, 104)  However, over the last 10 years advances in neoadjuvant 
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chemotherapy regimens to reduce the burden of disease has meant that an 
increasing number of patients have a good response to chemotherapy, effectively 
"downsizing" their disease to within operable limits.  Similarly, in patients who may 
have been deemed inoperable on the basis of an inadequate remnant liver volume, 
techniques such as portal vein embolisation or two-stage resections are now used 
to allow the remnant liver to hypertrophy before resection of the main tumour mass.  
For example, when a right hemihepatectomy is planned in a patient with a small left 
lobe, embolisation of the right portal vein 6-8 weeks preoperatively will divert portal 
flow away from the right lobe.  The right lobe will begin to atrophy and the small left 
lobe begins to hypertrophy in response, providing a left lobe of sufficient volume to 
allow the resection to be performed safely without fear of inducing liver failure.  
Alternatively, when a patient presents with disease in both the right and left lobes of 
the liver which cannot all be resected safely for fear of small remnant volume, 
resection of the disease in one side, an interval to allow the remnant liver to 
hypertrophy, followed by a second operation to resect the disease in the other half 
of the liver may also allow resection of all disease whilst leaving an adequate 
remnant volume (a so-called "2-stage resection").(105, 106)  As a result of these 
techniques, and improvements in the peri-operative surgical and anaesthetic 
management of liver resection patients, there has been a change in many 
surgeons' interpretation of "resectability", and a further 10-40% of patients 
previously considered unresectable may now be suitable for potentially curative 
surgery.   
 
1.4 Chemotherapy for CRC and CRCLM 
Chemotherapy can be given at any one of a number of stages in the natural history 
of CRC and CRCLM.  In patients presenting with CRC, "adjuvant" chemotherapy 
may be given following resection of the primary CRC to control microscopic disease 
with the aim of reducing the risk of CRC recurrence or CRCLM in the future.  
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Chemotherapy may also be given to patients with established CRCLMs.  In those 
patients presenting with operable CRCLMs "adjuvant" chemotherapy may be given 
either just before or just after surgery, with the same aim of reducing the risk of 
disease recurrence and improving patient survival following surgery.  By contrast, 
those patients presenting with inoperable CRCLMs may be offered neoadjuvant 
chemotherapy if there is a chance that they have a distribution or burden of disease 
which may become operable if they respond to chemotherapy and the burden of 
disease is reduced.  The aim of such neoadjuvant chemotherapy is to convert 
patients from inoperable to operable disease and thus to be able to perform 
potentially curative liver resection following chemotherapy.  In those patients with 
inoperable CRCLM where neoadjvant chemotherapy is not appropriate, be it due to 
patient factors or the burden of disease, palliative chemotherapy may be offered 
with the aim of slowing disease progression and extending life.  Finally, other drugs 
may be given as long term therapies for the chemoprevention of both CRC and 
CRCLM.  These will be discussed in section 1.5. 
1.4.1 Adjuvant chemotherapy for CRC 
The mainstay of CRC treatment is complete surgical resection, with adequate 
margins (>5cm) and lymphadenectomy (>12 nodes).  Survival is influenced by the 
extent of tumour spread.  The TNM classification describes the extent of local, 
lymph node and metastatic disease and is used to assign an overall tumour "stage"  
(Table 1.1 and 1.2).  Staging of tumours helps to plan further treatments such as 
chemotherapy and can give an estimate of prognosis (Table 1.2).   
Adjuvant chemotherapy aims to improve patient disease-free survival (DFS) and 
overall survival (OS) by killing residual tumour cells, either those persisting locally 
or those that have metastasised to distant sites.  The role of adjuvant 
chemotherapy in Stage III disease is well established.  FOLFOX (folinic acid + 
fluorouracil + oxaliplatin) chemotherapy is now the standard regimen for Stage III 
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disease, following the publication of the MOSAIC and NSABP C-07 trials 
demonstrating a clear survival advantage (7% absolute increase in OS at 3 years) 
with the addition of oxaliplatin to original fluorouracil (FU) based regimens.(107, 
108)  Capcitabine, an oral fluoropyrimidine, can be substituted in place of FU 
without loss of efficacy.(109)  Studies of the addition of irinotecan or newer 
biologics such as the monoclonal antibodies cetuximab (against EGFR) and 
bevacizumab (against VEGF) have not demonstrated any survival benefit.(110-113)  
The evidence for adjuvant chemotherapy in stage II disease is more contentious.  
The QUASAR study demonstrated a 2.9% increase in OS with FU + folinic acid 
compared to no chemotherapy in patients with stage II CRC.(114)  Some, including 
the American Society of Clinical Oncology, advocate adjuvant chemotherapy in 
medically fit patients with “high-risk” stage II CRC, i.e. T4 lesion or tumour 
perforation, poorly differentiated tumour on histology, or less than 12 lymph nodes 
sampled (i.e. an inadequate sampling which may understage lymph node 
status).(115)  However, the MOSAIC study demonstrated no improvement in 6yr 
OS with oxaliplatin + FU in patients with Stage II CRC, and a non-significant 2.3% 
increase in OS in those deemed “high-risk”.(107)  On balance, the risks and 
benefits of chemotherapy need to be discussed with individual patients with Stage II 
disease, although it is clear from the QUASAR and MOSAIC studies that 
chemotherapy does not offer a survival advantage to those aged 70 years and 
older, either with Stage II or Stage III disease.(107, 108) 
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Table 1.1.  The TNM staging of colorectal cancer.  T describes the layer of the bowel wall 
that the tumour has extended into.  The mucosa is the innermost lining of the bowel wall, 
the muscularis propria is the thick muscle layer, and the serosa is the outermost layer of 
connective tissue covering the colon.  Once a tumour has grown through the serosa, it 
either directly invades adjacent tissue (either other parts of the bowel or adjacent organs) or 
there is perforation of the bowel.  N describes the number of lymph nodes that are involved, 
and M describes the presence or absence of metastatic disease.   
 
 
 
 
 
 
Table 1.2.  Staging of CRC.  Staging is a means of defining and describing the spread of 
CRC and is based on the TNM classification of tumour, nodal and metastatic extent of 
disease.   Staging groups CRCs with a similar extent of disease, and is used to plan 
treatment.  It can also help to give an estimate of prognosis.  *Survival in stage IV disease 
depends on the extent of metastatic disease.  If metastatic disease can be fully resected, 
the prognosis is much better than in patients with inoperable disease.  
  
 T (Tumour) N (lymph node) M (metastases) 
0 No evidence of 
tumour 
No lymph nodes involved No metastases 
1 Into mucosa 1-3 lymph nodes Metastases 
present 
2 Into muscularis 
propria 
4 or more lymph nodes  
3 Into serosa   
4 Through serosa   
Stage Definition 5yr survival after 
surgery 
I T1 or T2, no lymph node or metastatic 
involvement 
93% 
II T3 or T4, no lymph node or metastatic 
involvement 
77% 
III Any T, with lymph node involvement 
(N1 or N2) but no metastases 
48% 
IV Metastatic disease (any T, any N) 6%-40%* 
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1.4.2 Adjuvant chemotherapy for CRCLM 
The evidence for adjuvant chemotherapy for CRCLM is less well established than 
that for primary CRC, with only limited randomised controlled trial (RCT) evidence 
for the use of adjuvant chemotherapy in patients presenting with resectable 
CRCLM.  The EORTC 40983 trial (n=364) compared 6 cycles of FOLFOX pre- and 
post- liver resection to surgery alone and demonstrated an increase in 3yr DFS 
from 28.1 to 36.2%.(116)  Other studies have demonstrated a non-significant 
increase in DFS with postoperative FOLFOX or FOLFIRI (folinic acid + fluorouracil 
+ irinotecan).(117, 118)  Whilst the results of the EORTC trial has led to many 
centres advocating pre-operative rather than post-operative adjuvant chemotherapy 
for earlier control of micrometastatic disease, there is currently no evidence 
supporting one over the other, and pre-operative chemotherapy is associated with 
increased steatosis, steatohepatitis, liver vascular lesions, and significantly higher 
postoperative complications.(119, 120) 
1.4.3 Neoadjuvant chemotherapy for CRCLM 
Neoadjuvant chemotherapy to downsize disease is based on FU in combination 
with either irinotecan or oxaliplatin.  In a recent review by the United Kingdom 
National Institute for Health Research, resection rates increased from 7-9% to 35-
51% with these regimens.(121)  More recently cetuximab has been approved by the 
National Institute for Health and Care Excellence (NICE) for first line combination 
therapy with either FOLFOX or FOLFIRI for patients with unresectable CRCLM if 
disease is confined to the liver, the primary tumour has already been resected or is 
potentially operable, and the patient is fit for resection if they demonstrate adequate 
response to chemotherapy.  This approval is based on the results of two studies in 
patients with inoperable CRCLM.  The CRYSTAL study (n=1198) demonstrated 
that addition of cetuximab to FOLFIRI was associated with increased DFS, and a 
non-significant increase in OS from 21 months to 24.9 months.  Post-hoc subgroup-
analysis of patients who were KRAS wildtype demonstrated an increased median 
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DFS from 8.7 to 9.9 months and increased response rate from 43.2% to 
59.3%.(122)  Similar results were seen in the OPUS study (n=337), with the 
addition of cetuximab to FOLFOX increasing response rates from 36% to 45% 
(37% to 60.7% in KRAS-WT) and a statistically significant increase in DFS from 7.2 
months to 7.7 months, although this small increase in DFS is of limited clinical 
relevance.(123)  A further study has evaluated the effect of giving both oxaliplatin 
and irinotecan in combination with folinic acid and FU (FOLFOXIRI) compared to 
FOLFIRI alone for patients with unresectable disease.(124)  The addition of 
oxaliplatin was associated with an increase in response rate from 34% to 60%, an 
increase in R0 resection rate from 6% to 15%, and significantly increased DFS (6.9 
months to 9.8 months) and OS (16.7 months to 22.6 months).  The FOLFOXIRI 
combination was however associated with significantly increased peripheral 
neurotoxicity and neutropaenia.(124) 
 
1.5 Chemoprevention of CRCLM 
One further approach to treating CRCLM is through chemoprevention, with the aim 
of preventing the development of CRC and CRCLM in the first place.  A large body 
of evidence has accumulated to support COX inhibition as a potential target for 
prevention of CRC in humans.(41, 125, 126)   Large population-cohort and case-
control studies have consistently demonstrated a reduction in CRC incidence with 
regular use of aspirin or other non-steroidal anti-inflammatory drugs.  In a recent 
meta-analysis of 12 such studies, including over 405,000 patients, the pooled 
relative risk (RR) of CRC in patients taking regular non-aspirin NSAIDs was 0.74, 
and RR 0.5 for patients taking regular NSAIDs including aspirin.(127)  Three RCTs 
of the chemopreventative efficacy of the selective COX-2 inhibitors rofecoxib and 
celecoxib in patients with recently removed sporadic colorectal adenomas all 
demonstrated significant reductions in polyp incidence at 3 years follow up of 
between 25-37%.(128-130)  A fourth RCT demonstrated a 28% reduction in polyp 
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number after 6 months of celecoxib supplementation in patients with FAP.(131)  
However, analysis of safety data from these trials demonstrated an increased risk 
of cardiovascular events in the COX-2 inhibitor groups, primarily myocardial 
infarction and ischaemic cerebrovascular events.  A meta-analysis of 145,373 
patients in 138 placebo controlled COX-2 inhibitor trials demonstrated an increased 
risk of myocardial infarction (hazard ratio HR 1.86), but no difference in thrombotic 
strokes in the COX-2 inhibitor group.(132)  This increased cardiovascular risk led to 
rofecoxib being withdrawn in 2004, and the premature closure of another large RCT 
(anticipated n=7000) comparing rofecoxib to placebo for chemoprevention following 
CRC resection, which would have more specifically included CRCLM development 
in their endpoints of DFS and OS.(133)  Further study into the toxicity and tissue 
specificity of COX-2 inhibitors is required if they are to have a role in CRC 
chemoprevention.(134)  
RCTs have also investigated the chemopreventative effect of aspirin.  In patients 
with previously resected colorectal cancer (n=635), 325mg daily aspirin reduced 
adenoma incidence at 3yr colonoscopy by 37% compared to placebo, together with 
a 39% reduction in mean adenoma number and an increase in time to development 
of first adenoma.(135)  A similar study by the same group compared daily aspirin 
81mg vs. 325mg vs. placebo in patients with recently documented adenoma 
(n=1121).  At 3 year colonoscopy the 81mg aspirin group had a 19% reduction in 
adenoma incidence compared to placebo. There was a 4% reduction in adenoma 
risk (non-significant) in the aspirin 325mg group compared to placebo.(136)  In the 
latter study, risk of advanced adenomas (>1cm or with tubulovillous or villous 
features, severe dysplasia or invasive cancer) was reduced in both aspirin groups, 
although again this did not reach statistical significance in the high dose aspirin 
group (HR 0.59 and 0.83 respectively, 40% and 18% reduction respectively), 
whereas no difference in advanced adenomas was seen in the former study.  
Aspirin 600mg daily has also been shown to reduce the risk of colorectal cancer in 
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patients with HNPCC (n=861).  At 4 year follow-up CRC incidence in the aspirin 
group was 4.2% compared to 6.9% in the placebo group (39% reduction).(137)  
Recent meta-analyses of five studies of aspirin in primary and secondary 
cardiovascular protection have shown a reduction in 20-year CRC incidence of up 
to 70% in patients taking aspirin for 5 years or more (n=14,033).  There was no 
increased benefit of taking aspirin doses above 75mg daily.(138).  A second meta-
analysis by the same group of 8 studies of aspirin vs. placebo for at least 4 years, 
demonstrated a reduction in all-cancer death at 20 years follow-up in the aspirin 
group compared to placebo group.(139)  Again, there was no increased benefit to 
aspirin doses greater than 75mg daily.  The benefit for reduced CRC incidence was 
only apparent after 10 years follow-up, with a HR 0.51 at 10-20yrs follow-up.  This 
is consistent with the lag phase in colorectal carcinogenesis, widely taken to be 
approximately 10 years for the development of CRC from a colorectal adenoma.  
As with COX-2 inhibitors, the side-effect profile of aspirin with an increased 
tendency for gastrointestinal bleeding (140) may limit its attractiveness as a long-
term chemopreventative agent, especially in those without cardiovascular disease 
or cardiovascular risk factors.  However, based on the findings of these recent 
meta-analyses there is renewed interest in the risk-benefit ratio of long-term low-
dose aspirin for the chemoprevention of CRC.(141, 142)  
 
1.6 Omega-3 Polyunsaturated Fatty Acids (PUFAs) 
‘Essential’ fatty acids are those which are required for biological processes, but 
which humans are unable to synthesize and must therefore obtain from dietary 
sources.  The parent ω-3 PUFA α-linolenic acid (ALA, 18:3) and parent ω-6 PUFA 
linoleic acid (LA, 18:2) are both found in vegetable oils.  Humans can easily 
metabolise LA to form the ω-6 PUFA arachidonic acid (AA, 20:4).  However, 
endogenous production of the ω-3 PUFAs eicosapentaenoic acid (EPA, 21:5) and 
docosahexaenoic acid (DHA, 22:6) from ALA by humans is so small as to be 
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insignificant.(143)  Therefore, the main ω-3 PUFAs EPA and DHA are considered 
‘essential’ and are obtained predominantly from cold water, oily fish such as 
mackerel, salmon and sardines.  White fish, such as cod and haddock, and shellfish 
typically have much lower ω-3 PUFAs levels.(144)  Table 1.3 details the EPA and 
DHA content of commonly consumed fish.   
 
Fish 
EPA+DHA (mg) per 
140g (5oz) serving 
Salmon 1500 - 3000 
Anchovies, Herring 2900-3000 
Mackerel 1700 - 2650 
Tuna: Bluefin 2150 
Sardines 1400 - 2000 
Oysters: Pacific 1950 
Trout: Freshwater 1250 - 1400 
Mussels 1150 
Squid 950 
Crab 250 - 700 
Tuna: Skipjack and Yellowfin 200 - 450 
Plaice, and Sole 450 
Tuna: Light canned 200 - 400 
Cod 250 
Scallops 250 
Haddock 250 
Shrimp 150 
 
Table 1.3.  EPA and DHA content of common fish and seafood.  Figures are rounded to 
the nearest 50mg per typical 140g cooked weight portion. 
 
PUFAs are biologically important, with roles in phospholipid membrane structure 
and function, as well as cellular signalling and lipid metabolism.  PUFAs can be 
liberated from phospholipid membranes by the phospholipase A2 family of enzymes 
and are metabolised by three main pathways: i) the cyclooxygenase (COX) 
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pathway, ii) the lipoxgenase (LOX) pathway and iii) the cytochrome P450 
monoxygenase (CYP450) pathway.   Metabolites derived from the ω-6 PUFA AA, 
such as prostaglandin (PG)E2, are typically pro-inflammatory and have been linked 
with initiation and progression of colorectal carcinogenesis, whereas those derived 
from ω-3 PUFAs (e.g. PGE3) are less pro-inflammatory, and may even have anti-
cancer properties.  Excellent reviews are already available on the metabolism of ω-
3 PUFAs,(145) the implications of inhibition of AA metabolism on cell proliferation 
(146) and the effects of ω-6 and ω-3 PUFAs metabolites on colorectal 
carcinogenesis.(147) 
 
1.7 Mechanisms of the anti-neoplastic activity of ω-3 PUFAs  
Current knowledge of the anti-neoplastic activity of ω-3 PUFAs has been 
comprehensively reviewed in articles by Calviello, Chapkin and Smith.(145, 147, 
148)  The main mechanisms that have been proposed for anti-neoplastic activities 
of ω-3 PUFAs are:  
 i) modulation of COX activity 
 ii) alteration of membrane dynamics and cell surface receptor function  
 iii) increased cellular oxidative stress 
 iv) production of novel anti-inflammatory lipid mediators including resolvins, 
 protectins and maresins  
The relative contributions of and interactions between these activities to the anti-
cancer properties of ω-3 PUFAs, however, remains unclear.  A summary of each of 
these mechanisms focusing on more recent findings is provided here.  Two further 
mechanisms by which ω-3 PUFAs may also have anti-neoplastic activity will also 
be briefly discussed; the direct activation of G protein-coupled receptors (GPCRs), 
and the effect on nuclear factor kappa beta (NFκB) signalling. 
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1.7.1 Modulation of COX activity 
EPA can act as an alternative substrate for COX-2, instead of AA, leading to a 
reduction in formation of pro-tumorigenic ‘2-series’ PGs (e.g. PGE2) in favour of ‘3-
series’ PGs (e.g. PGE3) in several cell types including CRC cells (Figure 1.5).(145, 
149, 150)  PGE3 has anti-tumorigenic activity against human lung cancer cells in 
vitro (150) and inhibits pro-tumorigenic PGE2-EP4 receptor signaling in human CRC 
cells.(149)  Recently, a ‘PGE2 to PGE3 switch’ has been demonstrated in colorectal 
mucosa of rats treated with fish oil.(151)  However, reduction of PGE2 synthesis 
and/or generation of PGE3 following EPA treatment remains to be demonstrated in 
human CRC tissue.  Meanwhile, one study demonstrated that in vitro and in vivo 
growth of HCT-116 CRC cells was inhibited by ω-3 PUFAs irrespective of whether 
the cells expressed COX, suggesting that inhibition can occur via COX-independent 
mechanisms.(152) 
1.7.2 Alteration of membrane dynamics and cell surface receptor function 
There is some evidence that the incorporation of ω-3 PUFAs into cell phospholipid 
membranes alters the fluidity, structure and/or function of lipid rafts or 
calveolae.(153)  These are sphingolipid and cholesterol rich microdomains that float 
freely in the cell membrane.  The localization of cell surface receptors, such as 
EGFR,(154) in lipid rafts is believed to be crucial for downstream receptor signaling 
controlling proliferation and apoptosis.(155, 156)  In a recent study DHA, but not 
EPA, suppressed CRC cell proliferation via an EGFR dependent mechanism, with a 
reduction in EGFR localisation to lipid rafts, suppression of EGFR signaling, and an 
increase in EGFR degradation.  A reduction in EGFR signaling was also seen in the 
colonic epithelium of mice supplemented with DHA.(157)  ω-3 PUFAs could alter 
EGFR function by changing receptor behaviour in lipid rafts but EPA could also 
decrease trans-activation of EGFR by reduction in PGE2 synthesis.(63)   
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Figure 1.5  The effect of eicosapentaenoic acid (EPA) with or without concurrent 
aspirin on cyclooxygenase (COX) activity.  Adapted from: Cockbain et al. Omega-3 
polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 
2012;61:135-149 
 
 A) When arachidonic acid (AA), derived mainly from the dietary ω-6 polyunsaturated fatty 
acid (PUFA) linoleic acid in "western" diets is the main substrate for COX-1 and COX-2, 
prostaglandin(PG)E2 is the predominant metabolite in colorectal tissue. B) EPA can act as 
an alternative substrate for both COX-1 and COX-2.  It effectively inhibits COX-1 activity, 
but modulates COX-2 activity such that PGH3 is the predominant metabolite.(145)  This is 
then converted to other three-series PGs, including PGE3, by PG synthases.  Enzymatic 
turnover of EPA is approximately three-fold less than that of AA, so the net result is a 
reduction in COX-2 synthesis of PGE2 and the production instead of (smaller quantities of) 
PGE3.(145)  C) Aspirin irreversibly acetylates COX-1 and COX-2.  COX-1 is effectively 
inhibited.  However, acetylated COX-2 can metabolise EPA to produce 18R-
hydroxyeicosapentaenoic acid (HEPE) and 18S-HEPE instead of PGH3.  HEPEs can be 
further metabolised by 5-lipoxygenase (5-LOX) to produce E-series resolvins, in 
combination with a reduction in PGE2 production.(158, 159)  D-series resolvins are 
produced via docosahexaenoic acid metabolism by LOX-dependent pathways.   
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1.7.3 Increased oxidative stress 
Omega-3 PUFAs may have an anti-neoplastic effect through alteration in the 
cellular redox state and increased oxidative stress.  PUFAs are highly 
peroxidisable, which generates reactive oxygen species (ROS) such as the 
superoxide radical.  Many tumour cells display altered cellular pathways for the 
handling of ROS including depletion of the major intracellular antioxidant, 
glutathione.  A subsequent elevation of intracellular ROS levels by ω-3 PUFAs has 
been hypothesised to induce cancer cell apoptosis.(160)  A potential beneficial 
interaction between ω-3 PUFAs and dietary fibre leading to induction of colonocyte 
apoptosis has been elegantly studied by Chapkin and colleagues.(161-163).   
1.7.4 Novel anti-inflammatory lipid mediators 
In the presence of aspirin, which irreversibly acetylates the COX enzyme, EPA 
drives COX-2-dependent production of resolvin (Rv) E1 (5S,12R,18R-
trihydroxyeicosapentaenoic acid) via metabolism of 18R-hydroxyeicosapentaenoic 
acid by 5-LOX (Figure 1.5).(164)  18R-RvE1 has been detected in plasma of 
healthy volunteers in ng/ml quantities after aspirin and EPA ingestion.(158)  More 
recently, synthesis of the 18S enantiomer of RvE1 has been demonstrated after 
EPA and aspirin treatment in healthy volunteers.(159) The precursors of E-series 
resolvins may also be produced independently of COX by direct CYP450 
metabolism of EPA.(165)   
Metabolism of DHA can produce D-series resolvins, via a LOX-dependent pathway 
to produce 17S-resolvins, or via acetylated-COX-2 leading to 17R-resolvin 
synthesis.(166)  DHA can also be metabolised by leucocyte-mediated pathways to 
produce 17S-docosatrienes termed protectins (167) or by macrophage-mediated 
pathways to produce 14-LOX-derived products termed maresins.(168)  These 
newly described families of EPA- and DHA-derived lipid mediators all share anti-
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inflammatory and inflammation resolution activity in animal models of acute 
inflammation.(168, 169)   
Cell signalling via these novel lipid mediator families is best characterised for RvE1.  
Both 18R and 18S enantiomers of RvE1 are ligands for ChemR23 and BLT1 
GPCRs.(159)  RvE1 has been demonstrated to induce expression of intestinal 
alkaline phosphatase in human CRC cells in a ChemR23-dependent manner and 
abrogate chemically-induced colitis in mice.(170)  It is currently not known whether 
ω-3 PUFA-derived resolvins exhibit anti-neoplastic activity.  However, it is known 
that ChemR23-dependent RvE1 signalling inhibits NFκB activation, which is a 
critical regulator of early-stage colorectal carcinogenesis.(171)  
1.7.5 Direct signalling via G protein-coupled receptors 
Omega-3 PUFAs are known to bind and directly activate GPCRs such as 
GPR120(172) and GPR40.(173)  Whilst the GPR120 signalling pathway has been 
shown to mediate potent anti-inflammatory effects,(172) the potential role of GPCR 
signalling in mediating an anti-cancer activity of ω-3 PUFAs has yet to be studied. 
1.7.6 NFκB signalling 
The transcription factor NFκB is a key component of immune and inflammatory 
signalling pathways, and has been implicated as a regulator of oncogenesis.(174)  
The NFκB family contains five proteins (p50, p52, p65, RelB and c-Rel) which exist 
as homo- or hetero-dimers.  The p50/p65 and p50/p50 dimers are the most 
common.(175)  These dimers are retained in cytoplasm bound to specific inhibitors 
(IκBs).  Cell stimulation activates IκB kinase (IκK) which in turn phosphorylates IκB 
inducing its degradation.  This releases the NFκB dimer which translocates to the 
nucleus and coordinates gene transcription.  NFκB activation promotes the 
expression of anti-apoptotic genes such as Bcl-2, proinflammatory cytokines such 
as IL-1B and TNFα, inducible enzymes such as COX-2, cell adhesion molecules 
such as ICAM-1 and proteases such as MMP-9.(176, 177)  The ability of NFκB to 
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promote cell proliferation, migration, metastasis and angiogenesis and to inhibit 
apoptosis has led to interest in the role of NFκB in carcinogenesis, and in its 
inhibition as a possible chemotherapeutic target.(Karin 2004)  Omega-3 PUFAs 
have been shown to inhibit IκB phosphorylation and reduce NFκB activation in CRC 
cell lines (178, 179) and inhibit NFκB activation in endothelial cells.(180)  Omega-3 
PUFA supplementation has also been associated with reduced expression of IKK 
and NFκB in a transgenic mouse prostate cancer model.(181)  In a breast cancer 
xenograft model, ω-3 PUFAs reduced NFκB DNA binding and NFκB-dependent 
transcription of the anti-apoptotic genes Bcl-2 and Bcl-XL.(182)  Modulation of 
NFκB signalling therefore represents a further mechanism by which ω-3 PUFAs 
might exert an anti-CRC effect.   
 
1.8 Pre-clinical studies of ω-3 PUFAs in the treatment of colorectal cancer 
1.8.1 In vitro studies 
Many in vitro studies have explored the anti-neoplastic activity of ω-3 PUFAs 
against human CRC cells, with both EPA and DHA treatment being associated with 
reduced cellular proliferation (152, 183-189) and increased apoptosis.(183, 184, 
187, 190)  It remains unclear from the few studies comparing EPA and DHA 
whether there is any significant difference in anti-proliferative and/or pro-apoptotic 
activity.  Calviello et al. reported a more pronounced reduction in cell number with 
EPA than with DHA,(186) whereas Chen et al. have reported a lower cell number 
with DHA than with EPA, and that only DHA induced apoptosis.(187)  Both ω-3  
PUFAs have been shown to reduce COX-2 expression and PGE2 production.(149, 
180, 184, 186)  Human CRC cell lines treated with ω-3 PUFAs have demonstrated 
increased membrane fluidity (188) and lipid peroxidation,(188, 189) reduced levels 
of VEGF, β-catenin, PPARγ, BCL-2 and matrix metalloproteinase, and reduced 
extracellular signal-related kinase-1/2 signalling.(156, 184, 186, 187, 190, 191)  
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Suppression of angiogenic factors by ω-3 PUFA treatment has also been 
demonstrated in a number of in vitro studies.  Calviello et al (2004) demonstrated 
that EPA supplementation of HT-29 cells resulted in a significant reduction of VEGF 
expression (90% reduction at 30µM EPA), COX-2 expression (37% reduction at 30 
µM EPA), and PGE2 production.(186)  The addition of excess PGE2 restored VEGF 
expression, demonstrating that one mechanism of inhibition of VEGF by ω-3 
PUFAs is via the COX-2 pathway.  EPA also reduced the phosphorylation of ERK-1 
and ERK-2 which has previously been shown to induce VEGF expression in 
response to PGE2 stimulation.(192)  Other in vitro studies have investigated the 
effects of ω-3 PUFAs on endothelial cells.  Studies culturing endothelial cells in the 
presence of ω-3 PUFAs, typically EPA or DHA added to culture medium at 
concentrations between 15µM and 100µM, have shown increased endothelial cell 
membrane EPA/DHA content,(193) reduced COX-2 expression and PGE2 
production,(180) reduced cell proliferation,(194, 195) reduced cell migration (194, 
196) and reduced VEGF-stimulated endothelial cell microtubule formation.(193, 
194, 196)  Omega-3 PUFAs have therefore been shown to have both direct and 
indirect anti-angiogenic properties through effects on endothelial and epithelial cells 
respectively. 
1.8.2 Animal studies 
The effect of ω-3 and ω-6 PUFA supplementation on the growth of human CRC cell 
lines grown as xenograft tumours in immunocompromised mice has been studied 
widely (Table 1.4).  There has been a consistent 40-60% reduction in xenograft size 
in rodents supplemented with ω-3 PUFAs compared with controls.(152, 186, 197)  
Similar findings have been reported for studies of rodent CRC cell allograft tumours 
(Table 1.4).(198-202)  The ω-3 PUFA content of tumours increased, at the expense 
of AA, in animals supplemented with ω-3 PUFA,(152, 201-203) together with a 
reduction in expression of COX-2 (186, 199) and a reduction in tissue PGE2 
levels.(186)  In the one study which measured tumour vascularity, oral ω-3 PUFA 
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supplementation (1g/kg body weight) was associated with a 46% reduction in 
tumour vascularity compared to controls.(186)  Reduced tumour vascularity has 
also been demonstrated in mammary tumours grown in mice given ω-3 PUFA 
supplemented diets.(204, 205)  Some studies have investigated the effects of 
conjugated EPA.  Conjugated EPA is a mixture of positional and geometric isomers 
of EPA, where the carbon-carbon double bonds form a "conjugated" chain of 
alternating double and single carbon-carbon bonds (Figure 1.6).  Conjugated EPA 
has been shown to suppress the growth of DLD-1 human CRC cell tumours in nude 
mice, which was associated with increased lipid peroxidation in the phospholipid 
membrane, increased levels of oxidative stress and increased apoptosis.(206)  
 
 
 
Figure 1.6.  Comparison of the structure of EPA and conjugated EPA.   
Note the spacing of the carbon-carbon double bonds in EPA (double bonds at carbons 
3,6,9,12,15), compared to the presence of alternating carbon-carbon single bond and 
carbon-carbon double bonds in conjugated EPA (double bonds at carbons 3,6,11,13,15).  In 
chemistry, conjugation is the overlapping of p-orbital electron fields, made possible in 
compounds with alternating single and double bonds.  The overlapping p-orbitals bridge the 
intervening single bond and electrons can delocalise across the aligned p-orbitals.  The 
system is thus said to be "conjugated".  Usage of the term "conjugated" in this sense is 
therefore different form the use of the term "conjugated" in biology where it is often used to 
describe the joining together of two compounds.   
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Study Model N= Treatment Groups Timing/Duration Outcome measure(s) Results (changes are for ω-3 PUFA group vs. 
control group unless stated) 
Cannizzo 
1989 (198) 
BALB/c mouse, CT26 CRC 
cells into 1) descending 
colon 2) tail vein 
330 5% & 25% MO1 vs.  
5% & 25% SAFO 
30 days pre- and 28 
days post- injection 
1) Tumour size 
2) No. lung mets 
3-5x↓ tumour size MO vs. SAFO grps  
↑ lung mets in 25% SAFO grp vs. all other grps 
Iigo 1997 
(202) 
CDF1 mouse 
Co 26Lu CRC cells subcut 
230 0.1/0.2ml EPA vs. DHA vs. 
OA vs. LA ig daily 
Day 5-21 post-injection  
 
 
Tumour size, no. lung mets 
Plasma/tumour PUFA   
 
EPA/DHA grps dose dependent ↓tumour size and 
↓lung mets 
↑EPA/DHA & ↓AA in plasma & tumour  
Calder 1998 
(203) 
Nude mouse 
HT-29 CRC cells subcut 
90 20% CO/SAFO/MO2/OO 
vs. 2.5% CO Ctrl 
3 wk pre- and 2 wk 
post- injection 
Tumour size and PUFA content 65-74% ↑tumour size in high fat grps except MO  
↑tumour EPA/DHA + 57%↓AA in MO grp 
Boudreau 
2001 (152) 
Nude mouse 
HCT116 CRC cells subcut  
102 18% MO3 vs.20% SAFO  
 
2 wk pre- and 3 wk 
post- injection 
Tumour size 
Tumour PUFA content  
50% ↓ tumour size  
↑ tumour EPA and 50% ↓ tumour AA   
Kato 2002 
(197) 
Nude mouse 
WiDR CRC cells subcut 
24 8% & 24% CO 
16% MO4 vs. 16% GAO 
53 days post-injection Tumour wt Tumour wt vs. 8% CO tumour wt: 
87%↓ (GAO), 54%↓ (MO), 36%↑ (24% CO) 
Togni 2003 
(201) 
Wistar rat 
Walker 256 tumour cells  
subcut 
78 1g/kg body wt. MaxEPA  
vs. CO vs. Ctrl 
 
 
10 wk pre- and 2 wk 
post- injection 
 
 
Tumour wt & PUFA content 
Cachexia biomarkers (serum 
glucose, chol, lactate, & 
liver/muscle glycogen)  
40/60% ↓ tumour wt vs. CO/Ctrl 
63/42%↓ tumour AA:EPA vs  CO/Ctrl 
↓cachexia biomarkers 
Calviello 
2004 (186) 
 
Nude mouse 
HT-29 CRC cells subcut 
45 1g/kg body wt. EPA vs. 
DHA vs. H2O Ctrl ig 
1wk pre- and 4 wk post- 
injection 
Tumour size, AI, PI, MVD 
Tumour COX-2 expression 
Tumour PGE2 
No difference in effect EPA vs DHA  
EPA/DHA  vs. Ctrl both showed 55%↓ tumour size,  
50%↓ PI, 1.5x↑ AI, ~50%↓ MVD, 40%↓ PGE2 , 
30%↓COX2 and ↓VEGF  
Tsuzuki 2004 
(206) 
Nude mouse 
DLD-1 CRC cells subcut 
40 50mg 20% CLA/EPA/CEPA 
daily vs. 50mg SAFO Ctrl 
 
4 wk post-injection Tumour wt, DNA fragmentation 
Membrane phospholipid 
peroxidation 
Tumour wt ↓80% CEPA vs Ctrl.   
DNA fragmentation ↑4x CEPA vs Ctrl 
↑ phospholipid peroxidation CEPA vs. all grps 
Pizato 2005 
(200) 
Wistar rat 
Walker 256 tumour cells  
subcut 
60 20% FO1 vs. 20% SUNO vs. 
Ctrl 
 
 
8 wk pre- and 2 wk 
post- injection 
 
 
Tumour wt 
Lipid peroxidation products 
Cachexia biomarkers (blood 
glucose, TAG, chol) 
60% ↓tumour wt 
34% ↑ lipid peroxidation products 
↓cachexia biomarkers 
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Table 1.4  In vivo pre-clinical studies of ω-3 PUFA supplementation for the treatment of CRC 
 
Abbreviations:  ↑ = increase, ↓ = decrease,    = no significant difference, AI = apoptosis index, chol = cholesterol, CO = corn oil, Ctrl = control, FO= fish oil (FO1 = 
13%EPA/20%DHA, FO2 = 18% EPA/12%DHA), GAO = golden algae oil (DHA only), grp = group, grps = groups, ig = intragastric, LA = linoleic acid, MaxEPA = 
18%EPA/12%DHA, mets = metastases, MO = menhaden oil (MO1, MO3, MO4 ω-3 PUFA content unspecified, MO2 11%EPA+5.2%DHA), MVD = microvessel 
density, OA = oleic acid, OO = olive oil, PI = proliferation index, SAFO = safflower oil, SAFO = safflower oil, subcut = subcutaneous, CLA = conjugated linoleic 
acid, CEPA = conjugated EPA,SUNO = sunflower oil, TAG = triacylglycerol, VEGF = vascular endothelial growth factor, wt = weight
Study Model N= Treatment Groups Timing/Duration Outcome measure(s) Results (changes are for ω-3 PUFA group vs. 
control group unless stated) 
Mund 2007 
(199) 
Wistar rat 
Walker 256 tumour cells  
subcut 
70 1g/kg FO2 vs CO vs Ctrl 
 
 
70 days pre- and 14 days 
post- injection 
Tumour weight, AI & COX-2 
Lipid peroxidation products 
Plasma PGE2 
Tumour weight 50%↓(FO) & 30%↑(CO)   
AI 4x ↑(FO) & 50% ↓ (CO) 
COX2 45%↓(FO) & 50%↑(CO) 
Plasma PGE2 ↓ (FO) &    (CO) 
FO 3x↑ lipid peroxidation products 
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1.8.3 Models of CRC metastasis 
Few pre-clinical studies have investigated the effect of ω-3 PUFA supplementation 
on the development of metastatic disease, with only four studies using a liver 
metastasis model, and a further two using a lung metastasis model.   Iwamoto et al. 
supplemented F344 rats with EPA (9.5% w/w as the ethyl ester) for 1 week pre- 
and 3 weeks post-injection of ACL-15 cells into the superior mesenteric vein.  They 
demonstrated a 40% reduction in number and 44% reduction in size of liver 
metastases in rats supplemented with EPA compared to controls fed a standard 
commercial diet containing 5.1% total fat .  This was associated with a reduction in 
tumour cell proliferation index, but no change in apoptosis index, and down-
regulation of vascular cell adhesion molecule 1 (VCAM-1).  Rats fed a diet high in 
ω-6 PUFA (10% w/w LA) showed a 3-fold increase in number and 1.5-fold increase 
in the size of metastases.(207)   
Gutt et al. supplemented WAG/Rij rats with an EPA/DHA mixture (3.23% ω-3 
PUFA; EPA:DHA ratio 3:2)  for 3-days pre- and 4 weeks post-injection of CC531 
cells into the spleen.  They demonstrated a 70% reduction in incidence and 50% 
reduction in size of hepatic and extra-hepatic metastases, as well as a 30% 
reduction in tumours expressing VCAM-1.(208) More recently, a study by Hawcroft 
et al. supplemented BALB/c mice with 5% w/w EPA (95% pure free fatty acid) for 
14 days pre- and 14 days post- injection of MC-26 cells into the spleen.  Notably in 
this study, injection was performed under anaesthesia percutaneously using 
ultrasound guidance rather than through a midline laparotomy as in other studies.  
They demonstrated a 36% reduction in liver weight (used as a measure of tumour 
burden) in mice supplemented with EPA compared to controls fed a diet containing 
5% corn oil.  This was associated in the EPA group with a 9-fold increase in tumour 
EPA content, 54% reduction in tumour AA content, and 19% reduction in tumour 
proliferation index.  There was also a 60% reduction in tumour PGE2 together with a 
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significant increase in tumour PGE3, the first in vivo demonstration in tumour tissue 
of a PGE2 to PGE3 switch with ω-3 PUFA supplementation.(209)    
By contrast, Griffini et al supplemented WAG/Rij rats with an EPA/DHA mixture 
(20% fish oil v/w; EPA:DHA ratio approximately 3:2) 3 weeks pre- and 3 weeks 
post-injection of CC531 cells into the portal vein.  They demonstrated a 10-fold 
increase in liver metastases in rats supplemented with ω-3 PUFAs compared to 5% 
soybean controls and a 4-fold increase compared to those animals supplemented 
with 20% safflower oil (high in ω-6 PUFA).(210)  This was associated with an 
increase in liver:body weight ratio and an increase in mitotic tumour cells in the ω-3 
PUFA group.  These results are difficult to reconcile with the studies of Gutt, 
Iwamoto and Hawcroft, and with the extensive in vitro and in vivo data suggesting 
an anti-CRC activity of ω-3 PUFAs.  The 20% fish oil preparation used in the Griffini 
study was a much higher dose than that used in any other in vivo study, and is far 
in excess of any clinically attainable dose in humans.   
Two further studies have modelled the effect of ω-3 PUFA supplementation on the 
development of pulmonary metastases, by measuring lung colonization after 
injection of CRC cells into the tail vein.(198, 202)  One demonstrated that 
supplementation of either EPA or DHA (0.1 ml aliquots daily of 98% pure EPA or 
DHA ethyl ester) was associated with significantly fewer lung colonisations at 12 
days compared to controls (54% and 58% fewer colonies respectively).(202)  The 
other study found that whilst supplementation with high-fat safflower oil (24.7% by 
weight for 30 days pre-inoculation) caused a 5-fold increase in the number of 
pulmonary colonies, there was no difference in low (5%) or high (24.7%) ω-3 PUFA 
intake on the number of metastases compared with controls.(198)   
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1.9 Clinical trials of ω-3 PUFAs in patients with CRC  
1.9.1 Single agent therapy 
Despite strong in vitro and in vivo evidence for direct anti-CRC activity of ω-3 
PUFAs, only two trials have investigated the anti-neoplastic effect of ω-3 PUFAs in 
patients with CRCLM and no such trial has been performed in patients with CRC.  
The first of these two trials was a recently published double-blind RCT by 
Dennison’s group in Leicester.  They randomized 20 patients to receive a 
continuous 72hr infusion of total parenteral nutrition (TPN) at 1.5ml/kg/hr.  For the 
ω-3 PUFA supplementation group, the standard 2000ml TPN was compounded 
with 500ml of Lipidem® (B Braun) which contained a 50:40:10 (vol/vol/vol) mix of 
medium-chain fatty acids, soybean oil and fish oil, including approximately 3.7g 
EPA + 2.55g DHA.  TPN in the control group was compounded with 500ml of 
Lipofundin® (B Braun) which contains a 50:50 (vol/vol) mix of medium-chain fatty 
acids and soybean oil.  Patients underwent resection of liver metastases a mean of 
9 days (range 5-12 days) after completion of TPN.  There was a rapid uptake of ω-3 
PUFAs into plasma phospholipids, but no change in AA levels, in the 72 hours of 
TPN administration.  However, there was also a rapid return to baseline ω-3 PUFA 
levels by the time of surgery.(211)  There was no significant difference between the 
two groups in tumour EPA, DHA or AA content, although there was a trend in the 
ω-3 PUFA group for a higher total tumour ω-3 PUFA content and lower tumour ω-
6:ω-3 ratio in those patients with a shorter interval between finishing TPN and 
resection of their tumour.(212)  This interval between TPN and surgery limits the 
interpretation of changes in tumour ω-3 PUFA content.  It is not clear how quickly 
tumoural ω-3 PUFA levels rise or fall after iv supplementation, and extrapolation of  
tumoural PUFA data back to the time of finishing TPN, when plasma levels of ω-3 
PUFA were elevated, may be unreliable.   
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The second trial of ω-3 PUFA supplementation in patients with CRCLM is a Phase 
II double-blind RCT trial of oral EPA supplementation prior to resection of CRCLM, 
which is the basis of this MD work (clinicaltrials.gov NCT01070355). 
1.9.2 Adjuvant therapy with traditional chemo-radiotherapy 
In vitro and in vivo studies have shown that ω-3 PUFAs can potentiate the anti-
proliferative and pro-apoptotic effects of chemotherapy and radiotherapy used to 
treat CRC and other solid tumours.(213-217)  Despite this, only one published 
human study of the anti-cancer effects of combining ω-3 PUFAs with chemotherapy 
exists.  A Phase II study evaluated addition of 1.8 g DHA daily to an anthracycline-
based chemotherapy regimen for metastatic breast cancer. Patients were 
dichotomized based on high or low DHA incorporation into plasma phospholipids.  
The high DHA-incorporation group had a significantly longer time to disease 
progression (median 8.7 months vs. 3.5 months) and overall survival (median 34 
months vs. 18 months).(218)  Similarly, only one clinical study of combining ω-3 
PUFAs with radiotherapy was identified. This retrospective study of 143 patients 
who had been prescribed ω-3 fish oil (0.9 g EPA, 1.5 g DHA daily) for 18 weeks 
following radiotherapy for brain metastases found reduced radionecrosis (3.5% vs. 
14.1%) and improved overall survival (median survival 88.8 wks vs. 54.1 wks) 
compared to the 262 patients who had not been prescribed fish oil.(219)  Whilst un-
blinded and non-randomized, this study nevertheless demonstrated a clear survival 
advantage linked to ω-3 PUFA supplementation.  One further study demonstrated 
improved tolerability of chemoradiation for oesophageal cancer in patients taking ω-
3 PUFA supplements, with a reduction in the incidence of grade 2-4 neutropenia, 
diarrhoea and pharyngitis compared to those not taking supplements.(220)   
A paper published in Cancer Cell found that endogenous mesenchymal stem cells 
(MSCs) can become activated during platinum-based chemotherapy treatment and 
secrete fatty acids that induce resistance to chemotherapy.(221)  Mesenchymal 
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stem cells are known to be recruited to the stroma of tumours and help to mediate 
tumour growth, angiogenesis and metastasis by the secretion of growth factors and 
cytokines.(222-224)  In this paper, MSCs activated by platinum-based 
chemotherapy were found to secrete two fatty acids, including the ω-3 fatty acid 
hexadeca-4,7,10,13-tetraenoic acid (16:4, ω-3), that abolished the effect of a 
variety of chemotherapy drugs on C26 (colon cancer cell line) and LLC (lung cancer 
cell line) tumours in vivo.  These fatty acids were only secreted by MSCs exposed 
to platinum-based and not other types of chemotherapy drugs.  Additionally, other 
PUFAs including EPA, did not confer resistance to chemotherapy drugs in this 
model.  Inhibition of thromboxane synthase or COX-1, but not COX-2, prevented 
the MSC-induced resistance of chemotherapy.  The two fatty acids implicated were 
subsequently identified in humans treated with platinum-based chemotherapy.  
Interestingly, 16:4 ω-3 is also found in commercially available fish oil products.  
Such fish oil products fed to mice also induced chemotherapy resistance.  This 
study demonstrates an important new mechanism of chemotherapy resistance 
which is mediated by platinum-based chemotherapy activation of mesenchymal 
stem cells, via the production of two specific fatty acids, and suggests a possible 
negative effect of the use of mixed ω-3 PUFA supplements in patients being treated 
with platinum-based chemotherapies.    
There is a clear need for further human studies to evaluate the role of ω-3 PUFA 
supplementation in improving the efficacy and/or tolerability of chemotherapy and 
radiotherapy.  Two ongoing studies are investigating the combination of fish oil and 
chemotherapy in patients with advanced pancreatic cancer (clincialtrials.gov 
NCT01019382, and International Clinical Trials Registry Platform JPN-
UMIN000003658) and one in advanced oesophagogastric cancer (clincialtrials.gov 
NCT01870791). 
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1.10 Omega-3 PUFAs for the prevention of colorectal cancer 
1.10.1 Animal studies 
The differential effect of ω-3 and ω-6 PUFAs on the prevention of CRC has been 
demonstrated in a number of animal models of early-stage colorectal 
carcinogenesis.  Studies of rodents fed an ω-3 PUFA-supplemented diet versus an 
equivalent ω-6 PUFA-supplemented diet or low-fat control diet control have 
consistently reported a 20-50% reduction in chemically-induced tumour 
incidence,(161, 225-233) together with a 30-70% reduction in tumour multiplicity, in 
both carcinogen and ApcMin/+ mouse studies (Table 1.5).(226, 227, 230, 232, 234-
237)  Studies using the number of aberrant crypt foci (ACFs) as the primary end-
point have reported a similar magnitude effect with ω-3 PUFA supplementation 
(Table 1.5).(228, 231, 235, 238, 239)  These effects are directly related to ω-3 
PUFA supplementation rather than simply a reduction in ω-6 PUFA intake.(199, 
230, 240)  Whilst most in vivo studies have compared a mixture of EPA and DHA, 
attention is drawn to the few studies either directly comparing EPA and DHA (241), 
or using EPA (227, 232, 236)  or DHA (237, 242, 243) as single agents.  In general, 
similar results have been demonstrated with each of the two main ω-3 PUFAs.  
Analysis of mucosal PUFA content has consistently demonstrated incorporation of 
ω-3 PUFA, at the expense of AA content, in rodents supplemented with ω-3 PUFA 
compared to controls,(226, 227, 242) together with a reduction in mucosal PGE2 
,(151, 227, 236, 241, 244) reduction in mucosal cell proliferation (225, 226, 238) 
and an increase in mucosal cell apoptosis (Table 1.5).(151, 161, 162, 238, 244).  
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Study  
 
Model N= Treatment Groups Timing/Duration Outcome measure(s) Results (maximal changes  ω-3 PUFA group 
vs. Ctrl unless stated) 
Carcinogen-induced models 
Nelson 1988 
(234) 
Sprague-Dawley rat 
DMH  
50 17% MO1 vs. 17% CO  
vs. Ctrl 
 
7 wk pre- & 17 wk post- 
DMH 
Tumour incidence & 
multiplicity 
Incidence of metastases 
    tumour incidence  
35% ↓ tumour multiplicty 
    incidence of metastases 
Minoura 
1988 (227) 
Donryu rat  
AOM  
100 4.7% EPA vs. 5% LA   
 
15 wk pre- & 20 wk post- 
AOM 
Tumour incidence 
Tumour & colonic mucosal 
PUFA + PGE2 content 
50%↓tumour incidence,  75%↓multiplicity  
↑ EPA & ↓ AA in tumour & mucosa   
 80%↓tumoural  PGE2  
Reddy 1988 
(245) 
F344 rat 
AOM  
234 4% - 12% MO1 
 vs. 24% & 5% CO 
38 wk post- AOM Tumour incidence 
Tumour PUFA content 
 
50% ↑ tumour incidence + multiplicity in 
24% CO vs. all other grps  
↑ tumoural EPA+DHA with MO diets 
Deschner 
1990 (225) 
CF1 mouse 
AOM  
 
300 4%-16%  MaxEPA vs. 
4% & 20% CO 
 
2 wks pre- & 1-45 wk 
post- AOM 
Colonic mucosa PI & FAD 1wk  
Tumour incidence 45 wk 
Dose dependent ↓ FAD  
38%↓ PI in 16% MO grp  vs. 20% CO 
50%↓ tumour incidence 16%/10% MO grp 
Reddy 1991 
(229) 
F344 rat 
AOM  
273 18% MO2 vs  
23.5% & 5% CO 
 
2 wk pre- & 36 wk post- 
AOM.  Diet crossover 3/7 
post- AOM. 
Tumour incidence 
 
↓ tumour incidence and multiplicity when 
MO vs. 23.5% CO given in either initiation or 
post-initiation phases 
Takahashi 
1993 (242) 
 
F344 rat 
DMH  
97 0.7ml DHA vs 0.7ml  
H2O ig daily 
1 day pre- & 4/8/12 wk 
post-DMH 
 
No. of colonic ACFs 
Serum chol & PUFA content 
60% ↓ ACFs (↓ ACFs seen when DHA given 
in either initiation or post-initiation phase) 
50%↓ AA, 50%↑ DHA & EPA, 20%↓ chol. 
Hendrickse 
1995 (226) 
 
Wistar rat + colon 
anastomosis vs sham  
AOM 
160 20% FO1 vs. 20% CO 
 
 
3 wk pre- & 15/23 wk 
post- AOM  
Colonic mucosal PI 
Tumour incidence, size, no. 
Mucosal PUFA content 
40%↓ tumour incidence, 50%↓ multiplicity  
60%↓ peri-anastamotic tumours.   ↓PI 
↑EPA/DHA & 90%↓ AA in tumour/mucosa 
Chang 1998 
(161) 
Sprague-Dawley rat 
AOM  
260 11.5% FO2 vs. 15% 
CO +/- 6% cellulose 
vs. 6% pectin 
1 week pre- & 16/32 wk 
post- AOM 
Colonic tumour incidence 
Crypt PI/AI/cell differentiation 
20%↓ tumour incidence 
    PI , 20%↑AI, ↑ cell differentiation 
↑AI FO-pectin grp vs all other fat-fibre grps   
Takahashi 
1997 (243) 
 
F344 rat 
AOM  
 
96 1ml  DHA vs 1ml 
water ig daily 
4/12/36 wk No. of ACF and tumours 
Plasma PUFAs &  PGE2 
25%↓ ACF (wk 4/12) & 35%↓ tumour 
multiplicity,  50%↓ plasma PGE2, 75%↓ 
plasma AA, 30x↑ EPA, 6x↑DHA (wk 36) 
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Study  
 
Model N= Treatment Groups Timing/Duration Outcome measure(s) Results (maximal changes  ω-3 PUFA group 
vs. Ctrl unless stated) 
Carcinogen-induced models (continued) 
Good 1998 
(233) 
F344 rats 
AOM  
161 18% MO3 vs.  
5% & 23% CO 
 
5% CO 12 wk post-
injection then 6-12 wk 
experimental diet 
No. ACF 
No. + size colonic tumours 
 
15-20%↑ ACF vs. both CO grps  
25%↓ tumour incidence but 50%↑ tumour 
size MO vs. CO grps (both NS) 
Singh 1998 
(230) 
F344 rat 
AOM  
 
144 21% FO3  vs. 24% CO 
vs. Ctrl  
1/12/36 wk post- AOM  Tumour incidence & 
multiplicity 
 
FO grp 30%↓ tumour incidence & 
multiplicity.  23.5% CO grp 33%↑tumour 
incidence & 90% ↑multiplicity 
Latham 
1999 (238) 
Wistar rat 
DMH  
68 8% FO4 vs. 8% CO 
 
FO vs. CO 24/48hrs post-
DMH then 18 wk CO 
Crypt cell AI & PI (24/48hr) 
No.  ACF (18wks) 
↑ AI and ↓ PI at 24/48hrs 
50% ↓ACF at 18 wk 
Rao 2001 
(228) 
F344 rat 
AOM  
360 17% FO3 vs. 5% CO 
vs. 
20% mixed lipids  
CO 2 wk pre-AOM 
Experimental diets for 8-
38 wk post-AOM 
No. ACF, tumour incidence 
Colonic mucosa AI  
 
44%↓ ACFs , 30%↓ tumour incidence, 60% 
↓ tumour multiplicity & 2x ↑AI vs. 20% 
mixed lipid diet. 
Crim 2008 
(162) 
Sprague-Dawley rat  
AOM 
80 11.5% FO2 vs 15% CO 
+/- 5% butyrate 
3 wk pre- & 8 wk post-
AOM 
No. ACF, colonic mucosa AI,  
 
↑ ACFs CO + butyrate vs all grps 
↓ large ACFs and ↑AI in  FO + butyrate grp 
vs. FO alone or control.  
Vanamala 
2008 (151) 
Sprague-Dawley rat  
AOM  
20 15% FO5 + pectin vs.  
15% CO + cellulose 
 
32 days pre- & 31 wk 
post- AOM  
Colonic mucosa AI 
Colonic mucosa PGE2/PGE3  
β-catenin & PPARδ expression 
2x↑ AI & 78%↓ mucosal PGE2  
↑PGE3 (PGE3 not detected in CO group) 
↓ β -catenin & PPARδ expression 
Moreira 
2009 (231) 
 
Wistar rat 
DMH  
20 18% FO6 vs. 18% 
SOYO 
 
2 wk pre- & 36 wk post- 
DMH  
No. ACFs, adenoma incidence 
Colon/liver PUFA content 
47%↓ ACF, 80%↓ adenoma incidence 
5 x↑ ω-3-PUFA in colon + liver 
 60%-75%↓ n-6 PUFA in colon + liver 
Woodworth 
2010 (246) 
SMAD3
−/− 
mouse 
Helicobacter  induced 
colitis 
122 0.75% - 6% DHA vs. 
6% SAFO vs. 7% CO 
vs. Ctrl 
1. 8 wk pre- infection 
2. 8 wk pre- & 4 wk post- 
infection 
Colon inflammation/dysplasia 
Hepatic PUFA content 
Body wt. 
↑ inflammation/dysplasia 2.25%-6% DHA vs 
Ctrl.  5x↑ hepatic DHA content, 85% less 
wt. gain  & 10-18% ↓4wk survival in 6% 
DHA grp vs CO/SAFO/Ctrl  
Burlamaqui 
2012 (239) 
Wistar rat 
AOM 
36 8.2% lipid diet 
(4.5:3:1  ω-9:6:3)   
vs. 1.6% lipid diet  
(3.2:8:1  ω-9:6:3)   
16wk pre- & 15wk post-
AOM 
No. ACFs 
Body wt. 
12% ↑ body wt 
No difference in total no. ACFs 
33% ↓ no. of ACFs with >4 crypts 
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Table 1.5   In vivo pre-clinical studies of ω-3 PUFA supplementation for the prevention of CRC 
 
Abbreviations:      = no significant difference, ↓ = decrease, ↑= increase,  ACF = aberrant crypt foci, AI = apoptosis index, AOM = azoxymethane, chol = 
cholesterol, CO = corn oil, Ctrl = control, DMH = 1,2-dimethylhydrazine, FAD = focal area of dysplasia, FO = fish oil (FO1= 18% EPA/15% DHA; FO2= 
unspecified ω-3 PUFA content; FO3 = 31% ω-3 PUFA; FO4= 18% EPA/8% DHA; FO5= 18%EPA/11%DHA; FO6= 24%EPA/20%DHA; FO7= 54% EPA/30% DHA),   
ig = intragastric, LA = linoleic acid,  MaxEPA= 18%EPA + 12% DHA, MO =menhaden oil (MO1 16% EPA + 11% DHA; MO2 2.4% EPA + 11% DHA; MO3= 
unspecified ω-3 PUFA content; MO4 = 13%EPA/12%DHA), PI = proliferation index, PPAR = peroxisome proliferator-activated receptor, SAFO = safflower oil, 
SOYO = soybean oil, wk = weeks, wt = weight 
Study  
 
Model N= Treatment Groups Timing/Duration Outcome measure(s) Results (maximal changes  ω-3 PUFA group 
vs. Ctrl unless stated) 
Apc mouse models 
Oshima 
1995 (237) 
 
Apc
∆716
  
 
20 3% DHA vs Ctrl 
 
7wk Colonic  polyp no. and size 69%↓ polyp no. in females mice only 
    polyp no. in male mice 
 ↓ polyp size, more marked in females 
Paulsen 
1997 (235) 
Apc
Min/+
 51 0.4%-2.5%  FO7   
vs 12% CO 
17 wk No. ACFs and adenomas 48-66%↓ no. and 26-38%↓ size of tumours 
↓ACFs in female mice on 2.5% diet only.  
Petrick 
2000a (241) 
Apc
Min/+
 77 3.1% EPA vs. 3.1% 
DHA vs. Ctrl 
 
7 wk 
 
Tumour size + no.  
Mucosal PUFA + PGE2  
 
30%/50%↓ tumour no. DHA/EPA grp vs Ctrl  
15%↓tumour size EPA/DHA grp vs Ctrl 
50%↓ PGE2 in EPA/DHA grp vs Ctrl 
Petrick 
2000b (236) 
Apc
Min/+
 20 1.5% EPA  vs.1.5% AA 
vs. Ctrl 
8 wk 
 
 
Tumour size + no.  
Mucosal PUFA + PGE2  
 
54-68%↓ tumour no. & 18%↓ tumour size 
EPA vs. Ctrl & AA grps.  
74%↓ mucosal PGE2 EPA vs AA grp 
Bose 2007 
(244) 
Apc
Min/+ 
95 12% MO4 vs.  
20% mixed lipid diet 
9 wk 
 
Tumour no. + size 
Tumour PI, AI, PGE2, β-catenin 
    tumour no, 50%↓ no. tumours >2cm  
3.7x↑AI,    PI, 89%↓ PGE2, 62%↓β-catenin 
Fini 2010 
(247) 
Apc
Min/+
 48 2.5% & 5% EPA vs. 
Ctrl 
12wk Mucosal PUFA + COX-2 
Polyp no. + size, body weight 
72%/79%↓ polyp size (2.5%/5% EPA grp)  
↓COX-2 & ↑ EPA in EPA grps,  
↓weight Ctrl grp 
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1.10.2 Epidemiological observations 
A link between dietary ω-3:ω-6 PUFA balance and CRC risk first emerged from 
epidemiological studies that observed reduced rates of CRC in Greenland and the 
Far East compared to Western populations.(248)  Whilst the results of 
epidemiological studies have been variable, they have tended, in general, to report 
a small reduction in CRC risk with increasing dietary fish intake, a view supported in 
2007 by The Second Expert Report into Food, Nutrition and the Prevention of 
Cancer, a meta-analysis by the World Cancer Research Fund (WCRF) and the 
American Institute for Cancer Research (AICR).(6)  Interpretation of epidemiological 
studies has been hampered by heterogeneity in study design.  The use of food 
questionnaires to record dietary intake is subjective, and does not always 
discriminate between oily fish such as sardines (high in ω-3 PUFAs) and lean fish 
such as cod (lower ω-3 PUFA content).  Moreover, studies do not always 
discriminate between processed (smoked or salted) and non-processed fish, or the 
cooking method, which may confound observational data on CRC risk.(6, 249)  
Meta-analyses have also been hampered by the wide variability in both the 
frequency of fish intake and the choice of reporting measures (e.g. grams/day, 
portions/week, ω-3 PUFA g/day).(250)   
Since the WCRF/AICR meta-analysis in 2007,(6) a prospective study of 53,988 
patients found no association between fish consumption and CRC risk, but did find 
a risk reduction with increased fish consumption in patients who also had low fibre 
consumption (OR 0.77).(251)  A systematic review of studies published since 2007 
found a risk reduction for CRC between the highest and lowest fish consuming 
groups in all three case control studies identified (total n=6357 patients, OR 0.58-
0.74) but mixed results in 6 prospective studies identified.(252)  Finally, a meta-
analysis of 41 studies published between 1990 and 2011 (total n=1,454,578 
patients) found a significant reduction in CRC risk between the highest and lowest 
fish consumption groups in 19 case control studies (OR 0.83) and a slight reduction 
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in CRC risk between the highest and lowest fish consumption groups in 21 
prospective cohort studies (OR 0.93).(253)  The results of these more recent 
studies therefore continue to suggest a possible beneficial effect of ω-3 PUFA 
consumption, but the conflicting results and significant heterogeneity between the 
studies makes it difficult to draw any firm conclusions. 
1.10.3 Translational studies of ω-3 PUFAs and CRC biomarkers. 
The long natural history of colorectal carcinogenesis in humans precludes the use 
of CRC incidence as a primary endpoint in clinical intervention studies.  Therefore 
many Investigators have measured the effect of ω-3 PUFA administration on 
putative mucosal biomarkers of future CRC risk, such as epithelial cell mitosis 
frequency in micro-dissected whole crypts or immunohistochemistry (IHC) for the 
Ki-67 ‘proliferation’ antigen.  The design of such studies and their main findings are 
summarised in Table 1.6.  8 studies of oral ω-3 PUFA supplementation in patients 
with previous ‘sporadic’ colorectal adenomas were identified (Table 1.6), in which 
colorectal mucosal biopsies were obtained at endoscopy before and after ω-3 
PUFA supplementation.  In 6 of 8 studies a 13-70% reduction in mucosal epithelial 
cell proliferation index (PI) was observed compared to the respective placebo 
group.(232, 254-258)  One further study noted a more modest 16% reduction in PI 
after 28 days supplementation in healthy volunteers.(259)  By contrast, two studies 
demonstrated no change in PI following administration of 2.4 g ω-3 PUFA daily for 
12 weeks (260) or low-dose ω-3 PUFA (400 mg DHA + 100 mg EPA/day) for 1-2 
years.(261) The latter study did demonstrate a 50% increase in apoptosis index (AI) 
and increased expression of the pro-apoptotic protein BAX.  AI has been measured 
in only two other studies, which demonstrated a significant increase in AI after 3-6 
months treatment with EPA 2g daily.(232, 257)  In those studies measuring 
mucosal PUFA content, significant increases in mucosal DHA and EPA, together 
with a reduction in mucosal AA, were observed in all but one study (Table 1.6). 
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The development of colonic adenomas (polyps) is an alternative to mucosal 
biomarker studies as a surrogate for CRC risk.  Such polyp prevention studies 
typically require a 3-5 yr intervention and follow-up period.  However, patients with 
FAP have a heterozygous germline mutation in the APC gene.  These patients 
develop multiple colorectal adenomas at a young age and prophylactic colectomy is 
advised in order to prevent CRC.  Those who undergo total colectomy with 
ileorectal anastomosis rather than panproctocolectomy (total colectomy + removal 
of rectum) require regular endoscopic surveillance of the remaining rectum which 
remains at risk of developing polyps.  Studies of potential chemopreventative 
agents in these patients allow polyp size and number to be used as endpoints over 
a much shorter  period of time (6-12 months).  A recent Phase III randomised, 
double-blind, placebo-controlled trial investigated treatment with EPA in the free 
fatty acid form (EPA-FFA) 2g daily for 6 months in patients (n=58) with FAP who 
had previously undergone colectomy and ileorectal anastomosis (Table 1.6).(262)  
Rectal polyp multiplicity and size were measured by blinded video-endoscopic 
assessment of a tattooed area at baseline and at 6 months.  There was a 22.4% 
reduction in polyp number in the EPA group compared with placebo (p=0.01), a 
similar magnitude reduction to that seen with the selective COX-2 inhibitor 
celecoxib.(131)  In keeping with previous studies, a significant increase in mucosal 
EPA levels was observed.  The demonstration of chemopreventative efficacy of 
EPA-FFA in FAP patients has led to funding of a randomised, placebo-controlled 
trial of EPA-FFA in patients who have had “sporadic” colorectal adenomas removed 
and who require further colonoscopic surveillance 
(www.eme.ac.uk/projectfiles/0910025info.pdf).   
Only one other polyp prevention study was identified (Table 1.6).(263)  In this small 
study, 5 patients who had previously undergone colectomy for FAP were given 2.2g 
DHA + 0.6 g EPA daily for 1-2 years.(263)  No significant change in polyp number 
was observed.  One patient developed proximal CRC, a second patient developed 
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lung cancer and a third patient developed endometrial cancer prior to termination of 
the study.  The published report does not make it clear whether this study was 
terminated prematurely and gives no indication of the planned sample size for the 
trial.  
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Study Design N= ω-3 PUFA dose Treatment 
Duration 
Primary 
outcome  
Tissue PUFA content Side effects (at highest 
given dose) 
Results 
Mucosal biomarker studies 
Anti 1992 
(255) 
R, DB, PC 
‘sporadic’ adenoma 
24 7.7g FO1 daily  12 wk PI  ↑EPA & ↓AA Not reported. No 
dropouts in FO grp.   
62% ↓PI  
Bartoli 1993 
(256) 
R, DB, PC 
‘sporadic’ adenoma 
40 2.5-7.7g  FO1 daily  30 days PI Dose dependent 
↑EPA/DHA & ↓AA 
Not reported. Dose dependent 
40-70%↓ PI 
Bartram 
1993 (259) 
DB crossover trial 
Healthy volunteer 
12 4.4g FO2 daily  4wk +4 wk PI ω-3 PUFA    
ω-6 PUFA↓( NS) 
Mild fish odour (9/12) 16%↓ PI & 35%↓ 
mucosal PGE2  
Anti 1994 
(254) 
R, DB, PC  
‘sporadic’ adenoma 
60 2.5-7.7g FO1 daily 30 days PI Dose dependent 
↑EPA/DHA & ↓AA 
2/15 dropout, 5/15 fish 
odour, 1/7 diarrhoea 
Dose independent  
50-70%↓PI  
Huang 1996 
(258) 
R, DB, PC 
Dukes A/B CRC or 
severely dysplastic polyp 
27 7.2g FO3 daily  6 months PI ↑EPA/DHA & ↓AA No SEs observed 71%↓PI (only in 
patients with high 
baseline PI)   
Gee 1999 
(260) 
R, PC, single blind 
Awaiting CRC surgery  
51 2.4g FO4 daily 7-21 days pre- 
and 8-12 wk 
post- surgery 
PI ↑EPA/DHA 
↑  ω-3 : ω-6 ratio 
1 dropout due to 
capsule intolerance 
(grp not stated) 
No effect on PI at 
surgery or 12wk 
post-op 
Cheng 2003 
(261) 
R, C, open label 
Previous CRC/adenoma 
41 Dietary advice +- 
500mg FO5 daily  
2 years PI/AI Not assessed Not reported PI↔, 50%↑AI, 
50%↑ Bax,  
COX2 ↔ 
Courtney 
2007 
(264) 
R, single blind 
‘sporadic’ adenoma 
30 EPA 2g daily as free 
fatty acid 
3 months PI/AI ↑EPA/DHA & ↓AA 1/15 dropout each grp   
3/15 mild diarrhoea + 
2/15 abdo pain 
20%↓PI 
7x↑ AI 
West 2009 
(232) 
R, DB, PC 
‘sporadic’ adenoma 
152 EPA 1g/2g daily as 
free fatty acid 
6 months PI/AI ↑EPA/DHA & ↓AA Not reported 13%↓PI 
57%↑ AI (NS) 
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Table 1.6.  Clinical studies of ω-3 PUFA treatment on colorectal mucosa biomarkers and polyp number  
 
Abbreviations:  ↑ = increase, ↓= decrease, ↔ = no change, abdo = abdominal, AI = apoptosis index, Ca = cancer, C= controlled, DB = double blind, FAP = 
familial adenomatous polyposis, FO= fish oil (FO1 = 54%EPA/46% DHA as ethyl esters; FO2 = 48%EPA/44%DHA, as triglycerides; FO3 = 
55%EPA/30%DHA/15% other ω-3 PUFAs; FO4=58% EPA/42%DHA; FO5 = 20%EPA/80%DHA; FO6 = 21%EPA/79%DHA), grp = group,    mo = month, NS = not 
statistically significant, PC = placebo controlled, PI = proliferation index,R = randomized, SE = side effects, wk = weeks 
Study Design N= ω-3 PUFA dose Treatment 
Duration 
Primary 
outcome  
Tissue PUFA content Side effects (at highest 
given dose) 
Results 
Polyp endpoint studies 
Akedo 1998 
(263) 
Open label 
FAP 
5 Dietary advice & 
2.8g FO6 daily 
1-2 years 
?trial stopped 
early 
Polyp no. 
 
 
Not assessed 1x diarrhoea 
1x itching 
1x hypermenorrhoea 
Polyp no. ↔ 
1 x CRC, 1x lung Ca 
1x endometrial Ca 
West 2010 
(262) 
R, DB, PC 
FAP 
58 EPA 2g as free fatty 
acid 
6 months No. rectal 
polyps 
↑EPA 
DHA & AA   
↑nausea EPA grp (31% 
vs 10%).  Other SEs ↔  
22%↓ polyp no.  
30%↓ polyp size 
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1.11 Summary and context for the thesis 
Recent advances in neoadjuvant chemotherapy and the surgical management of 
CRCLM have successfully increased the number of patients suitable for potentially 
curative surgery.  However, we may now be at the limit of our definition of 
resectable disease and advances in adjuvant chemotherapeutic agents such as the 
new monoclonal antibody therapies have demonstrated only very modest survival 
advantages in patients with CRCLM.  At the same time, the use of COX-2 inhibitors 
and other NSAIDs for the chemoprevention of CRC has been limited by the 
recognition of cardiovascular and gastrointestinal side effects associated with long 
term use (although the balance of risk-benefit may favour the use of aspirin for 
prevention of CRC).(142)  There is therefore an urgent need for novel, safe agents 
for the prevention and treatment of CRC and CRCLM.  Accumulating experimental 
evidence suggests that ω-3 PUFAs such as EPA have anti-CRC activity, and 
clinical trial data for ω-3 PUFAs has recently been published from mucosal 
biomarker and polyp prevention studies.  This thesis presents the first clinical trial of 
oral EPA supplementation for the treatment of patients with CRCLM, together with 
supplementary in vitro studies of the effect of EPA on angiogenesis.      
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Chapter 2: Aims and hypotheses to be tested 
 
The primary aim of this research is to investigate the effect of EPA on biomarkers of 
growth and vascularity of human CRCLM in a Phase II randomised, double-blind, 
placebo-controlled trial of EPA in patients awaiting surgery for CRCLM.  The 
following specific hypotheses will be tested. 
Treatment with EPA: 
1. Is safe and well tolerated in patients with CRCLM 
2. Does not inhibit platelet aggregation, and does not cause an increased risk 
of bleeding during liver resection or other post-operative complications 
3. Is associated with reduced tumour cell proliferation compared with placebo 
4. Is associated with increased tumour cell apoptosis compared with placebo 
5. Is associated with reduced tumour microvessel density compared with 
placebo 
6. Leads to an increase in tumour EPA content  
7. Is associated with a reduction in intra-tumoural PGE2 and an increase in 
PGE3 levels  
8. Is associated with a reduction in urinary PGE-M levels 
9. Causes a reduction in active transcription factor NFκB levels in peripheral 
blood mononuclear cells 
A secondary aim of this research is to investigate the effect of EPA on human 
endothelial cells in vitro.  The following specific hypotheses will be tested: 
10. EPA inhibits angiogenesis in vitro 
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Chapter 3: The EMT Trial 
 
3.1 Introduction 
The EPA for Metastasis Treatment (EMT Trial) was a Phase II randomised, 
placebo-controlled, double-blind trial of the safety and efficacy of EPA 2g daily in 
patients awaiting surgery for CRCLM.  It was the first clinical trial of the anti-
neoplastic activity of an oral ω-3 PUFA in patients with CRCLM.  The EMT Trial 
was sponsored by The University of Leeds, and was a collaboration between The 
University of Leeds and the Leeds Teaching Hospitals NHS Trust Department of 
Hepatobiliary Surgery, based at St James’ University Hospital, Leeds, UK.  The 
Trial was been adopted onto the National Institute of Health Research Clinical 
Research Network Portfolio. 
(http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=8946).  
 
3.2 Regulatory approvals 
The EMT Trial was granted regulatory approval from the NHS Research Ethics 
Committee (REC), the Medicines and Healthcare related products Regulatory 
Authority (MHRA) and the Leeds Teaching Hospitals NHS Trust Research and 
Development (R&D) office.  These approvals were all obtained prior to 
commencement of trial recruitment (Table 3.1).  The trial was registered on 
clincialtrials.gov, a publically accessible database of clinical trials, prior to 
commencing recruitment.  
(http://clinicaltrials.gov/ct2/show/NCT01070355?term=EPA&rank=12). 
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 Reference number Approval date 
EUDRACT no. 2009-015903-22 07/09/2009 
Leeds (West) 
Research Ethics 
Committee 
09/H1307/94 20/10/2009 
MHRA 16767/0240/001-0001 15/12/2009 
Leeds NHS Trust 
R&D 
GA09/9094 09/02/2010 
Clinicaltrials.gov  NCT01070355 12/02/2010 
 
Table 3.1.  A summary of the regulatory approvals for The EMT Trial 
 
3.3 Trial Steering Committee  
An internal Trial Steering Committee (TSC) met quarterly to review trial progress, 
and received input from an external Data Monitor on a quarterly basis. The TSC 
included: 
Prof Chris Twelves  Independent Chair (Academic Clinical Oncologist) 
Prof Mark Hull   Professor of Molecular Gastroenterology 
Mr Giles Toogood  Consultant Hepatobiliary & Transplant Surgeon 
Mr Andrew Cockbain  Research Fellow 
Mr Richard Maltby  Patient Representative 
 
3.4 Data Monitoring Committee 
The Trial was subject to review from the University of Leeds and Leeds Teaching 
Hospitals NHS Trust joint Data Monitoring Committee.    
There have been some concerns about an anti-platelet activity and possible 
increased risk of bleeding with ω-3 PUFA consumption,(265-267) however, no 
significant bleeding episodes have been seen in over 4000 clinical trial patients 
undergoing invasive interventions or operations whilst taking ω-3 fish oil 
51 
 
 
supplementation alone or in combination with aspirin.(268)  Similarly, other clinical 
trials have shown that ω-3 PUFAs are safe even when given with conventional anti-
platelet or anticoagulant treatments.(269)  Nevertheless, in this first trial of an oral 
ω-3 PUFA supplement in patients undergoing liver resection, the potential for a 
small risk of increased bleeding during surgery could not be excluded.  Therefore, 
patient bleeding complications were proactively and prospectively recorded on a 
Peri-operative Outcome Form (POF), namely the number of units of blood 
components transfused and whether the patient required reoperation for bleeding. 
An independent Data Monitor, who was unblinded to patient allocation, reviewed 
POFs every 3 months and was asked specifically to feed back to the TSC if the 
number of "significant bleeding events" (defined as a packed red blood cell 
transfusion greater than 2 units or reoperation for bleeding) in the EPA group 
exceeded that in the placebo group by 5 at any time, so that the TSC could 
consider stopping the Trial. 
 
3.5 Trial Subject Selection 
3.5.1 Eligibility Criteria 
Patients undergoing liver resection for treatment of CRC liver metastasis(es) 
 
Inclusion Criteria 
(a) Age greater than or equal to 18 years 
(b) Either sex 
(c) Liver resection deemed clinically appropriate for management of metastatic 
CRC liver disease 
(d) Duration between decision to perform liver resection and surgery expected to be 
greater than 2 weeks 
(e) Ability to give written informed consent and follow study protocol 
(f)  Telephone contact possible 
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Exclusion Criteria 
(a)  Neo-adjuvant chemotherapy for CRC liver metastasis 
(b)  Chemotherapy for any cancer in the previous 3 months 
(c)  Known bleeding diathesis or anticoagulation therapy 
(d)  Fish or seafood allergy 
(e)  Use of fish oil supplements (e.g. cod liver oil) and unwilling to stop for         
the duration of the study 
(f)  Pregnancy 
(g)  Use of non-aspirin non-steroidal anti-inflammatories (NSAIDs) or use of   
systemic steroids (i.e. oral or intravenous preparations) 
(h)  Renal impairment (serum creatinine >150µg/l) 
(i)   Active inflammatory disease (e.g. inflammatory bowel disease, rheumatoid 
arthritis) 
 
3.5.2 Recruitment 
Patients with suspected or confirmed CRCLM are referred to the Department of 
Hepatobiliary Surgery at St James's University Hospital by General Practitioners, 
Oncologists and Colorectal Consultants from across the Yorkshire region.  A 
number of patients are also referred to the Department from outside the region.   All 
referral letters were screened prior to each clinic to identify patients who may be 
eligible for participation in The EMT Trial.  Patients were seen in the surgical 
outpatient clinic by a Consultant Hepatobiliary Surgeon, and a decision made 
whether surgical resection of their CRCLM was appropriate.  At the same clinic 
appointment, all patients who were offered liver resection were then approached to 
discuss participation in the EMT Trial, unless pre-screening of their referral letter 
clearly identified that they meet one or more of the trial exclusion criteria.  Patients 
were given a verbal explanation of the trial and a copy of the Patient Information 
Leaflet.  This included detailed information about the rationale, design and personal 
implications of the study.   
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3.5.3  Consent 
Patients referred to the Hepatobiliary department at St James’ University Hospital 
have often travelled considerable distance to attend their outpatient clinic, 
sometimes taking 2-3hrs each way.  It was decided that it would be both impractical 
and an undue burden on the patient to discuss the study on one visit and then 
return the following day after a cooling off period for a second appointment to sign 
the consent form (they would not routinely have a second appointment before being 
admitted a few weeks later for surgery).  A pragmatic approach was therefore 
adopted.  After approaching patients and discussing participation in the Trial, 
patients were given a period of time (at least 1 hour) to read the patient information 
sheet and consider participation.  Since these patients usually attend outpatient 
clinics with their family members, this gave patients the opportunity to discuss the 
trial with their family.  After 1 hour, or when patients returned to the outpatient 
department, they were asked if they had had enough time to consider the 
information provided and address any further questions.  Only if patients were sure 
that they have had been given sufficient time to consider participation, and had the 
opportunity to discuss with their family members if desired, were they asked if they 
were willing to take part in the trial.  This process was clearly documented in the 
patients' medical notes. 
Patients who wished to participate in the Trial were then formally assessed for 
eligibility and invited to provide informed, written consent.  The right of patients to 
refuse consent without giving reasons was explained and respected.  Patients were 
informed that they could also withdraw from the study at any time without giving 
reasons and without prejudicing any further treatment. One copy of the consent was 
given to the patient, a second filed in the Trial Master File, a third filed in the 
hospital notes and a fourth sent to the Sponsor.  The consenting process was 
clearly documented in the patient’s medical notes.  
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3.6 Randomisation and blinding 
Consented patients were randomised 1:1 EPA-FFA:placebo by Leeds Teaching 
Hospitals Trust Pharmacy in a random permutated block of 4 using random number 
tables.  The blind was held by Leeds Teaching Hospitals NHS Trust Pharmacy.  
Unblinding only occurred after all patients have completed follow up, and all 
collected samples had been analysed.  Unblinding before the end of the study was 
only permitted if deemed necessary by the Chief Investigator and the Sponsor in 
the event of a patient safety issue.  This situation did not arise. 
    
3.7 Trial Medication 
EPA-FFA and placebo were manufactured in Germany on behalf of SLA Pharma 
(UK).   SLA Pharma (UK) supplied EPA and placebo free of charge for The EMT 
Trial.  EPA was presented as an enteric-coated soft blue gelatin capsule containing 
500mg of 99% pure EPA in the free fatty acid form.  Placebo capsules were 
identical in form, except for the replacement of EPA with the medium chain 
triglycerides capric and caprylic acid.  These were the same preparations used in 
the Phase III polyp prevention study in patients with FAP.(262)  EPA is unlicensed 
for the treatment of CRCLM.  It was therefore considered an Investigative Medicinal 
Product (IMP) for the purpose of this trial, and approval for use in this trial was 
obtained from the MHRA.  Supplies of EPA and placebo were repackaged, labelled, 
stored and dispensed by Leeds Teaching Hospitals NHS Trust Clinical Trials 
Pharmacy in accordance with Good Clinical Practice (GCP).     
 
3.8 Trial design and patient throughput 
The trial design is outlined in Figure 3.1 and patient flow through the trial is 
described below.   
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Study visit 1 (routine out-patient appointment) 
Immediately after a decision was made to offer surgery for CRCLM, patients were 
seen for trial screening and enrolment.  Randomisation occurred immediately after 
consent had been obtained.  Blood and urine samples were taken, and participants 
asked to complete the EPIC food frequency questionnaire (FFQ; Appendix 1) in 
order to determine dietary ω-3 PUFA intake.(270)  Participants received study 
medication at the same visit.  Patients took EPA 2g, or placebo, daily (as two 
capsules twice daily with food) until the day before surgery (2-4 weeks).  Patients 
were followed up by telephone every 2 weeks to monitor for adverse effects and 
maximise compliance.  
Study visit 2 (admission for surgery) 
Patients were admitted to hospital either the day before or on the day of their 
operation and asked again about symptoms or side effects from medication.  Blood 
and urine sampling were repeated, and the FFQ repeated to determine whether 
there had been any change in dietary ω-3 PUFA intake during the intervention 
period.  Patients were asked to return all study medication for pill counting.  CRCLM 
tissue was collected from the resected liver specimen immediately after resection.  
Patients were then managed according to Leeds Hepatobiliary Unit protocol during 
the post-operative phase.   
Study visit 3 (routine post-operative out-patient appointment) 
At the first routine post-operative outpatient appointment, approximately 6 weeks 
following discharge, a final blood and urine sample were taken.  This marked the 
end of participation in the Trial.  Patients then continued routine follow-up under the 
care of their Consultant Surgeon. 
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6 weeks 
2-4 weeks 
Inclusion Criteria 
 
 Age ≥18 years 
 Either sex 
 Duration between decision 
to perform liver resection 
and surgery greater than 2 
weeks  
 Ability to give written 
informed consent and 
follow study protocol  
 Telephone contact 
possible 
 
Exclusion Criteria  
 Chemotherapy for any cancer 
in the previous 3 months 
 Unwilling to stop use of fish oil 
supplements for duration of 
the study  
 Known bleeding diathesis or 
anticoagulation therapy 
 Fish or seafood allergy 
 Pregnancy  
 Non-aspirin non-steroidal anti-
inflammatory (NSAID) use  
 Active inflammatory disease  
 Neo-adjuvant chemotherapy 
for CRCLM 
 Renal impairment (serum 
creatinine >150) 
STUDY FLOW 
CHART 
Interventions 
performed on each 
study day are listed in 
BLOCK CAPITALS below 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY DAY 1 
Preoperative outpatient 
appointment 
BLOOD, URINE 
FOOD FREQUENCY 
QUESTIONNAIRE 
 
 
 
STUDY DAY 2 
Admission for surgery 
BLOOD, URINE 
FOOD FREQUENCY 
QUESTIONNAIRE 
 
 
Day of operation 
TISSUE SAMPLING OF 
RESECTED CANCER 
 
 
 
 
 
STUDY DAY 3 
1
st
 postoperative 
outpatient appointment 
BLOOD, URINE 
DECISION TO PERFORM LIVER RESECTION FOR CRCLM 
Study Information Provided 
 
  
Consent & Randomisation 
 
 
 
 
PLACEBO EPA 
Postoperative Recovery + Discharge 
 
Admission for surgery 
OPERATION 
Review in outpatient clinic 
END OF STUDY PARTICIPATION 
Figure 3.1. Flow chart of patient participation in The EMT Trial 
 
If eligible 
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3.9 Power calculation and sample size  
There are no existing data on the effects of EPA on tumour cell proliferation in 
human CRCLM.  In a previous double-blind RCT of CRCLM patients (271), the Ki-
67 proliferation index (PI) in the placebo arm was 50 (mean) ± 22 (SD).  From in 
vitro and in vivo studies of the effect of EPA on CRC cells, a 30% decrease in PI 
compared with placebo was predicted.(186, 199)  Therefore a minimum of 35 
patients in each of the 2 arms of the study (total 70 patients) was required to detect 
a 30% difference in PI between the groups with 80% power and a 5% 2-sided 
significance level.  To allow for 20% drop out, a target recruitment of 44 patients in 
each arm (total 88 patients) was set. 
The Leeds Hepatobiliary Unit performs approximately 200 liver resections for 
metastatic CRC per year, of which up to 20% receive neo-adjuvant chemotherapy 
(an exclusion criterion).  Allowing for up to 45% ineligibility in the remaining 160 
patients (either do not fulfil inclusion criteria or do not provide informed consent to 
enter the trial), recruitment of 88 eligible patients was predicted to take 1 calendar 
year.  The recruitment rate was monitored monthly. 
 
3.10 Design issues 
Being unable to standardize the duration of study medication was an unavoidable 
consequence of ensuring that study participation did not delay patients’ surgery.  
However, Leeds Hepatobiliary Unit data (unpublished) showed that the median time 
from decision to operate to surgery was 4 weeks and, importantly, the maximal 
increase in tissue and erythrocyte EPA content associated with oral EPA intake has 
been shown to occur over a similar time period.(272, 273)  A variable pre-surgery 
treatment period was also a feature of the previous RCT of rofecoxib (271) when 
randomisation ensured well-balanced active and placebo groups.  The variability in 
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treatment period was therefore considered to be an acceptable limitation in study 
design. 
A second limitation of the study design is that there was no baseline (pre-treatment) 
tumour available for comparison with the post-treatment tumour samples.  This is 
because pre-operative biopsy of CRCLMs is contra-indicated due to the risk of 
seeding tumour cells along the biopsy tract.(274, 275)  Suspected CRCLMs are 
diagnosed radiologically and patients proceed to surgery based on this radiological 
diagnosis.  Biopsy is reserved only for the small proportion of liver lesions which are 
of uncertain radiological diagnosis or of unknown origin, where tissue diagnosis 
may alter a patient’s management.  To obtain pre-treatment tumour samples in this 
trial would have been contrary to the accepted management of CRCLM, and 
unethical due to the risk of tumour seeding.  The lack of pre-treatment tumour 
samples was therefore considered to be an unavoidable but acceptable limitation in 
study design.               
 
3.11 Statistical analysis 
For continuous variables, the difference in means (or medians where appropriate) 
between the EPA and placebo were compared, and significance tested by 
parametric (such as Student’s t test) and non-parametric tests (such as the Mann-
Whitney U test and Wilcoxon rank sum test).  For outcomes that were measured 
serially, e.g. PGE-M, changes within a treatment group over time were compared 
using paired statistical tests, and differences between the two treatment groups at 
each time point were compared using unpaired statistical tests.  Categorical data 
was compared using the χ2 test.  Due to the limitation of being unable to sample 
tumours at baseline, no comparison of tumour tissue pre- and post- treatment could 
be made.  The effect of EPA on tumour tissue parameters was therefore evaluated 
by comparison of the EPA and placebo groups post-treatment only.  In addition, the 
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effect of variability in the duration of treatment on each outcome measure was 
investigated using linear regression.  Statistically significance was set at p<0.05 for 
all comparisons.   
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Chapter 4: Laboratory Methods 
 
4.1 Sample collection and storage 
4.1.1 Blood sampling 
All patients were consented at recruitment into the trial for blood sampling on each 
of the three trial visits.  On each occasion, venepuncture was performed aseptically 
using a 21G needle and vacuette® device.  Venous blood was collected into the 
following sample tubes, and stored at either room temperature or 4oC on crushed 
ice until further processing within 3 hrs: 
 2x 4ml EDTA coated vacuette® collection tubes (Greiner Bio-One, 
Kremsmunster, Austria) for separation of plasma and red cells.  Stored on 
crushed ice.  
 1x Hirudin (25µg/ml) coated collection tube (Dynabyte, Munich, Germany) 
for platelet aggregation.  Stored at room temperature. 
 4x 8ml BD Vacutainer® CPT™ collection tubes (BD, New Jersey, USA) for 
isolation of peripheral blood mononuclear cells.  Stored at room 
temperature. 
Separation of plasma and red cells:  EDTA collection tubes were centrifuged at 
700 x g for 10mins at 4 oC within 3 hours of venepuncture. A plastic Pasteur pipette 
was used to remove the plasma layer which was aliquoted into cryogenic vials.  The 
buffy coat was discarded and the red blood cells aliquoted into cryogenic vials.  
Samples were stored at -80oC for future analysis of i) fatty acid content of red cell 
membranes by gas chromatography – mass spectrometry (GC-MS) and ii) plasma 
PGE2 and PGE3 levels by liquid chromatography – tandem mass spectrometry (LC-
MS/MS).  These analyses have not been performed due to time and funding 
constraints.  Samples remain stored for possible analysis at a later date. 
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4.1.2 Urine sampling 
Patients were asked to provide a fresh urine sample in a sterile 30ml universal 
container at each study visit.  Specimens were stored at 4oC on crushed ice prior to 
aliquoting into cryogenic vials and storage at -80oC for subsequent batch analysis 
of urinary PGE-M by LC-MS/MS.  
4.1.3 Tumour sampling 
Immediately after resection of the specimen containing the CRCLM, the specimen 
was passed out of the sterile surgical field and dissected with care not to disturb the 
resection margin (Figure 4.1).  The tumour was palpated and a perpendicular 
incision made through the centre of the tumour.  A wedge of tumour tissue 
incorporating normal liver margin and at least 1cm of tumour directed towards 
centre of the tumour was taken and placed in formalin (10% v/v).  The orientation of 
the excised wedge from tumour margin to tumour centre was confirmed by making 
radial incisions in the remaining tumour, radiating from the deepest extent of 
excised wedge back out to the tumour margin in at least 2 opposing directions. A 
further 6-8 x 5mm cube-shaped samples of tumour were taken from an area 5mm 
from the macroscopic tumour margin, with care not to include any normal liver, and 
placed in a universal container for storage at 4oC on crushed ice.  The remaining 
resected liver specimen was placed in formalin (10% v/v) and sent to the pathology 
department for routine histopathological assessment, as per standard NHS 
protocols. 
Tumour specimens were returned immediately to the laboratory.  Two cube shaped 
tumour samples were mounted in Cryo-M-Bed (Bright Instruments, Huntington, UK) 
on corks, snap frozen in isopentane cooled in liquid nitrogen, and stored at -80oC 
until subsequent analysis of tumour COX expression.  The remaining cube-shaped 
tumour samples were placed in individual cryogenic vials, snap frozen in liquid 
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nitrogen, and stored at -80oC until subsequent analysis of tumour prostaglandins 
and fatty acid content. 
The wedge of liver was removed from formalin after 24 hours, washed twice in 
phosphate buffered saline (PBS) and stored in 70% (v/v) ethanol before processing 
in an automated tissue processor and embedding in paraffin.  Blocks were stored at 
room temperature for future immunohistochemical analysis. 
 
 
Figure 4.1.  Tumour sampling technique.  Dotted lines indicate area of sampling.  
The tumour was palpated within the liver parenchyma, and a perpendicular incision made 
through the liver capsule and liver parenchyma into the liver tumour.  Having identified and 
incised the tumour with this first incision, the tumour was inspected and re-palpated to 
confirm that the tumour had been incised through its centre.  Additional incisions radially out 
of the tumour were made when required to confirm that the centre of the tumour had been 
incised.  (A) Having identified the centre of the tumour, a 2-3mm section orientated through 
the liver capsule, liver parenchyma and centre of the tumour was obtained for formalin 
fixation.  (B) Secondly 6-8 cubes of tissue (at least 5x5x5mm) were taken from the 
remaining tumour, at least 5mm from the tumour edge, and snap frozen in liquid nitrogen.  
 
 
 
A B 
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4.2 Platelet aggregation studies 
Overview:   
There is no consensus regarding which ex vivo platelet function assay is best suited 
to measuring platelet function,(276-278) let alone which is best suited to measuring 
the effect of ω-3 PUFAs.  Most work has been in the cardiovascular and 
anaesthetic fields looking at detection of 'aspirin resistance'.  A summary of different 
platelet aggregation assays can be found in these two reviews.(279, 280)  Whole 
blood platelet aggregation studies in this study were performed using the 
Multiplate® (Dynabyte, Munich, Germany)  whole blood platelet aggregometer.  
Whole blood is added to a test cell containing two pairs of silver coated sensor 
wires.  The addition of an agonist stimulates platelets to aggregate on the wires, 
causing an increase in electrical resistance measured across the wires (Figure 4.2). 
The change in resistance over time is a function of platelet aggregation, which 
when plotted and "aggregation" measured as the area under the curve. 
 
 
Figure 4.2  Schematic diagram of Multiplate® test cell.  Each cell contains two 
pairs of sensor wires and a stirring magnet (a).  Whole blood is added (b) and addition of 
agonist stimulates platelets (c), causing aggregation of platelets on sensor wires (d).   
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This has the advantage over the traditional gold-standard of light transmission 
aggregometry (LTA) of platelet-rich plasma in that it is less time-consuming, less 
time-sensitive, and does not require a highly-trained operator.  Multiplate® has 
been shown to be as effective as LTA in detecting aspirin- and clopidogrel- induced 
inhibition of platelet aggregation.(281)      
Similarly, there are a range of different agonists which can be used to stimulate 
platelet aggregation in both LTA and whole blood platelet aggregation assays.  AA 
is typically used as the agonist when testing for the anti-platelet effect of aspirin.  
Acetylated COX does not metabolise AA to thromboxane A2 and therefore platelet 
aggregation is reduced.  Other commonly used agonists are adenosine 
diphosphate (ADP) and collagen.  ADP binds to the P2RY12 cell surface receptor, 
a G-protein coupled receptor which activates the glycoproteinIIb/IIIa complex and 
induces platelet binding to fibrinogen which is the major cofactor in platelet 
aggregation.  Collagen stimulates platelet aggregation upstream of AA metabolism 
by COX, this being the first step in platelet activation in vivo when a platelet 
adheres to exposed subendothelial collagen after vessel wall injury.  Amongst other 
effects, this results in liberation of AA from the cell membrane by phospholipase A2 
and also stimulates the release of platelet endogenous ADP.  A more 
comprehensive discussion of the different agonists can be found in these two 
reviews.(282, 283)  In the absence of consensus on the precise mechanism by 
which EPA might inhibit platelet aggregation, or on the optimal agonist for detecting 
platelet inhibition by EPA, in this study Multiplate® whole blood platelet aggregation 
in response to AA, ADP, low dose collagen and high dose collagen was 
investigated. 
Method:  0.3ml 0.9% saline + 0.3ml hirudin-anticoagulated whole blood were 
added to each of four test cells and left to incubate for 3 minutes at 37oC with a 
PTFE coated stirring magnet.  20µl of each agonist (arachidonic acid 0.5mM, 
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adenosine diphosphate 6.5µM, collagen 3.2µg/ml, or collagen 0.64µg/ml) was 
added to respective test cells, and the electrical resistance across duplicate pairs of 
silver coated sensor wires was continuously measured for 6 minutes.  Resistance is 
automatically transformed into arbitrary “aggregation units” and a plot of 
aggregation over time was generated, with maximal resistance, velocity and area 
under the curve recorded. 
 
4.3 Peripheral blood mononuclear cell studies 
Overview:  Peripheral blood mononuclear cells (PBMCs) were isolated from whole 
blood and cultured for 24 hours with and without lipopolysaccharide (LPS) 
stimulation.  Cell conditioned media was collected and frozen for future analysis of 
PGE2/PGE3 content.  PBMCs were then either frozen for future COX RNA analysis, 
or further processed to obtain nuclear extract which was then frozen for subsequent 
batch analysis of nuclear NFκB activation.   
4.3.1 PBMC culture 
Blood collected in CPT™ tubes at each study visit was centrifuged within 3 hours of 
venepuncture at 1500 x g for 20mins to give a layer of mononuclear cells (Figure 
4.3).  The mononuclear cell layers were aspirated into two falcon tubes, washed 
with 15mls of Dulbecco’s phosphate buffered saline (DPBS) and centrifuged at 300 
x g for 15 mins.  The wash step was repeated.  The cells from each tube were re-
suspended in 6 mls GlutaMAX + 10 % foetal calf serum (FCS) with or without 
1µg/ml Escherichia coli serotype 026:B6 LPS (Sigma-Aldrich, MO, USA) 
respectively.  After re-suspension in culture medium, a 20µl sample of LPS-
stimulated and LPS unstimulated cells was taken, diluted 1:10 in DPBS and cells 
counted using a Neubauer chamber. The remaining cells were transferred to a 6 
well culture plate (Figure 4.4) and incubated for 24hrs at 37oC.  
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Figure 4.3.  Separation of mononuclear cells after centrifugation of CPT™ tubes 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.  Layout of 6 well plate for culture of PBMCs.  Following 24 hour culture, 
cells from wells 3 and 6 were harvested and frozen for future COX RNA analysis.  Cells 
from wells 1,2,4 and 5 were processed further to obtain nuclear extract for the measurement 
of nuclear NFκB activation.     
 
 
‘+’ i.e. LPS 
stimulated 
‘-‘ i.e.  LPS 
unstimulated 
1 2 
4 6 5 
3 
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Culture medium from each well was aspirated into four 15µl falcon tubes as 
described below: 
 i) Wells 1+2 : LPS stimulated for NFκB nuclear expression 
 ii) Well 3 : LPS stimulated for COX RNA expression 
 iii) Wells 4+5 : LPS unstimulated for NFκB nuclear expression 
 iv) Well 6 : LPS unstimulated for COX RNA expression 
Tubes were centrifuged at 300 x g at 4oC for 10mins, and the culture medium 
aliquoted into cryogenic vials and stored at -80oC until subsequent analysis of 
culture medium PGE2 and PGE3 content by LC-MS/MS.  Cell pellets were left in the 
respective falcon tubes. 
4.3.2 Harvest of PBMCs for COX expression analysis 
Wells 3 and 6 were washed with 7mls DPBS, cells gently scraped using a cell 
scraper, and the cells aspirated back into their respective falcon tubes and 
centrifuged at 300 x g at 4oC for 10mins.  The supernatant was discarded and cells 
re-suspended in 1ml DPBS, transferred to a microcentrifuge tube and centrifuged at 
300 x g at 4oC for 5mins.  The supernatant was discarded, cells re-suspended in 
1ml TRIzol® (Invitrogen, Life Technologies, CA, USA) and stored at -80oC.  
Analysis of COX RNA expression by real-time polymerase chain reaction (RT-PCR) 
was not performed due to time and funding constraints.  Samples remain stored for 
analysis at a later date. 
4.3.3 Isolation of PBMC nuclear extract 
PBMC nuclear extract was obtained using the Active Motif Nuclear Extract Kit 
(Active Motif, CA, USA).  Wells 1,2,4 and 5 were washed with 7mls of phosphate 
buffered saline - phosphatase inhibitor solution (PBS-PI), cells gently scraped using 
a cell scraper, and aspirated back into their respective falcon tubes.  Addition of 
phosphatase inhibitor protects proteins from dephosphorylation.  Tubes were 
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centrifuged at 300 x g at 4oC for 10mins, the supernatant discarded, and cells re-
suspended in 1ml PBS-PI.  Cells were transferred to microcentrifuge tubes and 
centrifuged at 300g at 4oC for 5mins.  The supernatant was discarded and cells re-
suspended in 1ml hypotonic buffer solution and incubated on ice for 15mins.  
Hypotonic buffer causes cell swelling, making the cell membrane more fragile. 
50μl detergent was added to each microcentrifuge tube and vortexed gently.  
Detergent causes leakage of cytoplasmic proteins into the supernatant.  Tubes 
were centrifuged at 14,000 x g at 4oC for 30secs, and the supernatant (cytoplasmic 
fraction) aspirated and stored in cryogenic vials at -80oC. 
The nuclear pellet was re-suspended in 100µl of complete lysis buffer, vortexed for 
10 seconds, and incubated on ice for 30mins on rocking platform at 150rpm.  This 
causes lysis of nuclei, and nuclear proteins are solubilised in the lysis buffer, which 
contains a protease inhibitor cocktail to protect proteins from proteolysis.  Tubes 
were centrifuged at 14,000g for 10mins at 4oC, and the supernatant (containing the 
solubilised nuclear proteins) aspirated and aliquoted into microcentrifuge tubes and 
stored at -80oC until subsequent batch analysis of nuclear NFκB activation (see 
section 4.3.4).   
4.3.4 Quantification of PBMC nuclear NFκB activation 
Overview: Nuclear NFκB activation was quantified using the Active Motif 
TransAM™ NFκB p65 enzyme-linked immunosorbent assay (ELISA) (Active Motif, 
CA, USA).  Each well of the supplied 96-well plate is pre-bound with a double-
stranded oligonucleotide containing the NFκB consensus binding site.  Activated 
NFκB in the PBMC nuclear extract samples binds to the oligonucleotide, and in 
doing so an epitope on the p65 NFκB subunit is exposed.  A primary antibody 
directed against this epitope is added.  The primary antibody therefore only binds to 
activated, DNA-bound NFκB.  Binding of an anti-rabbit horseradish peroxidise 
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(HRP)-conjugated secondary antibody provides a colorimetric reaction which can 
be quantified by spectrophotometry.  Nuclear extract from Jurkat cells (an 
immortalised T-lymphocyte cell line) was supplied with the assay for use as a 
positive control.  
Protein concentration of samples: The protein concentration in each nuclear 
extract sample was determined using the Bio-Rad DC Protein Assay (Bio-Rad, CA, 
USA), a modification of the Lowry assay.(284, 285)  Bovine serum albumin (Sigma-
Aldrich, MO, USA) was prepared in DPBS to standard concentrations of 2mg/ml, 
1mg/ml, 0.5mg/ml and 0.1mg/m.  5µl of each standard and sample were added in 
duplicate to separate wells of a 96-well plate.  25µl reagent A’ and 200µl reagent B 
were added to each well and incubated at room temperature for 15 mins.  Optical 
density was read at 750nm on an Opsys MR™ plate reader (Dynex Technologies, 
VA, USA).  The mean of the duplicate samples and standards was calculated.  A 
graph of OD vs. protein concentration was plotted for the standards, and a line of 
best fit generated.  The protein concentration of each sample was calculated 
according to the equation for the line of best fit. 
Binding of NFκB to its consensus sequence: For each nuclear extract sample, 
5µg of nuclear extract protein diluted in 20µl of complete lysis buffer (CLB) were 
added in duplicate to the TransAM™ NFκB 96-well plate.  5µg Jurkat nuclear 
extract in 20µl CLB and 20µl CLB were added in duplicate as positive and negative 
controls respectively.  The plate was left to incubate for 1hr at room temperature at 
100rpm on a rocking platform.  Wells were washed three times with 200µl wash 
buffer. 
Binding of primary antibody: 100µl of NFκB antibody (1:1000 dilution in antibody 
binding buffer) was added to each well and the plate incubated for 1hr at room 
temperature.  Wells were washed three times with 200µl wash buffer. 
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Binding of secondary antibody: 100µl of HRP-conjugated antibody (1:1000 
dilution in antibody binding buffer) was added to each well and the plate incubated 
for 1hr at room temperature.  Wells were washed four times with 200µl wash buffer. 
Colorimetric reaction: 100µl developing solution was added to each well and 
incubated for 4.5 mins at room temperature.  100µl of stop solution was added, and 
OD measured at 450nm and 630nm read on an Opsys MR™ plate reader (Dynex 
Technologies, VA, USA). 
Quantification of NFκB: Optical density at 630nm (reference OD) was subtracted 
from OD at 430nm.  The mean corrected OD of each duplicate sample was 
calculated, and divided by the mean corrected OD of the positive control wells to 
give the nuclear NFκB activation of each sample relative to that of the Jurkat 
nuclear extract standard. 
 
4.4 Urinary PGE-M analysis 
Analysis of urinary PGE-M involves 3 stages, 1) solid phase extraction, 2) liquid 
chromatography, and 3) tandem mass spectrometry.   
1) Solid phase extraction (SPE)  
Overview:  SPE is a process which separates substances dissolved or suspended 
in a liquid based on their physical and chemical properties.  This involves passage 
of liquid (the mobile phase, in this case urine) through a solid (the stationary phase) 
for which the substances of interest (anylates, in this case PGE-M) have an affinity.  
In reversed phase SPE, substances are separated based on their polarity.  The 
stationary phase is typically a cartridge containing a sorbent such as octadecyl-
bonded silica gel, which is silica bound to the hydrocarbon octadecane 
(CH3(CH2)16CH3).  In analytical chemistry this is referred to as simply "C18".  C18 
binds non-polar substances (e.g. PGE-M) by weak non-polar or hydrophobic 
71 
 
 
interactions (Van der Waal forces), whilst polar substances do not bind and remain 
dissolved or suspended in the liquid (urine) and exit the cartridge.  The non-polar 
analytes of interest can be eluted from the cartridge by selectively washing with 
different concentrations of non-polar solvents.  In this case, heptane was used as a 
weak solvent to wash through any impurities bound by weak non-polar attractions, 
and ethyl acetate then washed through to elute PGE-M and other compounds 
bound by strong non-polar attractions. 
Method:  Urine samples were thawed to 20oC. Standards for the calculation of a 
calibration curve were formed by the serial dilution of commercially available PGE-
M (Caymen Chemicals, Tallinn, Estonia) to give a concentration range from 0-
100ng/ml PGE-M. The volume of each calibrant was 1ml. 20µl of 1µg/ml deuterated 
PGE-M (d6-PGE-M) was added to each sample as an internal standard. 
Varian Bond Elut C18 SPE columns were mounted on a ‘VacMaster ‘ extraction 
manifold (Biotage AB) and primed with 1ml methanol followed by 1ml of distilled 
water (acidified to pH 3 with acetic acid).  100µl 10% acetic acid was added to all 
samples and standards prior to being loaded into the columns.  Columns were then 
sequentially washed with 1ml dH2O pH3 and 1ml heptane before eluting the bound 
PGE-M with 1ml ethyl acetate.  The eluted solutions were evaporated to dryness in 
a Genevac EZ-2 centrifugal evaporator (Genevac Ltd, Ipswich, UK) at 37oC.  
2&3) LC-MS/MS 
Overview: The next stage involves sequential liquid chromatography (LC) and 
tandem-mass spectrometry (MS/MS) to give a highly accurate and sensitive 
quantification of PGE-M levels in the eluted sample.  Liquid chromatography 
physically separates PGE-M and structurally similar compounds from other 
compounds remaining in the sample.  The sample is introduced into a stream of 
fluid, known as the mobile phase, passing through a separation column.  The time 
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at which compounds emerge at the other end of the column (retention time) 
depends on their physical and chemical interactions with the stationary phase of the 
column.  This stage is important prior to mass spectrometry because the retention 
time of compounds with the same mass as PGE-M, e.g. isomers, will be different 
because of the different chemical structure and therefore different physical and 
chemical properties.  Mass spectrometry is unable to differentiate between 
compounds of the same mass, but by analysing only those compounds emerging 
from the LC column at a specific retention time, the specificity of quantifying the 
compound of interest is increased.(286, 287) Secondly, purification of the sample 
before it enters the mass spectrometer reduces the interactions between different 
chemicals.  Such interactions can reduce the efficiency of ionisation within the 
spectrometer, which is a particular problem when attempting to detect compounds 
that are present only in small concentrations.(286, 287) 
Whilst mass spectrometry is an analytical tool for measuring the mass of a 
compound, tandem mass spectrometry fragments the sample and uses multiple 
analyzers to detect the mass of the fragments produced.  This allows the structure 
of the compound to be elucidated.  In the case of quantifying PGE-M, using MS/MS 
allows fragments corresponding to the breakdown of PGE-M to be discriminated 
from the breakdown fragments of other compounds in the urine with the same LC 
retention time. The sample delivered from the LC is ionized to give the compounds 
charge.  The compounds pass through the mass analyser in gaseous phase and 
are accelerated into a finely focused beam.  A voltage gradient is applied across the 
analyser to cause deflection of the ionized compounds based on their mass/charge 
ratio.  The analyser is pre-set to only allow compounds with a specific mass/charge 
ratio to exit the analyser, thereby acting as a mass filter.  These selected 
compounds then enter a collision chamber where they are accelerated to high 
speed and bombarded with inert gas to cause fragmentation (collision induced 
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fragmentation).  These fragments pass through a second analyser, again pre-set to 
only allow fragments with a specific mass/charge ratio to exit and reach the 
detector.  In this way the MS/MS can be set to detect and measure fragments with 
a mass/charge ratio corresponding to the known fragmentation products of PGE-
M.(81)  
Measurement of urinary PGE-M by LC-MS/MS is a highly accurate and sensitive 
technique,(81, 288) but requires specific expertise and equipment which are not 
available in our laboratory.  These analyses were therefore performed by our 
collaborators Dr Paul Loadman and Amanda Race at the Institute of Cancer 
Therapeutics at the University of Bradford. 
Method: Liquid chromatography was performed using an Acquity Ultra 
Performance LC™ (UPLC™) 2.1 x 100 mm, 1.7µm particle size BEH C18 column 
attached to an Acquity UPLC™ System (Waters, Milford, USA).  Mobile Phase A 
was 95% dH2O, 5% acetronitrile, 0.1% acetic acid, and mobile phase B was 50% 
dH2O, 50% acetronitrile, 0.1% acetic acid. Samples were removed from the 
centrifuge evaporator and reconstituted in 25µl of mobile phase (60:40 A:B).  
Analytes were separated by a 95%-5% gradient of mobile phase A over 15min at a 
flow rate of 0.3ml/min prior to delivery to a Waters Quattro Premier™ XE bench-top 
tandem quadrupole mass spectrometer operating in negative ion mode and multiple 
reaction monitoring (MRM) mode.  Capillary voltage was set at 3.5V, cone voltage 
at 20V and collision voltage at 16V.  MRM channels were set for PGE-M at 327.4 
→291 and 327.4 →309 and for d6-PGE-M at 333.4 → 296.8 and 333.4 →315.5.  At 
the known LC retention time for PGE-M, the relative abundance of these 
fragmentation products of PGE-M and d6-PGE-M was recorded.   
Quantification of PGE-M level in each sample was performed by calculating the 
ratio of detected PGE-M fragments to d6-PGE-M fragments for each sample.  Since 
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a known concentration of d6-PGE-M was added to each sample at the start, this 
controlled for variability in the efficiency of the SPE process between samples.  The 
ratio of PGE-M:d6-PGE-M was plotted for the PGE-M standards to give a 
calibration curve, against which the PGE-M:d6-PGE-M ratio for each patient sample 
was plotted and the PGE-M concentration calculated.  
Standardisation for urinary creatinine: Urine volume is influenced by whole body 
fluid and electrolyte homeostasis.  The concentration of analyte in random urine 
samples will therefore exhibit both inter- and intra-subject variability based on, for 
example, urine volume, time of day and dehydration status.  Urinary PGE-M was 
therefore corrected for urinary creatinine as a marker of urine concentration.  
Urinary creatinine was measured by The Leeds Teaching Hospitals NHS Trust 
chemical pathology department based on a 'Jaffe' colorimetric assay(289) using an 
AVIDA 1800 (Siemens) analyser.  Urinary PGE-M concentration was divided by 
urinary creatinine (Cr) concentration to give a corrected urinary PGE-M level in 
ng/mg Cr. 
 
4.5 Tumoural PGE2/PGE3 analysis 
PGE2 and PGE3 levels in fresh frozen tumour tissue were analysed using LC-
MS/MS by Dr Paul Loadman and Ms Amanda Race at the Institute of Cancer 
Therapeutics at the University of Bradford.  The principles of LC-MS/MS have 
already been described in this chapter (section 4.4).  The methodology is the same 
as for analysis of urinary PGE-M (section 4.4) with a few minor modifications as 
described below. 
Sample preparation: Fresh frozen tumour samples were defrosted and weighed.  
0.9% saline was added to each sample in a microcentrifuge tube to make a 
homogenate of 1 part tumour to 9 parts saline, with the tumour tissue homogenised 
using ten strokes of a hand pestle.  The homogenised tissue was centrifuged at 
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10,000 x g for 5mins and the supernatant removed to a fresh microcentrifuge tube.  
Standards for the calculation of a calibration curve were formed by the serial 
dilution of commercially available PGE2 and PGE3 (Caymen Chemicals) to give a 
concentration range from 0-100ng/ml. The volume of each calibrant was 1ml.  20µl 
of 1µg/ml deuterated PGE2 (d4-PGE2) standard was added to each sample as an 
internal standard.  100µl 1% (v/v) acetic acid was added to all samples and 
standards.  
SPE and LC-MS/MS: SPE and LC-MS/MS was then performed as described for 
urine samples in section 4.4, with the exception that the MRM channels for MS/MS 
detection of PGE2 and PGE3 fragments were set at 351.5 → 271, 315, 333 for 
PGE2 and 349.5 → 269, 313, 331 for PGE3.  At the known LC retention time for 
PGE2 and PGE3, the relative abundance of these fragmentation products of PGE2 
and PGE3 and d4-PGE2 was recorded. 
Quantification of PGE2 levels in each sample was performed by calculating the ratio 
of detected PGE2 fragments to d4-PGE2 fragments for each sample.  Since a 
known concentration of d4-PGE2 was added to each sample at the start, this 
controlled for variability in the efficiency of the SPE process between samples.  The 
ratio of PGE2:d4-PGE2 was plotted for the PGE2 standards to give a calibration 
curve, against which the PGE2:d4-PGE2 ratio for each patient sample was plotted 
and the PGE2 concentration calculated.  PGE3 levels were calculated in the same 
way using the ratio of detected PGE3 fragments to d4-PGE2 fragments for each 
sample, and plotting this against a calibration curve drawn from the PGE3 
standards.   
 
4.6 Tumoural PUFA analysis 
Measurement of tumour PUFA content was performed by gas-chromatography 
mass-spectrometry (GC-MS).  This is a highly accurate and sensitive technique, but 
76 
 
 
requires specific expertise and equipment which are not available in our laboratory.  
These analyses were therefore performed by our collaborators Dr Andrea Belluzzi 
and Dr Alessandra Munarini at the Saint Orsola-Malpighi Hospital, University of 
Bologna.   
Overview: The principles of GC-MS are the same as for LC-MS/MS, using 
chromatography to first separate compounds in a sample based on their chemical 
and physical properties, and then using mass-spectrometry to quantify the level of a 
specific compound emerging at a particular retention time.  In contrast to LC-
MS/MS, GC-MS uses a gas rather than a liquid as the mobile phase for 
chromatography.  The MS stage is similar in both GC-MS and LC-MS/MS, with 
ionization and fragmentation of compounds entering the spectrometer at a specific 
chromatographic retention time.  With the single MS setup of GC-MS, these 
fragments are separated based on their mass/charge ratio and the fragments of 
interest then detected and quantified, whereas the tandem MS setup of LC-MS/MS 
utilizes a second phase of fragmentation and separation before detection and 
quantification of the fragments of interest. 
Method: This is a summary of the method used by Drs Belluzzi and Munarini, 
which has previously been reported.(209, 247)  
Sample extraction: Tissue samples were homogenised by hand in a pestle and 
mortar in 0.25ml of PBS.  Homogenates were transferred to a Sovirel extraction 
tube and extracted with 3ml of chloroform:methanol (2:1, vol/vol) by a modification 
of the Folch method.(290)  The mixture was shaken for 30min, the centrifuged at 
1.5 x g for 10min and the supernatant transferred to a clean tube.  This was 
repeated three times.  The supernatant was evaporated to dryness under nitrogen 
and the solid residue resuspended in 2ml KOH 0.5M in methanol.  This was then 
heated at 80oC for 10min.  2.5ml of 14% BF3 in methanol was added and the 
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mixture again heated at 80oC for 10min to transesterify the lipids.  Lipid 
methylesters were then extracted by the addition of 3ml hexane and evaporation 
under nitrogen.  The residue was re-dissolved in 100µl ciclohexane. 
GC-MS:  GC-MS analysis was carried out using an Agilent HP6890 GC with PTV 
injector linked to an HP4973 mass spectrometer.  Chromatography was performed 
using SUPELCO SP™2330 columns with Helium as the carrier gas at 0.5ml/min at 
a constant pressure.  The column temperature started at 100oC for 1.25mins, then 
rose by 30oC/min to 185oC.  It then rose at 0.5oC/min to 205oC.  Total GC runtime 
was 32min.  MS was performed in the electron ionization mode at 70eV, and set to 
detect fragments of mass/charge ratio in the range m/z 40 to m/z 550.  Peak 
identification was confirmed by comparison to GC retention times and MS peaks of 
commercially available standards.  Data for each PUFA are quoted as the 
percentage of the total fatty acid content of the tumour. 
 
4.7 Immunohistochemistry 
Fresh 4µm sections were cut from each paraffin-embedded tissue block, mounted 
on a glass slide and left to dry at 37oC overnight.  Sections were then stored at 
room temperature, and stained within two weeks of sectioning to minimise antigen 
degradation.  All immunohistochemistry was performed in runs of 23 slides.  Each 
run contained 1 slide to which the primary antibody step was omitted ("no primary").  
For each antibody protocol, 3 representative sections from the first run were 
selected and consecutive sections from these tumours used in each subsequent 
run as internal controls.  The same batch of antibody was used for all runs to 
minimise variability of staining between runs. 
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Stock solutions consisted of: 
 Low pH buffer: 15ml of Antigen Unmasking Solution (Vector Laboratories, 
Peterborough, UK) in 1.5L distilled H2O 
 Tris Buffered Saline (TBS): 60ml 2.5M NaCl + 20ml 1M Tris HCl (pH7.4) in 
1l distilled H2O 
 Tris Buffered Saline Tween-20 (TBST): 1.2ml 10% (v/v) Tween-20 in 1L 
TBS 
 DAB solution: 20µl of 3,3’-diaminobenzidine (DAB) chromogen substrate in 
1ml of pH7.5 substrate buffer 
4.7.1 Tumour proliferation (Ki-67) 
Staining: Sections were dewaxed and rehydrated in serial xylene and ethanol (both 
x3), and rinsed under running water for 5mins.  Antigen retrieval was performed 
using a pressure cooker.  Briefly, 1.5L of low pH buffer was brought to the boil in a 
stainless steel pressure cooker, the sections added and the lid locked shut.  
Sections were heated for 2mins once full pressure had been reached, then 
removed and cooled immediately in running water for 5mins.  Endogenous 
peroxidase activity was blocked using 0.3%(v/v) H2O2 for 10mins, then the sections 
were rinsed twice in TBS for 5 mins each.   
Slides were placed on a humidified slide chamber and 100µl of antibody diluent 
solution (Zymed Laboratories, San Francisco, USA) added to each slide to block 
non-specific binding sites and immediately drained off.  Mouse monoclonal anti-
human Ki-67 antibody (MIB1 clone) (Dako, Glostrup, Denmark) was used as the 
primary antibody at 1:50 dilution in antibody diluent solution.  100µl of primary 
antibody was added to each slide and left to incubate for 60mins at room 
temperature.  Slides were then rinsed twice in TBST and once in TBS, each for 
5mins.  
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The Dako EnVision™ kit (Dako, Glostrup, Denmark) was used for the following 
steps. 100µl of EnVision™ secondary antibody (HRP-labeled polymer bound to 
goat anti-mouse immunoglobulin) was added to each slide and left to incubate for 
30mins at room temperature.  Slides were then rinsed twice in TBST and once in 
TBS, each for 5mins. 
100µl of DAB solution was added to each slide and incubated for 10mins before 
rinsing slides in running water for 5mins.  Slides were counterstained with 
haematoxylin, dehydrated in serial ethanol and xylene (both x3), and coverslips 
mounted using DePeX mounting medium.  Slides were left to dry at room 
temperature overnight.                        
Scoring: A single high powered (x20) field of view was selected on each slide and 
photographed using a Nikon Eclipse E1000 microscope with NIS Elements software 
(Nikon Instruments Europe, Amsterdam, The Netherlands).  The field of view was 
systematically selected according to a pre-determined method to minimise selection 
bias (Figure 4.5).  The slide was placed on the stage and scanned at low power.  
The edge of the slide containing a tumour-liver interface was identified at low 
power.  Where tumour-liver interface was present at more than one edge of the 
slide, the pre-determined hierarchy of right edge>left edge>top edge>bottom edge 
was used to select the edge of interest.  The midpoint of the tumour-liver interface 
along this edge of the slide was identified at high power.  The high powered field of 
view was moved incrementally towards the centre of the slide to select and 
photograph the first high powered field of view of viable tumour without capsule or 
normal liver.  The edge rather than the centre of the tumour was chosen as the area 
of interest because this would a) likely capture the most highly proliferating area of 
tumour at the advancing edge, b) minimize the risk of selecting central necrotic 
areas of tumour, and c) minimise any potential discrepancy in proliferation between 
large tumours with necrotic centers and small tumours without central necrosis.  
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Photographs were analysed in Image J, a Java-based image processing and 
analysis software (http://rsbweb.nih.gov/ij/), using the cell counter plugin.  All 
positively stained (brown) and negatively stained (blue) tumour cells were counted.  
The proliferation index was taken as the percentage of positively stained cells out of 
the total cell count, with a minimum count of 500 cells.  If less than 500 cells were 
present, a second high powered field of view, immediately adjacent to the first, was 
selected and the cell counts combined. 
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Figure 4.5. Protocol for selection of a high-powered field of view for 
measurement of Ki-67 proliferation index.   a) The section was viewed under low 
power, and the edge of the slide containing liver-tumour interface was selected (X).  
Where more than one edge of the slide contains liver-tumour interface, the 
hierarchy right edge > left edge > top edge > bottom edge was used.  b) the 
midpoint of tumour along this edge of the slide was located (y=y). c) The first high 
powered field of view at this mid-point which excluded capsule and normal liver was 
selected and photographed (circled).  Images were opened in Image J for manual 
cell counts.     
X 
 
X 
 
X 
 
X 
 
y 
y 
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4.7.2 Tumour microvessel density (CD31) 
Staining: Sections were stained using the same protocol as for Ki-67, with the 
following exceptions: 
 1.  No antibody retrieval step was performed 
 2. The primary antibody used was mouse monoclonal anti-human CD31 
 antibody clone JC70A (Dako, Glostrup, Denmark) at 1:40 concentration 
 diluted in antibody diluent, with overnight incubation at 4oC. 
Scoring: There are a number of methods for the quantification of tumour 
microvessel density on immunohistochemical stained sections, based upon the 
counting of microvessels in a microscopic field view.(291)  These typically involve 
the identification of the most highly stained vascular regions of the section at low 
magnification, so called vascular "hotspots", followed by manual counting of the 
number of microvessels in these hotspots in one or more high powered fields of 
view.  Clearly there is subjectivity in the identification of hotspots that introduces 
intra-observer variability and selection bias.  Frequently, a single vessel will move in 
and out of the plane of section requiring the observer to decide whether to count 
two adjacent stained structures as a single vessel or two separate vessels.  One 
option to reduce this variability is to use a Chalkley graticule, a random grid of 
points which is overlaid on the image.  The Chalkley count is the number of points 
that hit a stained vascular structure, giving a relative vascular area rather than a 
true vessel count.(291)  Alternatively, automated counting with image analysis 
algorithms permits a more objective vessel count and can be used to count across 
the whole section, overcoming the highly subjective identification of vascular 
hotspots.  The drawback is the time and cost of the specialized equipment needed 
to firstly scan the whole slide at high magnification and secondly to analyse the 
scanned image. 
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Genentech (San Fransisco, USA) are a large biotechnology company who 
developed the anti-angiogenic drug bevacizumab (Avastin®).  I am grateful to Dr 
Adrian Jubb, Pathologist at Genentech, California, USA, who used to work in the 
Section of Pathology and Tumour Biology at Leeds Institute of Molecular Medicine, 
for offering us access to the image analysis software used by Genetech to evaluate 
microvessel density.  Stained tumour sections were scanned at x20 magnification 
using an Aperio ScanScope® slide scanner and digitally transferred to Genentech 
for image analysis.  Below is a summary of the image analysis algorithm, which has 
previously been reported.(292, 293) 
Scanned slides were analysed as 24bit RGB images using Matlab software 
(vR2010b by Mathworks, Natick, MA, USA).  Areas of tumour were marked up by 
hand by Dr Jubb, to exclude areas of white space and normal liver.  A segmentation 
algorithm was then applied to identify areas of viable tumour.  Cells were identified 
as either tumour or non-tumour based on the size, shape and density of 
haematoxylin staining.  Non-tumour areas were identified by the density of non-
tumour cells versus tumour cells.  Non-tumour areas were excluded from analysis.  
Brown DAB staining in each viable tumour region was isolated using a blue 
normalisation algorithm in addition to RGB colour.(294)   Vessel lumina were then 
identified by a segmentation algorithm as white areas surrounded by DAB staining.  
Noise was removed based on size and shape criteria.  Vessel number and 
perimeter were reported, as well as vessel area as a percentage of total tumour 
area.  After analysis was complete, the output for each slide was checked by Dr 
Jubb to ensure that the results were consistent with the original unprocessed 
images and to remove any artefacts or aberrantly identified vessels or tumour/non-
tumour areas. 
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4.7.3 Tumour apoptosis (M30) 
Staining: Sections were stained using the same protocol as for Ki-67, with the 
following exceptions: 
 1.  Antigen retrieval was performed by heating for 10mins in a microwave 
 oven at full power with slides submersed in 750ml of low pH buffer in a glass 
 bowl.  Slides were then left to cool for 20mins in the glass bowl before 
 proceeding with the protocol as for Ki-67 staining.  
 2. The primary antibody used was mouse monoclonal anti-human neo-
 cytokeratin 18 antibody (M30CytoDEATH; Roche, Mannheim, Germany) at 
 1:50 concentration diluted in antibody diluent, with 60mins incubation at 
 room temperature. 
Scoring: The M30 antibody recognises a neoepitope exposed by the activity of 
caspase-6 on the cytoskeletal protein cytokeratin-18 in epithelial cells.  This 
neoepitope appears early in apoptosis, before DNA fragmentation occurs.(295)  
M30 staining is therefore an earlier marker of cell apoptosis than the TUNEL 
assay.(295, 296)  The M30 epitope persists in late apoptosis, but is lost when cells 
become necrotic.   
Apoptosis staining in human CRC tissue is more sparse than staining for 
microvessel density or proliferation.  The difficulty in quantifying apoptosis is that 
the use of either a random or pre-determined field of view on a slide is likely to miss 
sparse apoptotic events.  In addition, apoptosis does not cluster in "hotspots", so 
there would be significant operator-variability in selecting hotspots on a slide by 
slide basis.  I therefore chose to score apoptosis across the whole slide using an 
automated image analysis algorithm.  An automated image analysis algorithm was 
designed in collaboration with Mr Alex Wright and Dr Darren Treanor of the Section 
of Pathology and Tumour Biology at Leeds Institute of Molecular Medicine. 
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Stained tumour sections were scanned at x20 magnification using an Aperio 
ScanScope® slide scanner.  Images were marked up by hand to select only areas 
of tumour, excluding normal liver and white space. A colour deconvolution 
programme was used to identify DAB staining, and individual DAB stained objects 
identified by thresholding.  Thresholds for the intensity of staining were set at 0.5 
standard deviations below the mean staining intensity.  Size thresholds were used 
to exclude objects below 10microns and to remove noise and artifact.  Total object 
count and area of staining as a percentage of total marked-up area  were reported.  
The algorithm was validated against a manual cell count by selecting 20 
representative 2000x2000pixel regions of interest from three different slides, 
incorporating regions of low, medium and high staining.  Manual image counting 
was performed on Image J using the cell counter plugin.  All positively stained 
(brown) tumour cells were counted.  The algorithm was then run on the same 
regions of interest.  Manual apoptotic cell counts were plotted against the algorithm 
object count and algorithm % stained area, and correlation assessed with 
Spearman's rank correlation coefficient. 
 
4.8 Human Umbilical Vein Endothelial Cell studies 
Overview: The effects of EPA on angiogenesis have not been investigated fully.  
Human umbilical vein endothelial cells (HUVECs) have been widely used as an in 
vitro model of angiogenesis.(297, 298)  I therefore performed a stand-alone series 
of assays investigating the effects of EPA on HUVEC proliferation, migration and 
tubule formation in vitro as a surrogate for endothelial cell behaviour and 
angiogenesis in tumours, but which would complement the microvessel density 
analysis of human CRCLMs in The EMT Trial.     
Cell culture: Human umbilical vein endothelial cells (TCS Cellworks, Buckingham, 
UK) were cultured in T75 flasks in 15 ml of large vessel endothelial cell culture 
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medium (TCS Cellworks, Buckingham, UK) supplemented with endothelial cell 
growth supplements as supplied by the manufacturer (TCS Cellworks, Buckingham, 
UK) containing 2% foetal bovine serum, gentamicin, amphotericin B, epidermal 
growth factor, basic fibroblast growth factor, heparin and hydrocortisone (herein 
referred to as “plain culture medium”).  The concentration of each of these 
supplements is not disclosed by the manufacturer.  Cells were incubated at 37oC 
with 5% CO2 and culture medium was replaced every 48 hrs.  Cells were split at 
80% confluence and cells between passage 3 and 6 were used for all experiments. 
Experimental culture medium: EPA-supplemented culture medium was created 
as follows.  EPA-FFA was supplied in 500mg capsules by SLA Pharma AG.  Three 
capsules were aspirated to dryness using a 21G needle and the aspirated content 
weighed.  The aspirated weights were 424mg, 427mg and 426mg (mean 425.6mg 
per capsule).  A stock of 0.1mM EPA solution was created by dissolving the 
aspirated EPA (425mg) in 14ml of 95% ethanol. 
[ EPA molecular weight = 302.451g  and  0.425mg/302.451g ÷ 14ml/1000ml = 0.1mM ] 
10µl of 0.1mM EPA was added to 10ml of plain culture medium to give a 100µM 
EPA stock solution with an ethanol (carrier) concentration of 0.1% (v/v).  This 
solution was further diluted with culture medium to provide a range of EPA-culture 
media with EPA concentrations from 0-100µM, with the maximum ethanol carrier 
concentration of 0.1% (v/v) at the 100µM EPA concentration. 
Experimental media were made fresh from new EPA-FFA capsules for each 
experiment to minimise potential oxidation of EPA.   
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4.8.1 MTT proliferation assay 
Acute EPA supplementation:  HUVECs were grown in T75 culture flasks in plain 
culture medium.  At 80% confluence, cells were trypsinised and centrifuged at 200 x 
g for 5mins.  Cell pellets were resuspended in plain medium and cell density 
counted in a Neubauer chamber.  Cells were seeded in 96-well plates at a density 
of 2000 cells/well in 100µl plain culture media.  Six wells were seeded with plain 
culture media alone as a "no cell" control.  After 24hrs incubation, the plain culture 
medium was aspirated and replaced with 100µl experimental media supplemented 
with EPA at concentrations ranging from 0µM to 100µM.  Each EPA concentration 
was replicated in 6 wells.  Six wells were replaced with culture medium + 0.1% (v/v) 
ethanol as a "carrier" control.  Plates were seeded in triplicate and incubated for 24, 
48 and 72hrs respectively.  After incubation, the culture medium was aspirated and 
50µl 1mg/ml Thiozolyl blue tetrazolium bromide (MTT) solution (Sigma-Aldrich, MO, 
USA) added to each well.  The plate was left in the dark for 3hrs.  Mitochondrial 
dehydrogenase in viable cells cleaves MTT to produce purple formazan crystals.  
After 3 hrs the MTT solution was aspirated and the purple crystals solubilised in 
100µl propan-1-ol.  The solution in each well was transferred to a fresh 96 well 
plate and optical density read at 570nm on a spectrophotometer.  The mean optical 
density (OD) of the 6 wells for each EPA concentration was calculated and a graph 
of OD over time was plotted. 
Further experiments were performed using the same method scaled up to a 48-well 
plate format, using 1x104 cells/well in 0.5ml culture medium, 100µl of 1mg/ml MTT 
solution and 200µl of propan-1-ol.  100µl of the solubilised purple formazan crystals 
was then transferred to a fresh 96-well plate for measuring OD as above. 
Chronic EPA supplementation: The effect of chronic EPA supplementation was 
studied by simultaneously growing batches of cells for two weeks in either plain 
culture medium or culture medium supplemented with 1µM EPA.  Culture medium 
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was changed every 48hrs and cells trypsinised and split at 80% confluence. Cells 
were counted and re-suspended in plain or 1µM EPA-supplemented culture 
medium and seeded at 1x104 cells per well with six replicates per condition on 3 
separate plates and incubated for 24, 48 and 72hrs respectively.  The media was 
not changed once cells had been seeded.  An MTT assay was performed as 
described above.   
The effects of VEGF and PGE2 on cell proliferation were studied by the 
supplementation of either 10ng/ml VEGF or 1µM PGE2 to the cell-conditioned 
media when cells were plated onto the 48 well plates.  This was performed with six 
replicates for both the EPA-naive cells and chronic EPA-supplemented cells.      
Concentration of PGE2 and 6-keto-PGF1α in HUVEC culture medium:  To begin 
to explore the mechanistic basis of the effect of EPA on HUVEC proliferation, the 
PG levels in HUVEC cell conditioned medium were analysed.  In the acute and 
chronic EPA supplementation assays, culture medium aspirated from each well 
prior to addition of MTT solution was combined for each of the replicate wells, and 
stored in 0.5ml cryovials at -80oC until analysis.   
Measurement of the concentration of PGE2 in culture medium was performed using 
the same methodology as the analysis of urinary PGE-M (see section 4.4), with the 
exception that the MRM channels were set for MS/MS detection of PGE2 as 
described in section 4.5.   
However, PGI2 rather than PGE2 is considered the main prostaglandin product of 
AA metabolism in vascular endothelium and previous studies in HUVEC cultures 
have shown greater production of PGI2 than PGE2.(299-301)  6-keto-PGF1α is a 
stable product of PGI2 produced by its non-enzymatic hydration.  Measurement of 
6-keto-PGF1α in HUVEC cell conditioned medium was performed using a 
competitive inhibition enzyme immunoassay (Enzo Life Sciences, Exeter, UK) 
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according to the manufacturer's instructions.  In brief, the kit includes a microtitre 
plate to which a donkey anti-sheep antibody is pre-bound to each well.  A polyclonal 
sheep antibody against 6-keto-PGF1α  is added which binds competitively to either 
6-keto-PGF1α in the sample or to an alkaline-phosphatase-6-keto-PGF1α conjugate 
which is added to each well.  The higher the concentration of 6-keto-PGF1α in the 
sample, the lower the concentration of alkaline-phospatase-6-keto-PGF1α conjugate 
that will competitively bind the sheep antibody and therefore bind to the well 
surface.  Reagents are washed away to remove any unbound 6-keto-PGF1α.  A 
substrate of p-nitrophenyl phosphate (pNpp) is added to each well.  This is 
catalysed by alkaline-phosphatase conjugate bound to the plate and produces a 
colour change.  The OD measured by spectrophotometry is inversely proportional 
to the original concentration of 6-keto-PGF1α in the sample, which can be read off 
the optical density on the standard curve produced from the 6-keto-PGF1α 
standards.  The detailed methodology is described below. 
The 6-keto-PGF1α standard was serially diluted in fresh HUVEC culture medium to 
give concentrations of 50000, 10000, 2000, 400, 80, 16 and 3.2pg/ml.  100µl of 
HUVEC culture medium was added to the "non-specific-binding" (NSB) well and the 
no-competitive binding (Bo) well.  100µl of standard or sample was added to the 
remaining wells in duplicate.  50µl of assay buffer was added to the NSB well.  50µl 
of alkaline-phosphatase-6-keto-PGF1α conjugate was added to each well.  50µl of 
polyclonal sheep antibody against 6-keto-PGF1α was added to each well except the 
NSB well.  The plate was incubated at room temperature on a plate shaker for 2hrs 
at 500rpm.   
The contents of each well were washed with 400µl of wash solution for a total of 
three washes.  200µl of pNpp substrate was added to each well and incubated at 
room temperature for 45mins without shaking.  50µl of stop solution was added to 
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each well.  Optical density was immediately measure on a spectrophotometer at 
405nm, with correction at 570nm.  
The OD for each sample and standard well was corrected for the average OD of the 
blank wells.  The net OD for each standard and sample was calculated by 
subtracting the average NSB OD from the average OD of each standard or sample.  
The percentage binding of each standard as a percentage of the maximum binding 
wells (Bo) was calculated by dividing the net OD of each standard by the net OD of 
the Bo wells.  For each standard, percentage binding was plotted against 6-keto-
PGF1α concentration to produce a standard curve.  Percentage binding of the 
samples was plotted on this graph to calculate the concentration of 6-keto-PGF1α in 
the samples. 
The primary antibody in this kit is specific for 6-keto-PGF1α.  The manufacture 
reports cross reactivity with other related prostaglandins at less than 3%.(302)  
They do not have data for cross-reactivity with the equivalent 3-series PGI3 
metabolite δ17-6-keto-PGF1α.  One historic paper has reported less than 10% 
cross-reactivity between the two compounds with two different antibodies against 6-
keto-PGF1α,(303) although this data is of limited value as the antibodies are 
different to those used in the Enzo Life Sciences kit.  Nevertheless, cross-reactivity 
is likely to be small, and given that 3-series prostaglandins might be expected to be 
produced in smaller quantities than the respective 2-series prostaglandins by as 
much as an order of magnitude,(209) any cross-reactivity could reasonably be 
expected to have a negligible effect on the results of the assay.    
4.8.2 Wound migration assay 
HUVECs were seeded in a 6 well plate at a density of 2x105 cells/well in 2ml plain 
culture medium and grown to confluence.  Each well was pre-marked on the 
reverse with two horizontal reference lines using a fine permanent marker (Figure 
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4.6).  Culture medium was replaced every 48hrs.  At confluence, culture medium 
was aspirated and a vertical score made in each well with a yellow pipette tip.  
Medium was replaced with 2ml experimental medium supplemented with EPA at 
concentrations ranging from 10µM to 50µM.  Photographs of each wound were 
taken immediately above and below the intersection of each reference line with the 
wound (4 photos per well) using an Olympus C7070 camera (Olympus, Essex, UK) 
attached to an Olympus CKX41 inverted light microscope (Olympus, Essex, UK) at 
x4 magnification (Figure 4.6).  The plate was incubated at 37oC and repeat 
photographs taken at regular intervals until the wounds had closed. 
Scoring:  Images were scored using TScratch, a freely available MATLAB (The 
Mathworks, Natick, MA, USA) based stand-alone programme designed by the 
Swiss Federal Institute of Technology (Zurich, Switzerland).(304)  TScratch detects 
the edges of the wound using an edge detection algorithm, then calculates the 
percentage open area (i.e. the area of the wound) in each image.  The detected 
open area is saved as an image overlay and available for review.  Thresholds for 
edge detection can be user defined, and in these assays they were set at 0.36 
arbitrary units which subjectively gave the best balance between sensitivity and 
specificity when the image overlays were reviewed.  All overlay images were 
manually reviewed and occasional erroneously detected areas, corresponding to 
patches of poor HUVEC confluence within the image, were deleted prior to the final 
percentage wound area being calculated. 
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Figure 4.6.  HUVEC wound migration assay.   
a) Parallel reference lines were drawn across the back of each well. b) At confluence a 
scratch was made in the HUVEC monolayer, and photographs taken at x4 magnification, 
immediately above and below the intersection of the score with the reference lines, as 
indicated by the dotted lines. c) An example of a photographed wound.   
C 
A 
B 
C 
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4.8.3 Matrigel tubule formation assay 
Matrigel™ (BD Biosciences, Oxford, UK) is a gelatinous reconstituted basement 
protein mixture extracted from the Engelbreth-Holm-Swarm mouse sarcoma.(305)  
It contains laminin, collagen, enactin, EGF, IGF-1, bFGF and other growth 
factors.(305)  HUVECs seeded on a layer of Matrigel form a network of tube-like 
structures which are the closest in vitro representation of capillary microvessels.  
The effect of EPA on HUVECs in a Matrigel assay therefore evaluates the effect on 
the more complex process of tube formation, rather than the more simplistic assays 
of proliferation or migration described above. 
Assay optimisation:  BD Matrigel Basement Membrane High Concentration (BD 
Biosciences, Oxford, UK) was defrosted on ice overnight.  Cold pipette tips, 
cryovials and PBS were used to dilute the liquid Matrigel with PBS into 0.5ml 
aliquots at 50%, 33%, 20%, 10% and 5% (v/v) Matrigel concentrations.  The 
remaining Matrigel was immediately re-frozen.  0.5ml of each Matrigel 
concentration was pipetted into a single well of a cold 6-well plate and spread 
evenly across the well.  These steps were performed on ice with cold equipment 
and reagents because Matrigel rapidly forms a gel above 10oC.  The 6 well plate 
was then placed at 37oC in an incubator for 30mins to allow the Matrigel to solidify. 
2x105 HUVECs in 2ml plain culture medium were seeded in each well of the 
Matrigel-coated 6 well plate.  The plates were reviewed regularly to assess the 
formation of tube-like structures.  Based on the results of this, a 33% Matrigel 
concentration was chosen for the HUVEC-Matrigel assays.  The remaining Matrigel 
was therefore diluted to 33% concentration and aliquoted into 0.5ml aliquots as 
described above and immediately refrozen.  The original Matrigel protein 
concentration was certified at 19.0mg/ml by the manufacturer based on the Lowry 
method.(285)  The 33% dilution therefore represents a 6.4mg/ml protein 
concentration. 
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Acute EPA supplementation assay: Wells of a 6-well plate were coated with 
0.5ml of 33% Matrigel as described above.  HUVECs were cultured in plain culture 
media, trypsinised, centrifuged, resuspended and counted as previously described.  
EPA-supplemented culture media was prepared as previously described.  2x105 
cells in 2ml of culture media supplemented with EPA to a concentration of 0-30µM 
EPA were added to each well.  The plate was incubated at 37oC  in a cell incubator.  
Plates were reviewed every 2hrs for the formation of tube-like structures, and 4 
non-overlapping representative photos taken of each well at each time point using 
an Olympus C7070 camera (Olympus, Essex, UK) attached to an Olympus CKX41 
inverted light microscope (Olympus, Essex, UK) at x4 magnification. 
Chronic EPA supplementation assay: HUVECs were grown for two weeks in 
either plain culture media or 1µM supplemented culture media as previously 
described.  2x105 cells in 2ml of plain culture media were seeded onto each well of 
a Matrigel-coated 6 well plate, 3 wells for the EPA-naive cells and 3 wells for the 
chronic-EPA supplemented cells.  Plates were incubated, reviewed and 
photographed as described above. 
Scoring: Images were analysed using a web-based image analysis service, 
WimTube (Wimasis GmbH, Munich, Germany).  Briefly, their algorithm involves 
filtering, segmenting, object recognition and data processing steps.  The tube-like 
structures identified are highlighted on an overlay image, and the metrics outputted 
are number of tube-like structures, mean tube length, number of branching points 
and number of complete rings formed.  This method has been validated against the 
alternative Angiosys system (TCS Cellworks, Buckingham, England) which requires 
the user to perform image processing in Adobe Photoshop followed by manual 
thresholding and skeletonisation steps in Angiosys.(306)  Angiosys then calculates 
the same metrics as Wimasis, with the exception of number of complete rings 
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formed.  Similar results have been obtained from either system, with the advantage 
that the Wimasis system required less user processing time.(306) 
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Chapter 5: Results - The EMT Trial 
5.1 Patient recruitment and baseline characteristics 
Between April 2010 and July 2011, 203 patients in the Leeds Hepatobiliary Unit 
outpatient clinics were screened for eligibility for The EMT Trial.  A total of 102 
patients did not fulfil the trial inclusion criteria, over half of these because of 
chemotherapy use in the last 3 months (Table 5.1 and Figure 5.1).  Other reasons 
for ineligibility are detailed in Table 5.1.  A further four patients were not 
approached for The EMT Trial because they were being considered for inclusion in 
other concurrent trials, and five patients were eligible but not approached because 
of time constraints in the outpatient clinic. Of the 92 eligible patients who were 
approached, the trial was well received with only four patients declining to 
participate.  Target recruitment of 88 patients (see power calculation, Chapter 3.9) 
was achieved in 15 months (Figure 5.2).   
 
Reason for ineligibility (n=102) N= (%) 
Chemotherapy within 3 months 57 (55.9%) 
Primary CRC in situ, or surgery within 6 weeks 11 (10.8%) 
Anticoagulation therapy 10 (9.8%) 
Inoperable disease 9 (8.8%) 
Regular NSAID use 4 (3.9%) 
Uncertain CRCLM diagnosis 4 (3.9%) 
CRCLM <9mm on cross-sectional imaging 4 (3.9%) 
Active Crohn's disease 1 (1.0%) 
Presence of other primary cancers 1 (1.0%) 
Active participant in another trial 1 (1.0%) 
 
Table 5.1. Patients screened but ineligible for inclusion in the EMT Trial  
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Assessed for eligibility 
(n = 203) 
Excluded (n = 115) 
Not meeting inclusion criteria (102) 
Refused to participate (4) 
Approached for other trials (4) 
Not seen at pre-operative clinic visit (5) 
Randomized (n = 88) 
Placebo 
(n = 45) 
 Reclassified as inoperable 
 at MDT (1) 
 Withdrew consent (1) 
 
CRCLM 
surgery (n = 43) 
 
 
Surgical 
outpatient 
review (n = 35) 
EPA 
(n = 43) 
 Reclassified as inoperable 
 at MDT (2) 
 Withdrew due to SEs (2) 
 Withdrew consent (1) 
 
CRCLM 
surgery (n = 38) 
 
 Transferred to oncology for 
adjuvant chemotherapy (n=4) 
 Inoperable disease at 
laparotomy (n=1) 
 Histological diagnosis of HCC 
(n=1) 
 Did not attend surgical follow-
up (n=1) 
 Died (n=1) 
 
 
 Transferred to oncology 
for adjuvant 
chemotherapy (n=2) 
 
 
Surgical 
outpatient 
review (n = 36) 
Median duration IMP 
26 days 
Median duration IMP 
30 days 
Not meeting inclusion criteria (102) 
Chemotherapy < 3months  (57) 
1
o
 CRC in situ or surgery < 6 weeks (11) 
Anticoagulant therapy (10) 
Deemed inoperable (9) 
Regular NSAIDs (4) 
Uncertain CRCLM diagnosis (4) 
CRCLM <9mm (4) 
Active Crohn's disease (1) 
Presence of another 1
o
 cancer (1) 
Participating in another trial (1) 
Figure 5.1.  CONSORT diagram 
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Figure 5.2.  Graph of cumulative recruitment into The EMT Trial 
 
Forty three patients were randomised to the EPA arm and 45 patients to the 
placebo arm of the trial (Figure 5.1).  The two groups were well matched at baseline 
(Table 5.2) with no significant difference in age, stage of primary bowel cancer, 
node positive primary disease, size or number of liver metastases, previous 
chemotherapy or interval between the end of chemotherapy and CRCLM resection.  
There was a non-significant higher proportion of females in the EPA group (39% vs. 
21%).  The placebo group had a higher proportion of synchronous disease (44% vs. 
30%), and a shorter interval between CRC resection and presentation with CRCLM 
in those patients with metachronous disease (median 19 months vs. 24 months).  
Neither measure reached statistical significance.  Similar proportions of patients in 
each group were taking antiplatelet agents.  Five patients in the EPA group and 
nine patients in the placebo group were already taking regular fish oil supplements 
before enrolment in the trial.  All of these patients stopped taking their own fish oil 
supplements for the duration of the trial.         
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Table 5.2.  Comparison of patient and disease-specific characteristics at baseline.  All 
data presented as n=(%) or median (range). Continuous variables were compared using 
Student t-test if data was normally distributed or Mann-Whitney U test if data was not 
normally-distributed.  Categorical variables were compared using Chi-square test.  
 
 Placebo n=45 EPA n=43 p= 
Patient characteristics    
Age (years)  71 (35-87) 68 (44-82) 0.97 
Sex M:F (% male) 35:10 (78%) 26:17 (61%) 0.08 
Aspirin 10 (22%) 10 (23%) 0.91 
Clopidogrel 3 (7%) 1 (2%) 0.33 
Previous fish oil 9 (20%) 5 (12%) 0.28 
 
Primary bowel cancer 
characteristics 
   
Dukes stage 
A 
B 
C 
D 
 
2 (4%) 
13 (29%) 
10 (22%) 
20 (44%) 
 
2 (5%) 
11 (26%) 
17 (40%) 
13 (30%) 
0.33 
Node Positive 25 (56%) 26 (61%) 0.64 
Synchronous CRCLM 20 (44%) 13 (30%) 0.17 
 
Liver metastasis characteristics    
Interval between primary CRC 
surgery and presentation with 
CRCLM (metachronous disease 
only) 
19 months (3-80) 
n= 30 
24 months (6-91) 
n= 32 
0.16 
Number of patients presenting for 
redo liver resection  
11 (24%) 6 (14%) 0.21 
Number of metastases  2 (1-5) 1 (1-9) 0.44 
Largest metastasis (cm)  2.6 (0.9-12) 3.1 (0.9-15) 0.15 
 
Previous chemotherapy     
Adjuvant chemotherapy > 3months 
prior to CRLM resection 
20 (44%) 20 (47%) 0.85 
Interval between end of 
chemotherapy and CRLM resection  
12 months (5-73) 13 months (6-82) 0.86 
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5.2  Withdrawals, duration of trial medication, and follow-up. 
5.2.1 Withdrawals 
Two patients in each group were withdrawn from the study following randomisation 
after their disease was reclassified as inoperable at the Leeds Hepatobiliary 
Multidisciplinary Team meeting.  One patient in each group withdrew their consent 
after randomisation (Figure 5.1).  One was a patient who decided a few days after 
randomisation that he wanted to start taking fish oil supplements and was not 
prepared to continue in the trial with a 50:50 chance of taking a placebo.  He 
therefore withdrew his consent so that he could start taking commercially available 
fish oil supplements.  The other was a patient who decided immediately after 
randomisation that he no longer wanted to take part in the trial.  He did not receive 
any trial mediation.  Two patients in the EPA group were withdrawn because of 
diarrhoea side effects, likely due to trial medication (see Section 5.3.4).    
5.2.2 Patients proceeding to surgery 
A total of 43 patients in the placebo group and 38 patients in the EPA group 
therefore proceeded to surgery.  There was no difference in the duration of trial 
medication between the two groups (p=0.62).  Median duration of trial medication 
was 26 days in the placebo group (range 15-73 days) and 30 days in the EPA 
group (range 12-65 days).  At surgery, one patient in the placebo group was found 
to have inoperable disease and no tumour tissue was obtained.  One patient in the 
EPA group had no identifiable tumour in the resected liver specimen, despite fine 
sectioning of the resected specimen.  The specimen was subsequently confirmed 
as having two fibrotic lesions but no identifiable tumour on the formal histopathology 
report.  One patient in the placebo group was diagnosed as having hepatocellular 
carcinoma not CRCLM after histological examination of the resected tumour and 
this patient was withdrawn from follow-up at this point.  Tumour samples from this 
HCC, and all preceding blood and urinary samples for this patient were excluded 
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from all analyses.  Samples of CRCLM for FFPE and subsequent 
immunohistochemical analysis, including the primary endpoint of Ki-67 proliferation 
index, were therefore obtained from 41 patients in the placebo group and 37 
patients in the EPA group. 
For two patients in the placebo group there was insufficient tumour to take fresh 
frozen tissue samples as well as for formalin-fixation.  FFPE samples were 
therefore prioritised in order to maximise the number of samples available for 
primary endpoint analysis.  This included one patient who had suspected lymph 
node involvement at the time of surgery which was confirmed on intra-operative 
fresh frozen histological examination.  At the time of confirmation, only a limited 
metastasectomy had been performed and tumour samples could only be taken for 
FFPE.  Similarly, the other patient had a very small tumour from which only a 
sample for FFPE could be obtained.  Two further patients in the placebo group had 
samples taken only for FFPE because their surgery was brought forward without 
our knowledge.  By the time these two patients had been identified, their tumour 
had already been fixed in formalin in the hospital's histopathology department.  
Formalin fixed tumour samples were taken and paraffin embedded in the same 
manner as all other samples, but it was not possible to obtain fresh tumour tissue.  
Fresh frozen tumour samples were therefore obtained from 37 patients in the 
placebo group and 37 patients in the EPA group. 
5.2.3 Loss to follow-up 
It is standard practice for patients to be reviewed 6 weeks after discharge from 
hospital in the surgical outpatient clinic to assess their recovery prior to referring 
patients to their local oncology centre for consideration of adjuvant chemotherapy.  
However, 6 patients (4 placebo group, 2 EPA group) who lived outside the 
Yorkshire region were not followed-up post-operatively in the surgical outpatient 
clinic and instead referred by their Consultant Surgeon directly to their local 
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oncology unit in order to minimise travelling.  These 6 patients therefore did not 
complete the final trial visit.  One further patient in the placebo group did not attend 
the final study visit, and another patient in the placebo group died before the final 
study visit.  Follow-up was therefore completed by 35 patients in the placebo group 
and 36 patients in the EPA group (Figure 5.1).  
  
5.3 Compliance, safety and tolerability 
5.3.1 Compliance  
Compliance was assessed by counting of capsules returned by the patient when 
they were admitted for their liver resection.  With the caveat that patients may not 
have returned all of their unused medication, mean compliance in the EPA group 
was 91% (range 50% - 100%) and in the placebo group 94% (range 43% - 100%). 
5.3.2 Suspected unexpected serious adverse reactions (SUSARs) 
There were no SUSARs recorded during this trial. 
5.3.3 Serious adverse events (SAEs) 
There were no SAEs reported whilst patients were taking study medication.  Seven 
SAEs were reported in the six week post-operative follow-up period.  These are 
detailed in Table 5.3.  Those SAEs that occurred in the post-operative period, 
including one death (1.1%), one pulmonary embolism (1.1%) and four patients 
requiring drainage of a subphrenic collection (4.5%) are all in keeping with the 
expected morbidity of liver resection surgery.  None of these were attributed to 
study medication and none required unblinding of the trial.    
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Patient 
ID 
Arm SAE category SAE description Time between 
surgery & 
SAE 
055 Placebo Death 
Elderly gentleman requiring 
a more extensive resection 
than anticipated developed 
intra-abdominal sepsis, 
multi-organ failure and died. 
31 days 
058 Placebo 
Life-threatening 
event 
Readmitted with pulmonary 
embolism 
21 days 
026 EPA Readmission 
Readmission for drainage of 
subphrenic collection 
21 days 
046 EPA Readmission 
Readmission for drainage of 
subphrenic collection 
16 days 
086 EPA Readmission 
Readmission for drainage of 
subphrenic collection 
31 days 
060 Placebo 
Intervention 
causing increased 
length of stay 
Drainage of subphrenic 
collection 
9 days 
084 Placebo Readmission 
Planned re-admission for 
resection of known lung 
metastases 
49 days 
 
Table 5.3.  Summary of SAEs reported during the trial 
 
5.3.4 Adverse events (AEs) 
Adverse events were classified as pre-operative or post-operative and graded in 
severity as either mild, moderate or severe.  AEs were graded mild if no 
intervention was required, the patient did not require hospitalisation or the AE did 
not prolong inpatient stay.  AEs were graded moderate if intervention was required 
(e.g. dose reduction of IMP) but the patient did not did not require hospitalisation or 
the AE did not prolong inpatient stay.  AEs were graded severe if the patient 
required hospitalisation, required re-operation, or required transfer to a higher level 
of care (e.g. from ward care to High Dependency Unit, HDU).  Based on this 
grading, all severe AEs qualify as SAEs and have been included in section 5.3.2. 
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A total of 16 pre-operative AEs were documented (Table 5.4).  These were all 
gastrointestinal symptoms, and were all considered likely attributable to study 
medication.  There was a greater proportion of patients in the EPA group reporting 
diarrhoea (19% vs. 7%) but this did not reach statistical significance. Of the eight 
patients reporting diarrhoea in the EPA group, two patients were withdrawn and two 
patients' symptoms were effectively controlled with a dose reduction from 2g to 1g 
daily.   Of the three patients reporting diarrhoea in the placebo group, one required 
a reduction in the dose of trial medication.  These AEs were all graded as moderate 
severity.  All other reported diarrhoea was mild in severity.  There was a significant 
increase in patients reporting upper gastrointestinal upset (abdominal pain, nausea, 
dyspepsia) in the EPA group compared to the placebo group (12% vs. 0%, p=0.01).  
None of these patients required dose reduction or withdrawal from the study.   
Adverse Event Placebo (n=45) EPA (n=43) p= 
Preoperative    
Diarrhoea 
 Mild 
 Moderate 
3 (7%) 
2 
1 
8 (19%) 
4 
4 
0.09 
Upper GI upset (mild) 0 5 (12%) 0.01 
Postoperative    
Encephalopathy (moderate) 1 1  
Intra-abdominal collection (mild) 2 1  
Bleeding (mild) 0 1  
Wound infection 
 no antibiotics (mild) 
  required antibiotics (moderate) 
4 
2 
2 
1 
1 
0 
 
Lower respiratory tract infection 
(moderate) 
4 0  
Urinary tract infection (moderate) 0 3  
 
Table 5.4.  Summary of AEs reported during the trial 
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A total of 18 post-operative AEs were documented in The EMT Trial (Table 5.4), all 
of which were considered to be in keeping with the expected complications of liver 
resection surgery, with none of these AEs considered attributable to study 
medication.    Combining the postoperative SAEs and AEs, morbidity was 33% in 
the placebo group and 23% in the EPA group, and the overall operative mortality 
(30-day mortality) was 1.1%.  This is in keeping with current outcome data for liver 
resection from the Leeds Hepatobiliary Unit which shows an operative mortality rate 
of 1.9%, and morbidity of 15.9-30%,(307, 308) of which postoperative collection 
was the most common complication occurring in approximately 7% of patients (307) 
as compared to in 8% of patients in The EMT Trial.  
 
5.5 Surgical outcomes 
Extent of liver resection was defined according to the International Hepato-
pancreatico-biliary Association (IHPBA) 2000 Brisbane classification.(309)  This 
defines liver resection as minor (<3 segments resected), major (3-4 segments 
resected), or extended (5 or more segments resected).  Approximately two-thirds of 
patients underwent minor liver resection and one-quarter of patients underwent a 
major liver resection.  There was no significant difference in the extent of resections 
performed between the two groups (Table 5.5). 
Length of hospital stay is a surrogate marker of surgical quality and complications.  
There was no significant difference in either the length of HDU stay or total length of 
hospital stay between the two groups (Table 5.5).  There was no significant 
difference in the requirement for transfusion of packed red cells between the two 
groups (Table 5.5).  
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Surgical outcomes Placebo n=43 EPA = 38 p= 
Extent of resection  
 Minor 
 Major 
 Extended 
 Inoperable 
 
30 (70%) 
9 (21%) 
3 (7%) 
1 (2%) 
 
25 (66%) 
10 (26%) 
3 (8%) 
0 (0%) 
0.75 
Packed red cell transfusion 4 (9%) 3 (8%) 0.82 
HDU stay (days) median + IQR  1 (1-3) 2 (0-2.25) 0.95 
Total hospital stay (days) median + IQR  7 (5-10) 6.5(5-9) 0.72 
 
Table 5.5.  Summary of surgical outcome measures 
 
5.6  Food Frequency Questionnaire 
Food frequency questionnaires were analysed for all patients who proceeded to 
surgery (n=81).  Baseline FFQs of those patients who were withdrawn prior to 
surgery (n=7) were not included in the analysis because no post-treatment outcome 
data was available for these patients.  FFQs were completed by 72 of 81 patients 
(89%) at baseline,  59 of 81 patients (73%) post-treatment and 67 of 71 patients 
(94%) at six week follow-up (Figure 5.3). 
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Figure 5.3.  FFQ completion rate 
 
Responses to the tick-box question concerning frequency of oily fish intake (Figure 
5.4A) were recorded and analysed according to the original questionnaire 
categories.    Patients' responses were analysed to compare oily fish consumption 
between the two groups at each time-point in the study, as well as comparing 
changes in individual patients' oily fish consumption during their participation in the 
study.  
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Figure 5.4.  Excerpt from the FFQ.  Arrows indicate the questions relating to oily fish 
intake which were analysed for comparison between groups.  Patients were asked to reflect 
on the last 1 month of food use, not 1 year as indicated on the questionnaire.   
 
 
At baseline, the EPA group were non-significantly higher consumers of oily fish than 
the placebo group (Figure 5.5), with 61% of patients consuming 1 or more portions 
per week compared to only 44% of patients in the placebo group (χ2  p=0.16).  This 
difference was not seen when patients were asked again post-treatment and at 
follow-up, with 42-47% of patients in each group consuming 1 or more portion per 
week at these time points.  When examining patients in the highest oily fish 
consumption category of 2-4 portions/week (Figure 5.5), the proportion of patients 
A 
B 
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in this category was similar between groups at baseline (17% placebo vs. 14% 
EPA, χ2 p=0.74).  This proportion fell in the placebo group and increased in the EPA 
group post-treatment (12.5% vs. 19.2%, Χ2 p=0.48), and at follow-up this proportion 
rose in the placebo group and fell in the EPA group (19% vs. 9%, χ2 p=0.20).  
Paired data was available for comparison of individual patients' change in oily fish 
intake between baseline and post-treatment for 26 of 43 patients in the placebo 
group (60%) and 24 of 38 patients in the EPA group (63%).  In the placebo group 
27% of patients report a higher category of fish intake post-treatment than at 
baseline, 27% report a lower category, and 46% reported the same category.  In 
the EPA group, 25% reported a higher category, 35% reported a lower category 
and 42% reported the same category. 
 
 
Figure 5.5.  Patient-reported consumption of oily fish portions per week/month.   
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Responses to the question "how many times did you eat fish or fish products" 
(Figure 5.3B) were analysed as the actual numerical response (Figure 5.6).  
Consumption of oily fish portions remained constant across the duration of the 
study in the placebo group (Wilcoxon matched-pairs signed rank test comparing 
baseline to post-treatment and post-treatment to follow-up, p=0.21 and p=0.56 
respectively).  The EPA group reported a increase in the number of oily fish 
portions consumed post-treatment compared to baseline.  This did not reach 
statistical significance when compared to baseline consumption in the EPA group 
(Wilcoxon matched-pairs signed rank test p=0.79), but was significantly higher than 
the oily fish consumption in the placebo group post-treatment (Mann-Whitney U test 
p=0.02). 
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Figure 5.6. Self-reported number of oily fish portions consumed per week at each 
time point in the trial  
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5.7 Tumour PUFA levels 
Tumour samples were available for analysis of PUFA content for 37 patients in the 
EPA group and 37 patients in the placebo group (as described in Section 5.2, fresh 
frozen tissue samples could not be obtained for all patients).  Levels of individual 
PUFAs in each tumour were analysed and expressed as a percentage of the total 
fatty acid content of the tumour (Table 5.6).  Mean PUFA levels were compared 
between groups (Figure 5.7), with statistical comparisons using unpaired student t-
tests.  Compared to the placebo group, tumours from the EPA group had 40% 
higher EPA levels (p<0.01), but no significant difference in AA levels.  The AA:EPA 
ratio was reduced in the EPA group compared to the placebo group, predominantly 
due to a higher level of EPA rather than a lower level of AA in the EPA group.   
Tumours from the EPA group also had 41% higher levels of the ω-3 PUFA DPA 
(p<0.01) and 11% lower levels the ω-3 PUFA DHA (p=0.05).  
There was no correlation between duration of EPA treatment and tumoural levels of 
AA (Pearson's correlation -0.073, p=0.67), EPA (correlation 0.031, p=0.86), DHA 
(correlation -0.053, p=0.74) or DPA (correlation 0.258, p=0.12).   
Tumour 
PUFA  
PLACEBO EPA % change 
compared to 
placebo 
p= 
EPA   1.30% (+-0.10) 1.82% (+-0.11) +40% <0.01* 
DPA 1.25% (+-0.08) 1.76% (+-0.09) +41% <0.01* 
DHA  2.89% (+-0.12) 2.56%(+-0.11) -11% 0.05* 
AA  12.82% (+-0.53) 12.03% (+-0.45) -6% 0.26 
AA:EPA ratio  11.35 (+-0.72) 7.58 (+-0.53) -33% <0.01* 
 
Table 5.6.  Tumour PUFA content.  Individual tumour PUFA levels were analysed and 
expressed as a % of the total tumour fatty acid content for each tumour.  Data represent 
mean (+-SEM) 
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Figure 5.7.  Scatter plots of PUFA levels in the tumours from each group.  PUFA levels 
were analysed and expressed as a % of the total tumour fatty acid content for each tumour.  
Error bars represent mean+-SEM.   
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Those patients who were either taking fish oil supplements prior to enrolment in the 
trial, or who were in the highest category of oily fish consumption at baseline (2-4 
portions oily fish per week) were identified and highlighted on the tumour PUFA 
graphs (Figure 5.8 A).  This represented 12 patients in the placebo group and 7 
patients in the EPA group.  Those patients in the placebo group who fell into this 
category had significantly higher tumoural EPA content than those patients in the 
placebo group who did not fall into this category (unpaired t-test p=0.04).  Re-
analysis of tumour PUFA levels excluding these patients shows that the magnitude 
of EPA increase, AA decrease, and AA:EPA decrease in the EPA group are all 
more pronounced when these patients are excluded (Table 5.7).   
Re-analysis of tumoural PUFA content excluding the 7 patients in the EPA group 
who were prior fish oil users or in the highest category of oily fish still demonstrated 
no correlation between duration of EPA treatment and tumour PUFA levels.   
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Figure 5.8.  Scatter plots of tumoural EPA content.  A) Tumours from patients who were 
pre-existing FO users or who reported the highest category of oily fish intake (2-4portions 
per week) are marked in red. B) Tumour EPA content after exclusion of those 12 patients in 
the placebo group and 7 patients in the EPA group highlighted in red in Figure A.  
 
 
 
 
Tumour 
PUFA  
PLACEBO EPA %change 
compared to 
placebo 
p= 
AA  13.45% (+-0.70) 12.31% (+-2.74) -8.5% 0.19 
EPA   1.16% (+-0.07) 1.81% (+-0.12) +56.0% <0.01 
DPA 1.22% (+-0.09) 1.81% (+-0.10) +48.4% <0.01 
DHA  2.77% (+-0.13) 2.54%(+-0.13) -8.3% 0.20 
AA:EPA 
ratio  
 12.42(+-0.78) 7.66 (+-0.57) -38.3% <0.01 
 
Table 5.7.  Subanalysis of tumour PUFA content.  Mean (+-SEM) levels of individual 
PUFAs in the tumours from each group after exclusion of patients who were either taking 
fish oil supplements or in the highest category of oily fish consumption prior to enrolment in 
the trial.   Individual tumour PUFA levels were analysed and expressed as a % of the total 
tumour fatty acid content for each tumour. 
A B 
116 
 
 
5.8 Tumour PGE2 and PGE3 levels 
Tumour samples were available for analysis of PGE2 and PGE3 levels for 37 
patients in the EPA group and 37 patients in the placebo group (see section 5.2).  
PGE2 was detected in all tumour samples (Figure 5.9).  Median (range) PGE2 
content of tumours was 6.62ng/g (0.44-33.40ng/g) in the EPA group and 5.87ng/g 
(1.89-447.00ng/g) in the placebo group.  There was no significant difference in 
tumoural PGE2 content between the two groups (MWU p=0.68).  Due to the 
potential confounding factor that aspirin irreversibly acetylates COX, one of the 
pathways by which EPA is proposed to exert anti-CRC activity, subanalysis 
excluding patients who were taking concurrent aspirin was performed for all 
mechanistic analyses.  This subanalysis showed no difference in tumoural PGE2 
content between the EPA and placebo groups (median 6.9 vs. 7.2ng/g respectively, 
MWU p=0.77).   
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Figure 5.9.  PGE2 content of tumours.  Error bars represent median+-IQR.   
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PGE3 was detected in only one tumour sample; that with the highest level of PGE2.  
PGE3 level in this tumour was 21.10ng/g.  If present, PGE3 in all other tumour 
samples was present at concentrations below the limit of detection (<10ng/g). 
 
There was no correlation between duration of EPA supplementation and tumoural 
PGE2 level (Pearson correlation -0.18, p=0.28).  There was a weak inverse 
relationship between tumoural EPA level and tumoural PGE2 (Figure 5.10; 
correlation -0.30, p=0.01), but not between tumoural AA level and tumoural PGE2 
(correlation -0.11, p=0.36). 
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Figure 5.10. Correlation between tumoural PGE2 level and tumoural EPA content    
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5.9 Ki-67 Proliferation index 
Immunohistochemistry for Ki-67 was performed on 78 tumour samples (EPA n=37, 
placebo n=41) in five batches.  Three sections, with a range of staining intensity, 
were chosen from the first batch and sequential sections from these tumours used 
as internal controls for each subsequent batch. Clearly identifiable distinct 
morphological regions of these internal controls were identified and photographed 
in each batch and scored for PI.  Subjectively, there was good consistency of 
staining with a similar pattern and intensity of staining to the naked eye across the 
five batches for each internal control (Figure 5.11).  Objectively there was low 
variance in the PI when calculated for each internal control across the five batches 
(Figure 5.11).  
Regions of interest (ROI) in the sample sections were then identified and scored as 
described in Chapter 4.7.1. The Ki-67 antigen is a nuclear protein expressed in all 
proliferating cells during late G1, S, M and G2 phases of the cell cycle.  Figures 
5.11 and 5.12 show that the pattern of Ki-67 staining is, as expected, localised to 
cell nuclei with no staining of acellular, mucinous or stromal regions of tumour.  
Figure 5.12 shows three representative ROIs, one from a typical cellular tumour 
with dense cellular staining, one from a tumour with a greater amount of stroma and 
more patchy areas of dense nuclear staining, and the other from a mucinous 
tumour with very sparse nuclear staining.  Mucinous tumours were found in 11 
patients (13.6%), six in the EPA group (16.2%) and 5 in the placebo group (12.2%).  
These mucinous tumours with sparse cellular areas typically required more than 
one ROI to be photographed and scored to satisfy the requirement of counting 
>500 cells.  One patient in the placebo group had a very mucinous tumour with no 
identifiable tumour cells in the section.  It was not possible to score this section for 
Ki-67 PI.  Ki-67 PI was therefore scored for 40 patients in the placebo group and 37 
patients in the EPA group. 
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Figure 5.11.  Internal control sections in each batch of Ki-67 staining.   
 
This Figure and legend is continued overleaf.  
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Figure 5.11.  Internal control sections in each batch of Ki-67 staining.  Three tumours 
with a range of Ki-67 staining  were selected for use as internal controls.  Adjacent sections 
of these tumours were used as internal controls in the five batches of Ki567 staining.  A 
distinctive ROI was identified in each internal control, and this ROI scored for proliferation 
index (PI) as a comparison of staining across the 5 batches.   The photographs of these 
ROIs demonstrates the consistency of staining of each internal control across the 5 different 
batches of Ki-67 IHC. The table shows the mean PI and variance for each internal control.  
Internal 
control ID 
Mean PI SEM Range 
Coefficient of 
variance 
10-1097A 77.6% 0.7 75.9 - 79.1 0.02% 
10-1136B 93.7% 0.7 92.5 - 96.1 0.02% 
10-1159A 83.0% 0.8 81.1 - 85.8 0.02% 
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Figure 5.12.  Examples of tumour staining for Ki-67.  These regions of interest show 
tumours with (A) a predominantly cellular architecture, (B) larger amounts of stroma, and (C) 
a predominantly mucinous architecture.  Note that regions of non-tumour cells were not 
counted in the calculation of PI.  Examples of these regions are marked in the dotted areas 
representing  in (A) inflammatory infiltrate, in (B) stroma, and in (C) mucin. 
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The PIs for each group are illustrated in Figure 5.13.  The mean PI in the placebo 
group was 72.96% +- 2.36 SEM (range 33.51% – 96.20%).  The mean PI in the 
EPA group was 70.70% +- 2.65 SEM (range 32.77% - 90.92%).  There was no 
significant difference in PI between the two groups (p=0.68).   
The variable duration of EPA supplementation in this study was a potential 
confounder for the Ki-67 proliferation analysis.  I therefore performed a linear 
regression analysis to investigate the effect of EPA treatment duration on tumour 
Ki-67 PI.  Duration of EPA supplementation was not associated with the Ki-67 PI 
(Figure 5.14, p=0.75).  It was also hypothesised that EPA might affect tumour 
proliferation by increasing tumour EPA content and driving a reduction in tumour 
PGE2 levels.  I therefore performed linear regression analysis to investigate for any 
association between these variables.  Tumour Ki-67 PI was not associated with 
either tumour EPA content (p=0.95) or with tumour PGE2 levels (p=0.64).  
Subanalysis performed after exclusion of patients who were taking concurrent 
aspirin also showed no difference in Ki-67 PI content between the EPA and placebo 
groups (p=0.86). 
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 Figure 5.13.  Ki-67 proliferation index.  Error bars represent mean+- SEM. 
 
 
E ffe c t o f  d u ra t io n  o f E P A  s u p p le m e n ta tio n
o n  tu m o u r  p r o life ra t io n
D a y s
K
i-
6
7
 P
I
0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0
0
2 0
4 0
6 0
8 0
1 0 0
  
Figure 5.14.  Relationship between the duration of EPA supplementation and tumour 
Ki-67 proliferation index.   
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5.10 neo-CK18 Apoptosis index 
Validation of the automated image analysis algorithm (Chapter 4.7.3) was 
performed on a total of 20 representative ROIs taken from 3 separate tumour 
sections.  The image analysis algorithm recorded both the number of positive pixels  
and the number of "objects" i.e. the number of discrete, separate areas of positive 
pixels.  From this, the percentage positive pixels (positive pixels / total pixels x 100) 
and an object count standardised to tumour size (number of objects per million 
pixels) were calculated.  Note that these measures are not referred to as an 
apoptosis index, since neither measure is a true cell count of positive and 
negatively stained cells. 
After reviewing the markup images from the automated image analysis (examples 
shown in Figure 5.15), it was clear that the areas of DAB staining detected by the 
algorithm included both discrete apoptotic epithelial cells in areas of glandular 
epithelium and extruded neo-CK18 positive cells and cell debris in more necrotic 
areas of tumour (Figure 5.15).  By contrast, areas of light brown non-specific 
staining in acellular areas of the tumour were not detected.  I decided that it was 
justifiable to include both of these detected regions in a measure of apoptosis, since 
counting only discrete apoptotic cells would exclude from the analysis those 
tumours with larger areas of necrotic apoptotic debris.  This would risk excluding 
large areas of staining which may be the result of pro-apoptotic activity of EPA.  
Secondly, to the naked eye the sections of low, medium and high intensity of 
apoptosis staining seemed to correlate with the distribution of low, medium and high 
detection on the algorithm markups.  I therefore proceeded to perform a formal 
comparison of manual AI scoring of the ROIs against each of the two measures of 
apoptosis obtained from the automated image analysis.     
There was a strong positive correlation (Figure 5.16) between the manual AI and 
the algorithm “object count” (Spearman r=0.81, p<0.01), and between the manual 
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AI and the algorithm “% positive pixels” (Spearman r=0.80, p<0.01).  Because a) 
the two measures of apoptosis obtained from the automated image analysis provide 
a slightly different means of quantifying apoptosis, b) neither of them represent a 
true apoptosis index, and c) they both correlated well with the manual cell count for 
AI, I decided to use both measures when comparing apoptosis between the EPA 
and placebo groups.  Furthermore, although the measures of apoptosis of the 
automated analysis are not directly comparable to AI scores in other studies, the 
manual AI scores of 0-7% in the tumour sections are comparable with the hotspot 
AI scores (0.07-8.44%) in the similarly designed rofecoxib study by Fenwick et 
al,(271) and with AI scores in various other studies of CRCLM by Marshall et al (2-
8%),(310) Howells et al (3% in control arm),(311) Backus et al (13% in control 
arm)(312) and Tatebe et al (4.8-8.2%).(313)  Therefore any changes in apoptosis 
scoring found on automated analysis could be considered representative of 
changes in AI scores in other studies, even though these different methods cannot 
be directly compared.   
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Figure 5.15.  Representative sections of neo-CK18 staining.  The neo-CK18 stained 
sections are shown (left) together with the corresponding automated image analysis mark-
ups (right).  Areas of apoptosis detected by the algorithm are highlighted in red.  Note that 
the algorithm has detected both apoptotic epithelial cells in glandular epithelium (solid black 
arrows) as well as positive cells or cell debris in necrotic areas of tumour (open arrows).     
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Figure 5.16.  Correlation between manual and automated scoring of neo CK-18 
staining.  Lines represent line of best fit.   
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Immunohistochemistry for neo-CK 18 was performed on 78 tumour samples (EPA 
n=37, placebo n=41) in 5 batches.  Three sections, with a range of staining 
intensity, were chosen from the first batch and sequential sections from these 
tumours used as internal controls for each subsequent batch.   
Subjectively the consistency of staining across the five batches was good, with a 
similar pattern and intensity of staining to the naked eye across the five batches for 
each internal control (Figure 5.17).  However, there was wide variation in both 
apoptotic object count and apoptotic area (% positive pixels) across the five 
batches for each of the internal controls (Table 5.9).  The high coefficient of 
variance in the internal controls was more likely due to the very low count of stained 
apoptotic bodies across a large area, with small variations in apoptotic count 
resulting in a large coefficient of variance,  rather than due to poor reproducibility of 
the assay.   
Internal 
control ID 
Object count per million pixels 
Mean SEM Range 
Coefficient of 
variance 
11-0266 4.26 1.21 1.44 - 8.33 65.6% 
11-0271 5.05 1.05 1.54 - 6.46 46.3% 
11-0586 13.91 1.24 10.70 - 15.90 19.9% 
 
Internal 
control ID 
% positive pixels 
Mean SEM Range 
Coefficient of 
variance 
11-0266 0.0028 0.0011 0.0004 - 0.0063 85.9% 
11-0271 0.0017 0.0004 0.0004 - 0.0029 54.0% 
11-0586 0.0102 0.0010 0.0080 - 0.0133 21.6% 
 
Table 5.8.  Measures of apoptosis for the internal control sections stained for neo-
CK18 in each batch.   
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Figure 5.17.  Internal control sections in each batch of neo-CK 18 staining.  Three 
tumours with a range of neo-CK 18 staining  were selected for use as internal controls.  
Adjacent sections of these tumours were used as internal controls in the five batches of 
neo-CK 18 staining.  A distinctive ROI was identified in each internal control, photographed, 
and presented here as an example of the consistency of staining between batches.  Note 
that the measures of apoptosis were scored for the whole of each slide, not just the 
representative ROIs in this figure.    
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Apoptosis was scored for all tumour samples.  The measures of apoptosis for each 
group are illustrated in Figure 5.18.  The median object count per million pixels was   
4.98 (interquartile range, IQR 2.43 - 10.52) in the EPA group and 3.83 (IQR 2.31 - 
8.23) in the placebo group (MWU p=0.56).  The median % positive pixels was 
0.0028 (+-0.0004 SEM) in the EPA group and 0.0020 (+- 0.0004 SEM) in the 
placebo group (MWU p=0.53).  There was no significant difference in the measures 
of apoptosis between the two groups.  Subanalysis performed after exclusion of 
patients who were taking concurrent aspirin also showed no difference in object 
count or % positive pixels between the EPA and placebo groups (p=1.00 and 
p=0.76 respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18.  Measures of neo-CK 18 positive apoptosis detected by automated image 
analysis.  Two measures of apoptosis, the standardised object count and percentage 
positive pixels were recorded for each tumour.  Error bars represent median +/- IQR.       
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5.11 CD31 Microvessel density 
Immunohistochemistry for CD31 was performed on 78 tumour samples (EPA n=37, 
placebo n=41) in 5 batches.  Examples of the automated CD31-stained vessel 
detection are shown in Figure 5.19 and Figure 5.20.   
Three sections, with a range of staining intensity, were chosen from the first batch 
and sequential sections from these tumours used as internal controls for each 
subsequent batch.  Subjectively there was good consistency of staining across the 
five batches (Figure 5.21) although there was wide variation in both tumour vessel 
density and percentage vascular area across the five batches for each of the 
internal controls (Table 5.10).  
 
Internal 
control 
ID 
Vessel density (vessels per million square microns) 
Mean SEM Range 
Coefficient of 
variance 
11-0587 157.46 18.21 105.49 - 198.45 25.9 
11-0261B 116.33 27.37 33.62 - 204.69 52.6 
11-0263B 26.52 4.89 18.40 - 45.61  41.1 
 
Internal 
control 
ID 
% vascular area 
Mean SEM Range 
Coefficient of 
variance 
11-0587 0.29 0.04 0.17 - 0.37 29.8 
11-0261B 0.38 0.10 0.09 - 0.66 55.9 
11-0263B 0.04 0.02 0.03 - 0.07 43.2 
 
Table 5.9.  Measures of tumour vascularity for the internal control sections stained 
for CD31 in each batch. 
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Figure 5.19.  Representative sections of immunohistochemistry for CD31 tumour 
vascularity.  CD31-stained endothelial vessels are visible in brown, and those vessels 
detected by the automated image analysis algorithm are highlighted in green on the 
corresponding markup image (examples of corresponding vessels marked with solid black 
arrows).  Note that the algorithm does not highlight areas of non-specific DAB staining as 
endothelial cells (examples marked with open arrows).  
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Figure 5.20.  Further representative sections of immunohistochemistry for CD31 
tumour vascularity.  CD31-stained endothelial vessels are visible in brown, and those 
vessels detected by the automated image analysis algorithm are highlighted in green on the 
corresponding markup image (examples of corresponding vessels marked with solid black 
arrows).  Note that the algorithm does not highlight areas of non-specific DAB staining as 
endothelial cells (examples marked with open arrows), which are more extensive in this 
section than in Figure 5.18.  
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Figure 5.21.  Internal control sections in each batch of CD31 staining.  Three tumours 
with a range of CD31 staining  were selected for use as internal controls.  Adjacent sections 
of these tumours were used as internal controls in the five batches of CD31 staining.  A 
distinctive ROI was identified in each internal control, photographed, and presented here as 
an example of the consistency of staining between batches.  Note that the measures of 
tumour vascularity were scored for the whole of each slide, not just the representative ROIs 
in this figure.    
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In the EPA group, one section was scanned out of focus and was unable to be 
scored, and in the placebo group two tumour sections were erroneously scanned in 
duplicate in place of two other tumour sections.  MVD was therefore scored for 36 
tumours in the EPA group and 39 tumours in the placebo group.  The measures of 
tumour vascularity for each group were log transformed to normalise the 
distribution, then summary statistics were converted back to the original scale for 
presentation in numerical and graphical form (Figure 5.22).  The geometric mean 
vessel density in the EPA group was 18.54 vessels per million square microns 
compared to 19.50 vessels per million square microns for the placebo group 
(p=0.87), and the geometric mean % vascular area was 0.030% in the EPA group 
compared to 0.034% in the placebo group (p=0.74).  There was no correlation 
between indices of tumour vascularity and either duration of treatment or tumoural 
PUFA content.  Subanalysis performed after exclusion of patients who were taking 
concurrent aspirin also showed no difference in vessel density or % vascular area 
between the EPA and placebo groups (p=0.66 and p=0.76 respectively).  
 
     
 
 
 
 
 
 
 
Figure 5.22.  Tumour vessel density and % vascular area. Error bars represent 
geometric mean and 95% confidence interval. 
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Subanalysis was performed excluding those patients who were either pre-existing 
FO users or who were in the highest oily fish consumption category at baseline.  
These patients are highlighted in red in Figure 5.23A.  When these patients were 
excluded (Figure 5.23B) and the data re-analysed there was a trend to reduced 
tumour vascularity in the EPA group compared to placebo. Geometric mean tumour 
vascular area was 48% lower in the EPA group lower compared to placebo 
(0.027% vs. 0.052%, p=0.07), and geometric mean tumour vessel density was 43% 
lower in the EPA group compared to placebo (16.87 vs. 29.58, p=0.09). 
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Figure 5.23.  Subanalysis of tumour vascularity.  A) Patients who were already taking ω-
3 PUFA supplements prior to inclusion in The EMT Trial, or who reported the highest 
category of oily fish consumption at baseline, are highlighted in red.  B) Sub-analysis 
comparing tumour vascularity in the EPA and placebo groups was then performed after 
excluding these patients. Error bars represent geometric mean and 95% confidence 
interval.   
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5.12 Urinary PGE-M 
Urine samples were not analysed from the seven patients withdrawn from the study 
before undergoing surgery and the one patient who had a histological diagnosis of 
HCC.  Baseline urine samples were therefore analysed for all 80 patients with 
CRCLM who underwent surgery (EPA n=38, placebo n=42).  Pre-operative urine 
samples were not obtainable from the two patients in the placebo group whose 
surgery was brought forward without my knowledge.  Pre-operatively urine samples 
were therefore analysed for 78 patients (EPA n=38, placebo n=40).  One patient in 
the EPA group was unable to provide a final urine sample at the final study visit, 
and final urine samples were not obtainable from the seven patients in the placebo 
group and two patients in the EPA group who were discharged from the 
Hepatobiliary Unit's care after recovering from their surgery and did not attend the 
final study visit.  Follow-up urine samples were therefore analysed for 68 patients 
(EPA n=35, placebo n=33).    
Urinary creatinine levels were below the limit of detection (<1.5mmol/l) in four 
samples in the placebo group and a technical problem with the MS/MS apparatus 
prevented detection of PGE-M in one sample in the EPA group.  PGE-M 
standardised to urinary creatinine could therefore not be calculated for these 
samples.  Ten samples in the EPA group and 7 in the placebo group had PGE-M 
levels below the limit of detection (LOD, <10ng/g), and were therefore recorded as 
this LOD value for the purpose of analysis.  Data was log transformed to normalise 
the distribution for analysis, then summary statistics were converted back to the 
original scale for presentation in tabular and graphical form.      
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EPA 
Baseline 
n=38 
Post-treatment 
n=37 
Follow-up 
n=34 
1
p= 
(37 pairs) 
2
p= 
(33 pairs) 
Geometric 
mean 
13.58 9.83 14.96 0.17 0.02 
95% CI 10.21 - 18.07 6.82 - 14.16 10.00 - 22.39   
Placebo 
Baseline 
n=39 
Post-treatment 
n=40 
Follow-up 
n=33 
1
p= 
(37 pairs) 
2
p= 
(31 pairs) 
Geometric 
mean 
15.92 20.37 15.52 0.10 0.14 
95% CI 11.75 - 21.63 16.41 - 25.29 11.32 - 21.28   
3
p= 0.44 <0.01 0.89   
 
Table 5.10. Urinary PGE-M.  Geometric mean and 95% confidence interval (CI) for PGE-M 
in ng/mg creatinine at baseline, post-treatment (i.e. completion of study medication), and at 
the six weeks follow-up appointment (off study medication). 
1
 Paired t-test comparing paired 
patient data at baseline and post-treatment.  
2
 Paired t-test comparing paired patient data at 
post-treatment and follow-up.  
3 
Unpaired t-test comparing EPA vs. placebo groups at each 
time point. 
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Figure 5.24.  Scatterplot of urinary PGE-M. Data given in ng/mg creatinine at baseline, 
post-treatment (i.e. completion of study medication), and at the six weeks follow-up 
appointment (off study medication). Error bars represent geometric mean and 95% 
confidence interval. 
p<0.01 
 
p=0.02 
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There was no significant difference in mean PGE-M between the two groups at 
baseline (Table 5.11 and Figure 5.24). Post-treatment PGE-M was 51.8% lower in 
the EPA group compared to placebo (p<0.01).  This represented a 27.6% reduction 
in urinary PGE-M in the EPA group between baseline and post-treatment, and a 
27.9% increase in urinary PGE-M in the placebo group between baseline and post-
treatment. Urinary PGE-M levels rose again by 52.2% at follow-up in the EPA group 
(p=0.02), and fell by 18.2% in the placebo group (p=0.14).  There was no significant 
difference in PGE-M between the two groups at the six weeks post-operative follow-
up appointment (p=0.89), and no significant change in urinary PGE-M between 
baseline and follow-up in either group (EPA p=0.61, placebo p=0.60).    
There was no correlation between the duration of treatment in the EPA group and 
the change in urinary PGE-M between baseline and post-treatment (Pearson 
correlation coefficient 0.059, p=0.73).  Sub-analysis by gender revealed no 
significant differences between the two groups or between male and females 
(Figure 5.25).  Sub-analysis excluding those patients who were already taking ω-3 
PUFA supplements prior to enrolment in the Trial or who were high consumers of 
oily fish did not reveal any significant differences between the two groups.  
Subanalysis performed after exclusion of patients who were taking concurrent 
aspirin also showed no difference between the two groups. 
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Figure 5.25.  Scatterplots of urinary PGE-M stratified by sex.  Error bars represent 
geometric mean and 95% confidence interval.   
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5.13 PBMC nuclear NFκB activation  
Blood samples were not analysed from the seven patients withdrawn from the study 
before undergoing surgery and the one patient who had a histological diagnosis of 
HCC.  Baseline blood samples were analysed for all 80 patients with CRCLM who 
underwent surgery (EPA n=38, placebo n=42).  Post-treatment blood samples were 
not obtainable from the two patients in the placebo group whose surgery was 
brought forward without my knowledge.  Post-treatment blood samples were 
therefore analysed for 78 patients (EPA n=38, placebo n=40).  Follow-up blood 
samples were not obtainable from seven patients in the placebo group and two 
patients in the EPA group who did not attend the final study visit.  Follow-up blood 
samples were analysed for 69 patients (EPA n=36, placebo n=33).  Paired samples 
were available for 40 placebo and 38 EPA patients between baseline and post-
treatment, and for 33 placebo and 36 EPA patients between post-treatment and 
follow-up.  One spuriously high LPS-stimulated sample from the EPA group, 
suggestive of protein contamination in the sample, was excluded from analysis.  
There was insufficient sample left to repeat this analysis.  
LPS stimulation of PBMCs consistently increased nuclear NFκB activation 
compared to un-stimulated PBMCs in both groups and at each time point (Figures 
5.26 and 5.27).  There was no significant difference between the two groups at any 
time point in either LPS-stimulated or LPS un-stimulated nuclear NFκB activation.  
Within the placebo group, there was no significant change in nuclear NFκB 
activation across the study period.  In the EPA group there was a reduction in both 
LPS-stimulated and un-stimulated nuclear NFκB activation post-treatment 
compared to baseline (15.5% and 20.3% reduction, p=0.03 and p=0.07 
respectively).  At follow-up, both LPS-stimulated and un-stimulated nuclear NFκB 
activation increased back to baseline values (28% and 29.5% increase, p<0.01 and 
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p=0.02 respectively).  Subanalysis performed after exclusion of patients who were 
taking concurrent aspirin also showed no difference between the two groups.    
      
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26.  Barchart of LPS un-stimulated mean nuclear NFκB activation. Paired t-
tests were used to compare change in nuclear NFκB activation over time within each group.  
All p-values not depicted were non-significant.  Error bars represent mean +- SEM.    
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Figure 5.27.  Barchart of LPS-stimulated mean nuclear NFκB activation. Paired t-tests 
were used to compare change in nuclear NFκB activation over time within each group.  All 
p-values not depicted were non-significant.  Error bars represent mean +- SEM.    
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5.14 Platelet aggregation  
Platelet aggregation (arbitrary units, AU) at baseline was stratified based on aspirin, 
clopidogrel, or fish oil (FO) supplementation use at the time of entry into the EMT 
Trial to assess the sensitivity of the assay to the anti-platelet effect of these 
medication (Figure 5.26).  Baseline blood samples were available for 15 aspirin 
users, 4 aspirin + FO users, 2 clopidogrel users, 1 clopidogrel + FO user, 9 FO 
users, and 54 patients who were naive to all of these.  One patient withdrew 
consent after randomisation and prior to baseline blood sampling.  One patient's 
blood sample was delayed in returning to the laboratory (greater than the 3 hours 
window for analysis recommended by the manufacturer) and had partially clotted.  
Another patient had poor venous access and blood sampling was technically 
difficult.  This patient's sample had partially clotted on return to the laboratory.  Both 
these partially clotted samples were discarded and not analysed. 
Mean (+-SEM) platelet aggregation in aspirin users compared to naive individuals 
was 83% lower in response to AA stimulation (13.1+-2.4AU vs. 78.2+-3.8 AU, 
p<0.01), 36% lower in response to collagen stimulation (48.6+-5.3AU vs. 75.6+-
3.3AU, p<0.01), and 62% lower in response to low dose collagen stimulation 
(22.6+-4.0AU vs. 59.1+-3.6AU, p<0.01).  Stimulation with ADP had no effect on 
platelet aggregation in aspirin users compared to naive individuals.  Platelet 
aggregation was further reduced in response to all agonists in the small number of 
patients taking aspirin and FO compared to aspirin alone, but this did not reach 
statistical significance (Figure 5.28A). 
Because of the small number of patients in the clopidogrel (n=2) and clopidogrel 
+FO (n=1) groups, these patients were grouped together for the purpose of 
evaluating the assays sensitivity to the anti-platelet effect of clopidogrel.  Mean (+-
SEM) platelet aggregation in clopidogrel users compared to naive individuals was 
58% lower in response to ADP stimulation (27.3+-3.2AU vs. 64.8+-3.9AU, p=0.03) 
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and non-significantly 35% lower in response to low dose collagen stimulation 
(38.7+-11.6AU vs. 59.1+-3.6AU, p=0.20).  Stimulation with AA or collagen had no 
effect on platelet aggregation in clopidogrel users compared to naive individuals 
(Figure 5.28B). 
There was no significant difference in platelet aggregation between FO users and 
naive individuals in response to either AA, ADP, collagen or low dose collagen 
stimulation (Figure 5.28C). 
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Figure 5.28.  Baseline platelet aggregation (arbitrary units) in response to different 
agonists.  Patients have been stratified by prior aspirin (A), clopidogel (B) and fish oil (FO) 
use (C) and compared to "naive" patients not taking these at baseline.  Error bars represent 
mean +- SEM.  AA=arachidonic acid, ADP=adenosine diphosphate, COL=collagen 
3.2µg/ml, COL-LO = low-dose collagen 0.64µg/ml.    
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Blood samples were not analysed from the seven patients withdrawn from the study 
before undergoing surgery and the one patient who had a histological diagnosis of 
HCC.  One patient in the placebo group had difficult venepuncture and his baseline 
blood sample partially clotted prior to analysis and was discarded.  Baseline blood 
samples were therefore analysed for 79 patients (EPA n=38, placebo n=41).  Post-
treatment blood samples were not obtainable from the two patients in the placebo 
group whose surgery was brought forward without my knowledge.  Post-treatment 
blood samples were therefore analysed for 78 patients (EPA n=38, placebo n=39).  
Follow-up blood samples were not obtainable from the seven patients in the 
placebo group and two patients in the EPA group who were discharged from the 
Hepatobiliary unit's care after recovering from their surgery and did not attend the 
final study visit.  Follow-up blood samples were analysed for 68 patients (EPA 
n=36, placebo n=32).   
There was no significant difference between the two groups in platelet aggregation 
in response to either AA, ADP, collagen or low dose collagen at any time point in 
the study (Figure 5.29, unpaired t-tests).  There was a small reduction in platelet 
aggregation in response to low dose collagen stimulation in the EPA group 
compared to the placebo group post-treatment, but this did not reach statistical 
significance (p=0.08), and was in fact due to an increase in platelet aggregation in 
the placebo group compared to baseline rather than a reduction in platelet 
aggregation in the EPA group compared to baseline.  Neither EPA nor placebo 
treatment was associated with a change in platelet aggregation in response to any 
of the four agonists between baseline and post-treatment (Figure 5.29, paired t-test 
analysis, all p=NS). 
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Figure 5.29. Platelet aggregation at baseline, post-treatment and follow-up.  Each 
graph shows platelet aggregation in response to a different agonists.  Error bars represent 
mean +- SEM.   AA=arachidonic acid, ADP=adenosine diphosphate. 
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Although no antiplatelet effect was seen in the EPA group, because of historic 
concerns about the risk of bleeding with ω-3 PUFA supplementation and because 
many patients are already takin aspirin pre-operatively, I performed subgroup 
analysis to investigate the effect on of EPA and aspirin when taken in combination.  
The antiplatelet effect of aspirin alone at baseline has already been shown in Figure 
5.28.  There were seven patients in each group who were taking aspirin and who 
had paired baseline and pre-operative samples available for analysis.  There was 
no significant difference in platelet aggregation at baseline between the aspirin 
consumers in each group (Figure 5.30 A).  Both at baseline, and post-treatment 
(Figure 5.30 B), platelet aggregation was non-significantly lower in the EPA group 
compared to the placebo group.  In both groups there was a significant increase in 
platelet aggregation between baseline and post-treatment (Figure 5.31 A and B)  
However, these results may have been confounded by patients stopping their 
aspririn pre-operatively before they came in to hospital.  Whilst it is not the policy of 
the Hepatobilary Unit to stop aspirin pre-operatively, it is conceivable that either 
patients chose to stop their aspirin because of a perceived bleeding risk of major 
surgery, or they are advised to do so by their GPs or other health professionals for 
the same reason.  Data was not collected on the date of last aspirin use, so this 
could not be investigated further, but on the basis of the available evidence EPA + 
aspirin did not impair platelet aggregation compared to aspirin alone.   
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Figure 5.30  Subanalysis between groups of platelet aggregation in aspirin users.  
Seven patients in each group were taking aspirin during the study and had paired baseline 
and pre-operative samples available for analysis.  Error bars represent mean +- SEM.  
Groups were compared at baseline (A) and pre-operative (B) using Mann Whitney U test.  
Selected p-values are presented, with all other p-values being non-significant.  
AA=arachidonic acid, ADP=adenosine diphosphate, COL=collagen 3.2µg/ml, COL-LO = 
low-dose collagen 0.64µg/ml.       
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Figure 5.31  Subanalysis over time of platelet aggregation in aspirin users.  Seven 
patients in each group were taking aspirin during the study and had paired baseline and 
post-treatment samples available for analysis (A= EPA group, B=placebo group).  Error bars 
represent mean +- SEM.  Comparison of aggregation over time within each group was 
performed using Wilcoxon matched-pairs signed rank test.  Selected p-values are 
presented, with all other p-values being non-significant. AA=arachidonic acid, 
ADP=adenosine diphosphate, COL=collagen 3.2µg/ml, COL-LO = low-dose collagen 
0.64µg/ml.           
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5.15 Discussion of results from The EMT Trial 
 
Safety and tolerability 
The EMT Trial has demonstrated that pre-operative supplementation of EPA is safe 
and well-tolerated in patients with CRCLM awaiting liver resection.  The type and 
frequency of side effects seen, namely gastrointestinal upset, are comparable to 
previous studies using the same preparation of EPA-FFA 2g daily.  In a phase III 
study of six months EPA supplementation in patients who had undergone subtotal 
colectomy for FAP,(262) diarrhoea was reported by 31% of patients taking EPA and 
35% of patients taking placebo.  Withdrawal due to EPA intolerance was 3.4%.  In 
an earlier phase II study in patients with previous colorectal adenoma, 3 months of 
EPA-FFA caused diarrhoea in 14% of patients who took 2g/day, but only in 2% of 
patients who took 1g/day.(257) The long-term tolerability of ω-3 PUFAs is further 
supported in large cardiovascular studies.  The GISSI prevention study gave low 
dose (0.85g) ω-3 PUFA to 2836 patients for 3.5 years.(314)  In this study 
gastrointestinal disturbance was reported by 4.9% of patients, nausea by 1.4% of 
patients, and only 3.8% of patients discontinued ω-3 PUFA supplementation.(314)  
Similar findings were seen in a study of higher dose (6.9g) ω-3 PUFA daily for 6 
months.(315)  Gastrointestinal disturbance was reported by 7% of 275 patients who 
received ω-3 PUFA supplementation, but also by 8% of patients who received the 
corn-oil placebo.(315) 
EPA supplementation was not associated with any increase in post-operative 
bleeding or infective complications, and ex vivo platelet function tests showed no 
evidence of anti-platelet activity of EPA.  The evidence concerning a risk of 
bleeding with ω-3 PUFA supplementation is mixed, with some studies raising 
concern that ω-3 PUFAs inhibit platelet aggregation, and others showing no effect.  
A cross-over study of dietary salmon and salmon oil supplementation versus an un-
supplemented control diet in 11 healthy volunteers found that the salmon 
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supplemented diet was associated with an increase in bleeding time (10mins vs. 
6.75mins, p<0.05) and a 24% reduction (p<0.05) in platelet aggregation in response 
to ADP (2µM) but not in response to AA or collagen.(266)  In a study of Type II 
diabetic patients (n=40), 6 weeks of supplementation of 1.2g/day ω-3 PUFA vs. 
placebo was associated with 15% reductions in platelet aggregation in response to 
ADP and collagen (both p<0.01).(267)  In contrast, a study of TPN following major 
abdominal surgery found that the addition of 0.2g/kg/day ω-3 PUFA to TPN had no 
effect on platelet aggregation as measured by resonance thrombography, and no 
effect on other measures of haemostasis including levels of the clotting factors VIIa 
and XII, the need for transfusion of packed red blood cells, or routine laboratory 
coagulation tests such as thromboplastin time and activated partial thromboplastin 
time.(316)  Similarly, recent reviews of over 4000 patients in 19 trials of ω-3 PUFAs 
who were undergoing either arterial surgery or trans-arterial angiography and 
angioplasty found no evidence that ω-3 PUFAs were associated with an increased 
risk of bleeding.(268, 269)   
Several recent studies have also investigated whether aspirin and ω-3 PUFAs in 
combination increases the risk of bleeding.  In one study, subjects were given a 
single dose of aspirin (625mg) on day 1, then received ω-3 PUFA (4g/day) for 28 
days, then took one day of combined ω-3 PUFA and aspirin on day 30.(317)  
Omega-3 PUFA supplementation alone did not inhibit aggregation in response to 
ADP, low- or high-dose collagen.  Aspirin alone inhibited aggregation in response to 
low-dose collagen only.  However, in combination, ω-3 PUFA and aspirin inhibited 
aggregation to all three agonists.  Similar results were seen in a double-blind, 
randomised, placebo-controlled cross-over study which gave 25 healthy volunteers 
either 3.4g EPA/DHA, 81mg aspirin, or both, and took blood for analysis of platelet 
aggregation at baseline and 4hrs post-treatment.(318)  They found that aspirin and 
ω-3 PUFA in combination, but neither alone, inhibited platelet aggregation 
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measured by the PFA-100 (Siemens, Deerfield, IL) system.  In a further study, 
addition of ω-3 PUFA potentiated the anti-platelet effect of combination aspirin and 
clopidogrel therapy in patients who had undergone coronary angioplasty.(319)   
There were only a small number of patients in The EMT Trial taking aspirin and ω-3 
PUFAs, but a possible potentiation of platelet inhibition with combination therapy 
was still seen.  At baseline, platelet aggregation was significantly lower in the small 
number  of patients who were taking fish oil supplements and aspirin compared to 
patients who were taking aspirin alone.  However, there was no significant 
difference in platelet aggregation in response to any of the four agonists between 
the EPA and placebo groups at the end of the period of supplementation.  It is also 
important to remember that there was no difference between the two groups in the 
rate of blood transfusion (10% vs. 8%), which for both groups was less than the 
17% transfusion rate reported in the last review of transfusion requirement (2004-
2008) in the Leeds Hepatobiliary Unit (320).  Whilst blood transfusion rates have 
likely fallen in the 5 years since this study, the 10% transfusion rate in The EMT 
Trial is considered to be in keeping with current transfusion requirements within the 
Unit.      
Therefore, despite the complexity of the platelet aggregation pathway and the lack 
of consensus regarding the techniques and agonists to best measure platelet 
aggregation, the results from The EMT Trial support the hypothesis that EPA does 
not significantly inhibit platelet aggregation and does not cause an increased risk of 
bleeding during liver resection, although the possibility that EPA might potentiate 
the platelet inhibitory effect of aspirin when given in combination should still be kept 
under consideration. 
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Tumour PUFA content 
Treatment with EPA was associated with significantly higher tumour EPA content 
compared to placebo.  This is the first study to demonstrate that oral EPA 
supplementation leads to incorporation into CRC or CRCLM.  An inherent limitation 
of The EMT Trial is that only post-treatment tumour tissue was available for 
analysis.  It is unethical to biopsy liver metastases before surgery because of the 
risk of tumour seeding, and MRI scan of the liver with liver-specific contrast such as 
Primovist® is the accepted modality for diagnosis of CRCLM.  Pre-operative biopsy 
is therefore only performed in the rare situations when there is doubt about the 
diagnosis of a liver lesion.  Comparison of individual patients' change in tumour 
PUFA content pre- and post-treatment was therefore not possible.  Instead, only 
comparison of post-treatment tumour PUFA content between the EPA and placebo 
groups could be performed.   
A further limitation of the study is that the median duration of supplementation was 
relatively short.  Few clinical studies have examined the effect of short-duration ω-3 
PUFA supplementation (Table 5.11), and only one of these examined ω-3 PUFA 
uptake by solid gastrointestinal tumours.(321)  In this study of 40 patients, five days 
of pre-operative oral ω-3 PUFA supplementation (3.7g ω-3 PUFA/day) versus un-
supplemented controls was associated with significant increases in the EPA content 
of liver tissue (1.25% vs. 0.4%), gastrointestinal mucosa (1% vs. 0.25%) and 
tumour tissue (0.75% vs. 0.25%).  This 0.5% absolute increase in tumour EPA 
content is comparable to the 0.65% absolute increase seen in The EMT Trial.  The 
remaining clinical data which is available for comparison comes from colonic 
mucosa biopsy studies, with periods of supplementation of up to 6 months (Table 
5.11).  These studies showed greater colonic mucosal uptake of EPA than the 
CRCLM uptake of EPA seen in The EMT Trial.  This includes studies of short 
duration (2-6 weeks)(254, 255, 273, 322) and two studies which used the same 
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preparation of EPA as in The EMT Trial (257, 262), albeit in these two studies EPA 
was given for 3-6 months rather than the median 30 days in The EMT Trial.  
Notably, the level of AA in tumours in the placebo group in The EMT Trial was 
much higher than the baseline levels of AA in colorectal mucosa in other studies.  
There are no studies reporting the AA content of solid GI tumours available to know 
whether there is a difference in AA content between human colonic mucosa and 
solid tumours.  It is also noticeable that in all the studies which performed serial 
colonic biopsies, mucosal EPA levels increased early, within 2-4 weeks, whereas 
mucosal AA levels did not fall until 12 weeks or more.(254, 255, 273)  The same 
trend of an early rise in EPA/DHA, with a delayed fall in AA was also seen in a 
separate study of the PUFA content of plasma and blood cells at 0, 2 and 12 weeks 
from eight healthy volunteers taking 1.4-4.2g EPA/day.(323)   
The study by Gee et al investigated the effect of fish oil supplementation (1.4g EPA 
+ 1.0g DHA/day) vs. placebo on 49 patients prior to colorectal surgery.(322)  Mean 
duration of supplementation was 12.3 days.  They found a significant increase in 
EPA content in the colorectal mucosa of patients in the fish oil group compared to 
placebo, but no difference in PUFA levels in mesenteric adipose tissue.  However, 
patients who self-reported use of FO supplements prior to the trial did have higher 
levels of EPA and higher ratios of ω-3:ω-6 PUFA in adipose tissue compared to 
patients who did not report previous FO supplementation.  This mirrors the findings 
of the similar subanalysis of patients already exposed to ω-3 PUFA intake in The 
EMT Trial. 
It is clear that the uptake of ω-3 PUFAs and reduction in AA is time dependent, and 
may vary between different tissues.  Whilst the results from The EMT Trial 
demonstrate an increase in tumour EPA content following EPA supplementation, it 
is likely that the duration of supplementation was too short to reach either the 
maximal EPA incorporation, or to observe a reduction in AA content.  
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Table 5.11.  Clinical studies reporting the change in PUFA content of colonic mucosal or gastrointestinal tumours following ω-3 PUFA 
supplementation.  Levels given are the ω-3 PUFA content as a % of total fatty acids.  *approximate figures read off graph 
Study Duration Tissue Daily  ω-3 PUFA 
(EPA/DHA) 
Baseline Post-treatment  
Placebo group 
Post treatment   
ω-3 PUFA group 
EPA DHA AA EPA DHA AA EPA DHA AA 
Senkal 
2005(321)  
5 days GI mucosa 3.7g - - - 0.3   1.0   
 Liver - - - 0.3   1.3   
 GI tumour - - - 0.3   0.8   
Gee 
1999*(322) 
12 days Colorectal 
mucosa 
2.4g (1.4g/1.0g) - - - 0.5 0.5 4.0 1.0 0.8 5.5 
Adipose 0.1   0.1   
Anti 
1992(255) 
2 weeks Colorectal 
mucosa  
7.7g (4.1g/3.6g) 1.3-1.5 1.5-1.8 5.7-6.1 1.3 1.9 6.3 2.6 1.9 5.0 
12 weeks 1.8 1.6 6.2 2.3 1.8 4.4 
Hillier 
1991(273) 
 
3 weeks Colorectal 
mucosa 
5.4g (3.2g/2.2g) 0.3-0.4 1.7-2.1 8.5-10.0 0.4 1.7 8.6 3.2 3.3 7.9 
6 weeks 0.4 1.7 7.5 3.1 3.1 8.3 
12 weeks 0.2 1.0 5.1 3.1 2.9 5.6 
Anti 
1994(254) 
4 weeks Colorectal 
mucosa 
2.5g (1.4g/1.1g) 0.8-1.2 1.3-2.0 5.8-6.5 1.1 1.5 6.1 1.6 2.2 5.0 
5.1g (2.7g/2.4g) 1.9 2.6 3.6 
7.7g (4.1g/3.6g) 2.5 4.0 4.2 
6 months  2.5g (1.4g/1.1g)       1.5 2.1 3.6 
Courtney 
2007(257) 
3 months Colorectal 
mucosa 
2g EPA-FFA 0.8-1.2 1.7-2.4 8.4-9.4 0.8 1.9 9.1 2.7 2.5 8.0 
West 
2010(262) 
6 months Colorectal 
mucosa 
2g EPA-FFA 0.7-1.0 1.4-1.9 8.5-9.6 1.3 1.4 9.9 2.5 1.7 8.8 
Sorensen 
2013 (324) 
7 days Colorectal 
mucosa 
2.g EPA + 1g 
DHA 
   0.2 0.9 2.0 0.6 1.3 2.6 
EMT Trial 
 
4 weeks CRCLM 2g EPA-FFA - - - 1.3 2.9 12.8 1.8 2.6 12.0 
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Tumour PGE2 and urinary PGE-M 
In this trial there was no difference in tumoural PGE2 levels between the EPA and 
placebo groups, despite previous in vitro and mouse models showing that EPA 
incorporation is associated with a reduction in PGE2 production.(149, 209)   
Notably, PGE2 levels varied widely in both the EPA and placebo groups.  There are 
no previous studies reporting PGE2 production in human CRCLM available for 
comparison.  Two studies have investigated this in human gastrointestinal 
mucosa.(259, 325)  In a study by Bartram et al,(259) 12 healthy volunteers received 
either fish oil (4.4g ω-3PUFA/day) or corn oil for two 4-week periods, with a 4 week 
washout period, in a double-blind crossover study.  They found no significant 
difference in ω-3 PUFA content of rectal biopsies after fish oil supplementation 
compared to after corn oil supplementation (4.00% vs. 4.03%), and a non-
significant increase in ω-6 PUFA content after corn-oil supplementation (19.23% vs. 
14.96%, p=0.11).  PGE2 levels in rectal biopsies were approximately 671 ng/g 
tissue after corn oil and 435.5 ng/g tissue after fish oil supplementation (p<0.05).  
This suggests that corn oil supplementation led to increased ω-6 PUFA and PGE2 
content, rather than fish oil supplementation leading to lower PGE2 content.  In a 
study by Mehta et al,(325) 52 patients with Barrett's oesophagus were randomised 
to receive 1.5g EPA-FFA/day or placebo for 6 months, with biopsies of the Barrett's 
oesophagus taken at baseline and post-treatment.  In the EPA group there was a 
significant increase in mucosal EPA post-treatment (2.4% vs. 0.8%, p<0.01), but no 
change in mucosal AA (6.4% vs. 6.0%, p=0.14) or mucosal PGE2 (36.1pg/µg 
protein vs. 33.1pg/µg protein). 
Median PGE2 levels in CRCLM in The EMT Trial were 6.62ng/g in the EPA group 
and 5.87ng/g in the placebo group.   This is lower than the PGE2 levels seen in the 
Bartram and Mehta studies, although methodological differences make direct 
comparison between the studies difficult.  In the Bartram study PGE2 was 
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measured in culture medium by radioimmunoassay after 2 hrs incubation with the 
rectal biopsies (259) and in the Mehta study PGE2 was standardised to protein 
content of the sample.(325) 
Notably, of the in vivo and clinical studies that have demonstrated a reduction in 
tumour/mucosa PGE2 with fish oil supplementation and also measured tissue PUFA 
content, all demonstrated a significant reduction in AA in addition to significant 
increases in EPA, resulting in AA:EPA ratios ranging between 0.59:1 and 
3.74:1(151, 209, 227, 236, 241, 259, 326) which are lower than the 7.58:1 AA:EPA 
ratio in tumours in the EPA group of The EMT Trial.  This may explain why there 
was no difference in tumour PGE2 levels in The EMT Trial, and again, may reflect 
the duration of supplementation having been too short to achieve maximal tumour 
EPA incorporation and AA reduction.     
In the limited number of in vivo studies that have measured tumour PGE3, levels 
were between 2-20 times lower than corresponding PGE2 levels.(151, 209, 326, 
327)  In The EMT Trial, PGE3 was detected in only one tumour, that with the 
highest level of PGE2 which was one of the placebo group tumours.  PGE3 in this 
tumour (21.10ng/g) was present at 20 times lower concentration than the level 
PGE2 (447ng/g).  The largest concentration of PGE2 in the EPA group was 
33.40ng/g.  Therefore any PGE3 in tumours in the EPA group, at a similar 2-20 
times lower concentration than PGE2 might have been present below the limit of 
detection (10ng/g) of LC-MS/MS, making it impossible to draw any conclusions 
about PGE3 production from this study.   
In addition to measuring tumoural PGE2 I also assayed urinary PGE-M, which being 
a measure of overall PGE2 synthesis, allowed a longitudinal analysis of the changes 
in PGE2 synthesis associated with EPA supplementation.  Baseline levels of PGE-
M in this study ranged from 7.93-28.93ng/mg of creatinine, with a median of 
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16.49ng/mg in the EPA group and 18.24ng/mg in the placebo group.  Studies of 
healthy volunteers have shown mean PGE-M levels of approximately 5-10ng/mg, 
(81, 82, 328) with levels being higher in men than in women (81-83) and higher in 
smokers than in non-smokers.(328)  Mean levels in patients with non-small cell lung 
cancer were approximately 20-30ng/mg,(81, 329, 330) and in the one study found 
of PGE-M in patients with CRC, 17 patients with inoperable or metastatic CRC had 
a mean PGE-M of 25ng/mg.(331) The PGE-M levels in patients with operable 
CRCLM in The EMT Trial therefore seem to be appropriately between those of 
healthy controls and patients with advanced inoperable disease.  
No other studies of the effect of ω-3 PUFAs on urinary PGE-M were found for 
comparison.  Although the 27% reduction in PGE-M between baseline and post-
treatment in the EPA group did not reach statistical significance, the magnitude of 
reduction is plausible, being lower than the 40-60% reductions seen with the more 
potent COX-2 inhibitor celecoxib (81, 83, 329) but higher than the 14% reduction in 
PGE-M seen in a study of 36 healthy volunteers who were supplemented with 7.5g 
of ω-3 PUFA for 10 weeks.(332)  PGE-M levels rose again in the EPA group at 
follow-up, having stopped EPA supplementation, but stayed the same in the 
placebo group, providing further evidence for an effect of EPA on systemic PGE2 
production.  Interestingly PGE-M levels did not fall in either group at follow-up 
despite this being after removal of their cancer.  Together with the finding that 
tumoural PGE2 levels were unaffected by EPA, this might suggest that systemic 
PGE2 production is a greater contributor to urinary PGE-M than tumoural PGE2 
production.  This hypothesis is supported by a study of patients with unresectable 
or metastatic CRC which found no difference in urinary PGE-M between those 
patients who did and those who did not respond to dual therapy with celecoxib and 
cetuximab.(331)  Alternatively, it might be that the six week interval between 
surgery and follow-up was too short for the systemic inflammation caused by 
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surgery to have subsided, and that this masked any reduction in PGE2 synthesis 
attributable to the removal of the tumour.  Such an inflammatory response to 
surgery might be expected to have subsided within 1 week (333, 334) although 
there are no studies examining this beyond 1 week.  An additional confounder that 
could have masked a reduction in PGE-M after removal of the tumour is that 
hepatic COX-2 expression and PGE2 synthesis increase following liver resection as 
part of the liver regeneration response.(335-337)  Whilst the duration of PGE2 rise 
following hepatectomy is unstudied in humans, liver regeneration would still be 
ongoing at six weeks, potentially contributing to elevated systemic PGE2, and 
hence raised urinary PGE-M, secondary to liver regeneration. 
Nevertheless, EPA therapy was associated with a small but statistically significant 
reduction in PGE-M indicative of an effect on PGE2 production, whether this be of 
tumoural or systemic origin.  This anti-inflammatory effect is consistent with the 
known COX inhibitory activity of EPA.(338)  
  
PBMC NFκB activation  
EPA therapy inhibited basal and LPS-stimulated NFκB activation in PBMCs, which 
similar to the PGE-M data, was reversible after cessation of EPA therapy.  This 
provides further evidence of a systemic anti-inflammatory effect of EPA therapy.    
Whilst there are no previous studies of PBMC NFκB activation in patients with 
either CRC or CRCLM, these results are consistent with other clinical studies which 
have demonstrated uptake of ω-3 PUFAs by PBMCs (339-341) with resultant anti-
inflammatory effects. (342-349)  The rate of uptake and washout of different PUFAs 
in these studies mirrors that seen in other cells and tissues in clinical studies 
discussed earlier in this section.  In a study of parenteral fish oil supplementation 
(three days, total 42g ω-3 PUFA), there was a significant increase in PBMC content 
of EPA and DHA, but not AA.(340)  EPA levels returned to normal by eight days, 
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with DHA and DPA levels remaining high up to day 11.  This is consistent with the 
ω-3 PUFA content in plasma and erythrocytes in the Leicester trial of parenteral 
supplementation in patients with CRCLM.(211)   In the study by Yaqoob et al of 12 
weeks oral ω-3 PUFA supplementation (2.1g EPA + 1.1g DH/day) peak EPA 
content of PBMCs occurred by 4 weeks, with a reduction in AA only detected at 12 
weeks.(341)  This is consistent with the majority of human mucosal biomarker 
studies (Table 5.11) and the CRCLM PUFA data in The EMT Trial.  Omega-3 PUFA 
incorporation into PBMCs has been demonstrated to reduce pro-inflammatory gene 
expression, including several NFκB target genes, pro-inflammatory cytokines and 
genes involved in eicosanoid synthesis.(342, 343)  It has also been associated with 
a reduction in PBMC production of PGF2α, PGE2, IFN-gamma, IL-1, IL-6 and 
TNFα,(344-349) and a reduction in paw oedema in vivo.(348)  A minority of studies 
have failed to show any effect of ω-3 PUFAs on PBMC cytokine production.(340, 
341) 
The finding in The EMT Trial that EPA inhibits NFκB activation in isolated human 
PBMCs is also consistent with pre-clinical studies of the effect of ω-3 PUFAs on 
NFκB activation in other cell lines in vitro and in vivo.  In human CRC cell lines, ω-3 
PUFA supplementation has been shown to inhibit IκB phosphorylation, reduce 
NFκB activation and reduce NFκB p65 expression.(178, 179)  Omega-3 PUFA 
supplementation has also been shown to inhibit NFκB activation in HUVECs.(180)  
Similar findings have been shown in pancreatic and breast cancer cell lines,(182, 
350, 351) in transgenic mouse prostate cancers,(181) and in a nude mouse model 
of breast cancer.(182)   
Therefore, whilst no previous studies have directly investigated the effect of ω-3 
PUFAs on NFκB activation in PBMCs, the results from The EMT Trial would be 
consistent with separate studies of the effects of ω-3 PUFAs on PBMCs and of ω-3 
PUFAs on NFκB activation in other cell lines.  Bringing these results together 
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supports the hypothesis of EPA having an anti-inflammatory effect, and potential 
anti-CRC activity, through inhibition of NFκB signalling.    
 
Immunohistochemistry 
In contrast with findings from the recent MC-26 mouse CRCLM model,(209) EPA 
was not associated with a change in either tumour proliferation or apoptosis.  
Subanalysis did, however, reveal reduced tumour vascularity in the EPA group 
compared to the placebo group after exclusion of patients who were either taking 
fish oil supplements or who had a high weekly intake of oily fish prior to the study.  
Whilst there are no other studies of the effect of EPA on CRCLM available, limited 
comparisons can be made with immunohistochemical findings in other studies of 
CRCLM.  The range of Ki-67 PI seen in The EMT Trial (mean 70.7% in the EPA 
group, 73.0% in the placebo group) is in keeping with the range of PIs seen in other 
studies.  Veremeulen et al. found a mean PI of 62.9% (35.8-93.5%) in 26 historic 
FFPE CRLM specimens,(352) and Tatebe et al. found a mean PI of 60.7% (55.3-
70.4%) in 15 historic FFPE CRCLM specimens.(313)  In a similarly designed study 
of the effect of rofecoxib on CRCLM by Fenwick et al, mean (range) PI in CRCLM 
tumours was 54.7% (0-96%) in the rofecoxib group and 52.6% (17-94%) in the 
placebo group.(271)  The lower mean PIs in the rofecoxib study may be due to the 
subjective choice of a high powered field of view for analysis (an area of high 
apoptosis was chosen for counting AI, then PI was counted from the equivalent field 
of view in an adjacent section of tumour), compared to the method of analysis in 
The EMT Trial which counted proliferation at a standardised point at the tumour 
edge.  It is plausible that the advancing edge of a tumour has a higher rate of 
proliferation than more central areas of the tumour which might display higher 
apoptosis counts.  Another study of 90 patients with resected CRCLM found that Ki-
67 PI was >50% in only 29% of tumours.(353)  However, these resected tumours 
were analysed in a tissue microarray, with non-necrotic sections of tumour placed in 
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the array in triplicate.  The random sampling from throughout the tumour might 
again explain why PI is lower in this study than in The EMT Trial which analysed PI 
from the edge of the tumour.   For comparison with other cancers, only one clinical 
trial was found which observed a 32% reduction in prostate cancer Ki-67 PI in 
patients supplemented with 5g ω-3 PUFA/day preoperatively for 4-6 weeks 
compared to those given placebo.(354) The study of the effect of rofecoxib by 
Fenwick et al is the only other study found which measured either apoptosis or 
vascularity in CRCLM.(271)  Similar to the effect of EPA in The EMT Trial, rofecoxib 
had no effect on tumour apoptosis but was associated with a 29% reduction in 
MVD, although as with EPA, this failed to reach statistical significance (p=0.15). 
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Chapter 6: Results – Studies of the effects of EPA on 
Human Umbilical Vein Endothelial Cells (HUVECs) 
 
6.1 MTT proliferation assay 
6.1.1 Assay optimisation 
Initial dose-finding experiments investigating the effect of EPA on HUVEC 
proliferation were performed using a 96-well plate with 6 replicates for each cell 
condition (Experiments 1 and 2).  There were no viable cells seen at 24hrs when 
cells were supplemented with EPA concentrations greater than 50µM, and MTT 
optical density readings at these concentration were equivalent to the no-cell 
controls (Figures 6.1 and 6.2).  This suggested that EPA ≥ 50µM was cytotoxic to 
cells.  There appeared to be a dose-dependent effect of EPA on HUVEC 
proliferation between EPA 5-50µM.  In Experiment 2, duplicate 96-well plates were 
seeded.  In one, culture media was left unchanged for 72hrs, and in the other, 
culture media in each well was changed after 48hrs.  Changing the culture media at 
48hrs was associated with increased proliferation across all cell conditions 
compared with not changing the culture medium (Figure 6.2).  However, because 
this affected all cell lines equally it was decided for future experiments not to 
change the culture media during the experiment in order to a) simplify the 
experiment, b) minimise wastage of expensive culture medium, and c) minimise 
error in repeatedly making up small volumes of EPA containing media.   
The assay was then scaled up to a 48 well format to increase the number of cells 
per well and allow better visualisation of the cells under microscopy (Experiment 3).   
The dose range of EPA was narrowed to 0-30µM.  Similar to the 96-well format, a 
dose-dependent reduction in HUVEC cell proliferation was observed (Figure 6.3). 
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Figure 6.1.  The effect of EPA on HUVEC proliferation: Experiment 1.  Each data 
point is the mean of 6 replicate wells. 
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Figure 6.2.  The effect of EPA on HUVEC proliferation: Experiment 2.     
In experiment 2a culture media was left for the duration of the experiment, whereas in 2b 
the culture media in each well was aspirated and replaced with fresh medium at 48hrs.  
Each data point is the mean of 6 replicate wells. 
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Figure 6.3.  The effect of EPA on HUVEC proliferation: Experiment 3.  In this 
experiment the effect of EPA 5-30µM was investigated in a 48-well format.  Each data point 
is the mean of 12 replicate wells. 
 
After scaling up the experiment to the 48-well format and observing similar results 
to the 96-well format, it was decided to validate the MTT assay before performing 
further experiments in the 48-well format.  The purpose of this was two-fold.  Firstly, 
to confirm that the MTT assay OD readings were proportional to cell number, and 
secondly to exclude the possibility that EPA had a direct effect on the assay itself 
by interfering with mitochondrial metabolism of MTT and the solubilisation of 
formazan crystals by propan-1-ol.   
To investigate whether MTT assay OD readings were proportional to cell number. 
serial 2-fold dilution of cells were plated at densities of 0 - 32000 cells/well and 
incubated for 24hrs before performing an MTT assay.  Figure 6.4 demonstrates that 
OD was proportional to seeded cell number.  This relationship was linear up to a 
cell number of 16000 (OD 0.43).  At the next cell density of 32000 cells, this 
relationship plateaued.  
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Figure 6.4.  Optical density vs. seeded cell number.  Serially diluted HUVECs were 
plated and allowed to attach for 24hrs.  MTT assay was then performed and optical density 
plotted against seeded cell number. A line of best fit has been added between cell densities 
of 0-16000 cells.  Each data point is the mean of 6 replicate wells.    
 
To investigate whether EPA directly affects the MTT assay rather than affecting cell 
proliferation, 1x104 cells were incubated in plain culture medium for 24hrs.  EPA 
100µM or an equivalent volume of ethanol carrier were added to one row each at 
the same time as adding the MTT to the cultured cells, and again to separate rows 
at the time of solubilising the formazan crystals with propan-1-ol.  These 
experimental conditions are summarized in Table 6.1. 
Figure 6.5 demonstrates that the addition of ethanol carrier had no effect at any 
stage of the MTT assay.  Addition of EPA at the MTT step caused a reduction in 
OD, whereas addition of EPA at the propan-1-ol step had no effect on OD.  Under 
microscopy (Figure 6.6) it was clear that the cells which received MTT+EPA were 
less viable than those which received MTT alone, and resembled the cells seen 
previously when grown in media supplemented with EPA50-100µM.  It is therefore 
likely that 100µM EPA had a cytotoxic effect on cells within the 3 hours incubation 
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period when added with the MTT, rather than EPA directly affecting the 
performance of the assay by preventing the metabolism of MTT by viable cells. 
 
 Culture 
conditions 
MTT step Propan-1-ol step 
No-cell 
control 
No cells MTT Propan-1-ol 
Standard  
assay 
Cells +  
plain media 
MTT Propan-1-ol 
MTT +  
EtOH 
Cells +  
plain media 
MTT + EtOH Propan-1-ol 
MTT +  
EPA 100µM 
Cells +  
plain media 
MTT + EPA 100µM Propan-1-ol 
Propan-1-ol 
+ EtOH 
Cells +  
plain media 
MTT Propan-1-ol + EtOH 
Propan-1-ol 
+ EPA 100µM 
Cells +  
plain media 
MTT Propan-1-ol + EPA 100µM 
 
Table 6.1.  Experimental conditions for each row of the 48-well plate.  These conditions 
were replicated in 6 wells per row. 
 
 
Figure 6.5.  Effect of EPA and ethanol (EtOH) carrier on the performance of the MTT 
assay.  Each data point represents a single value. 
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Figure 6.6.  Representative photos of cells seeded in a 48-well plate.  Photograph of 
cells (x10 magnification) remaining in wells after MTT incubation, from wells treated with (a) 
MTT alone as per the standard assay and (b) MTT + 100µM EPA. 
 
 
6.1.2 Acute EPA supplementation 
The effect of acute EPA supplementation on HUVEC proliferation was repeated 
using the 48-well setup and the methodology was altered slightly.  Cells were plated 
in replicate 48-well plates containing plain media and left for 24hrs.  MTT assay was 
performed on one plate after 24hrs of EPA-free culture (Time 0).  The media in the 
remaining plates was then changed to experimental EPA-containing media and 
cultured for 24, 48, or 72hrs before performing the MTT assays. The change in OD 
relative to the baseline OD at Time 0 could then be calculated, whereas in the 
previous methodology no baseline was calculable because the cells had already 
been exposed to experimental EPA-containing media for 24hrs at the time of the 
first MTT assay. 
This methodology was performed on two separate occasions (Experiments 4 and 
5).  In both experiments there was a dose-dependent EPA inhibition of HUVEC 
proliferation.  These results were pooled to give a mean of 12 replicate wells 
(Figure 6.7).  HUVECs supplemented with 10µM EPA showed approximately 26% 
less growth than un-supplemented cells at 24hrs (p=0.02), 33% less growth at 
A B 
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48hrs (p<0.01) and 33% less growth at 72hrs (p<0.01).  Cells supplemented with 
20µM EPA showed 34% less growth than un-supplemented cells at 24hrs (p<0.01), 
38% less growth at 48hrs (p<0.01), and 41% less growth at 72hrs.  At 48 and 
72hrs, cells supplemented with 25-30µM EPA showed 64-69% less growth than un-
supplemented cells (p<0.01).  All statistical analyses were performed using 
unpaired t-tests.      
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Figure 6.7.  Effect of EPA on HUVEC proliferation.  Each data point is the mean of 12 
replicate wells.  Note that for these experiments cells were plated for 24hrs in plain media, 
and then culture media change to EPA-containing media and cells incubated for a further 
24-72hrs.  One plate was read immediately prior to exposing cells to EPA, allowing optical 
density at each time point to be compared to mean optical density of the corresponding row 
of the baseline 48-well plate and expressed as a fold-increase.  Error bars represent 
mean+- SEM.    
 
 
 
173 
 
 
6.1.3 Chronic EPA supplementation 
Whilst the acute EPA supplementation experiments provided a simple, reproducible 
assay, the short period of HUVEC exposure to EPA was not representative of the 
duration of EPA supplementation in in vivo and human studies.  I therefore decided 
to also investigate the effect of a longer-duration, lower-dose EPA supplementation 
as a closer representation of conditions in in vivo and human studies.  HUVECs 
were incubated for two weeks in either plain medium or medium supplemented with 
1µM EPA.  Media was changed every 48 hrs.  After two weeks, cells were 
trypsinised, counted and seeded in 48-well plates and an MTT assay performed as 
in the acute EPA supplementation experiments.  This was performed on two 
separate occasions (Experiment 1 and 2).  In contrast to the acute EPA 
supplementation experiments, a baseline MTT assay could not be performed prior 
to EPA exposure because the cells had already been exposed to experimental 
medium for two weeks.  Results of the chronic EPA supplementation experiments 
are therefore quoted as the mean OD, rather than as the fold-change in OD 
compared to baseline.     
Cells chronically supplemented with EPA showed reduced proliferation compared to 
EPA naive cells at all time points in both experiments.  The proliferation curve was 
steeper in Experiment 2 than in Experiment 1, but the same trends were observed 
in both experiments (Figure 6.8).  At 96hrs, OD in EPA-supplemented cells was 
16.4% lower than in EPA-naive cells in Experiment 1 (p<0.01), and 33.9% lower in 
Experiment 2 (p<0.01). 
VEGF is known to stimulate HUVEC proliferation, and inhibition of VEGF-stimulated 
angiogenesis has been proposed as one mechanism by which EPA might inhibit 
angiogenesis.  To further investigate the mechanistic effect of chronic EPA 
supplementation on HUVEC proliferation, I decided to supplement cells with VEGF 
at the time of seeding onto the 48-well plates to test the hypothesis that EPA-
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supplemented cells would have an attenuated response to VEGF stimulation.  
Supplementation of VEGF 10nM to culture media stimulated proliferation in the 
EPA-naive cells in both Experiment 1 and Experiment 2 compared to VEGF 
unstimulated cells at 96hrs (12.7% and 18.9% increases in proliferation, p<0.01 and 
p=0.01 respectively).  However, VEGF had no significant effect on proliferation of 
cells chronically supplemented with EPA compared to VEGF unstimulated cells at 
96hrs (0.8% increase and 3% increase in proliferation, p=0.77 and p=0.56 
respectively).  The response to VEGF was indeed attenuated in the EPA-
supplemented cells.     
VEGF is known to be upregulated by PGE2,(73, 186) so EPA inhibition of the COX-
PGE2 pathway is a potential mechanism by which EPA might inhibit VEGF-
stimulated angiogenesis.  I therefore decided to supplement cells with PGE2 at the 
time of seeding onto 48-well plates to test the hypothesis that the addition of PGE2 
would restore proliferation in the EPA-supplemented cells to the same levels as that 
seen in control cells (i.e. a PGE2 rescue effect).  In Experiment 2, cells were 
supplemented with 1µM PGE2.  In the EPA-naive cells, PGE2 supplementation 
stimulated proliferation (20.6%, p=0.01), to a similar extent to that seen with VEGF 
supplementation.  PGE2 also stimulated proliferation in cells chronically 
supplemented with EPA, but this response was attenuated compared to the 
proliferation of EPA-naive cells and did not reach statistical significance (12.9%, 
p=0.08).  PGE2 supplementation therefore failed to show a rescue effect in cells 
chronically supplemented with EPA.    
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Figure 6.8.  The effect of chronic EPA supplementation on HUVEC proliferation 
(Experiments 1 and 2).  The effect of VEGF supplementation is shown in Experiment 1 and 
2, and the effect  of PGE2 supplementation is shown in Experiment 2.  Each data point is the 
mean of 6 replicates. 
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6.1.4 Concentration of PGE2 and 6-keto-PGF1α in HUVEC culture medium 
HUVEC cell-conditioned medium was collected from acute EPA supplementation 
Experiment 4 and Experiment 5 at 72 hours, and from chronic EPA 
supplementation Experiment 1 at 96 hours. For each EPA supplementation 
condition in each experiment, medium was collected from the six replicate wells and 
pooled and analysed as a single sample.  This was because it was impractical and 
prohibitively expensive to analyse PGE2 in the cell conditioned medium of each 
replicate well separately.  PGE2 was not detectable in any of the samples by LC-
MS/MS, most likely because PGE2 was present in pg/ml concentrations, i.e. below 
the 10ng/ml limit of detection of PGE2 by LC-MS/MS (Loadman et al, unpublished 
data).   
However, PGI2 rather than PGE2 is considered the main prostaglandin product of 
AA metabolism in vascular endothelium and previous studies in HUVEC cultures 
have shown greater levels of PGI2 than PGE2 production.(299-301)  I therefore 
decided to measure the levels of 6-keto-PGF1α, a stable product of PGI2 , in cell-
conditioned media.  The same batches of cell-conditioned media were used and 
levels of 6-keto-PGF1α measured using an enzyme immunoassay (EIA) as 
described in section 4.8.1. 
The standard curve of 6-keto-PGF1α concentration versus percentage binding for 
the assay is shown in Figure 6.9. 
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Figure 6.9.  Standard curve of 6-keto-PGF1α concentration versus percentage binding 
 
The results of the 6-keto-PGF1α analyses are presented alongside the 
corresponding MTT experiment data in Figures 6.10 - 6.12.  In the acute EPA 
supplementation experiments, the concentration of 6-keto-PGF1α in culture medium 
at 72 hours in Experiment 5 (Figure 6.10) was highest in those cells supplemented 
with the highest concentrations of EPA (20 and 30µM) and lowest in the control 
cells which were not supplemented with EPA (0um). By contrast, in Experiment 6 
(Figure 6.11) EPA supplementation had no effect on 6-keto-PGF1α concentration in 
the culture medium.  The range of 6-keto-PGF1α concentrations (17.9-26.7pg/ml) 
was small, and similar to the 6-keto-PGF1α concentration seen in the culture 
medium of EPA un-supplemented cells in Experiment 5 (22.1pg/ml).  In the chronic 
EPA supplementation experiment (Figure 6.12), 6-keto-PGF1α concentration in the 
culture medium of EPA supplemented cells was 39.8% lower than that in the culture 
media of control cells. The concentration range in this experiment (42.7 - 71.3pg/ml) 
more closely matches that of Experiment 5 of the acute EPA supplementation 
experiments.   
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Figure 6.10.  6-keto-PGF1α concentration in cell-conditioned media: Acute EPA 
supplementation Experiment 5.  Results from the MTT assay of the effect of acute EPA 
supplementation on HUVEC proliferation (Experiment 5, each data point is the mean of 6 
replicates) are shown together with the concentration of 6-keto-PGF1α in the cell conditioned 
medium when aspirated from the 48-well plate of the MTT assay at 72hours (each data 
point is a single replicate of pooled media). 
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Figure 6.11.  6-keto-PGF1α concentration in cell-conditioned media: Acute EPA 
supplementation Experiment 6.  Results from the MTT assay of the effect of acute EPA 
supplementation on HUVEC proliferation (Experiment 6, each data point is the mean of 6 
replicates) are shown together with the concentration of 6-keto-PGF1α in the cell conditioned 
medium when aspirated from the 48-well plate of the MTT assay at 72hours (each data 
point is a single replicate of pooled media). 
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Figure 6.12.  6-keto-PGF1α concentration in cell-conditioned media: Chronic EPA 
supplementation Experiment 1.  Results from the MTT assay of the effect of chronic EPA 
supplementation on HUVEC proliferation (Experiment 1, each data point is the mean of 6 
replicates) are shown together with the concentration of 6-keto-PGF1α in the cell conditioned 
medium when aspirated from the 48-well plate of the MTT assay at 72hours (each data 
point is a single replicate of pooled media) 
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It is not possible to draw any conclusions about the effect of EPA on PGI2 
production based on the inconsistent findings of this small number of experiments 
each with a small number of replicate readings.   
 
6.2 Wound migration assay 
6.2.1 Assay optimisation 
Several experiments were performed to optimise the technique of wound scoring in 
this assay.  The most consistent wound score of an appropriate width was achieved 
with a yellow pipette tip.  Other sized pipette tips produced scores that were too 
thin, too thick, or caused excessive detachment of cells from the sides of the 
wound.  A gentle technique of slowly aspirating and replacing culture media was 
required to prevent cells detaching from the plate in large sheets.  Lifting of cells 
from the plate was also minimised by aspirating culture medium from the cells, 
scoring the dry cell monolayer, then adding fresh culture medium, rather than 
scoring cells in the presence of culture medium. 
6.2.2 Acute EPA supplementation 
In the first dose finding experiment of the effect of acute EPA supplementation on 
HUVEC wound migration (Figure 6.13), 60µM EPA caused cell death, with cells 
seen floating in the culture medium and causing an artificial increase in the size of 
the measured wound.  At EPA concentrations up to 40µM, there appeared to be 
little difference in the closure of wounds, although the variability in wound closure in 
the 3 wells of the upper row of the 6 well plate was higher than that in the 3 wells of 
the lower row, which seemed to have more consistent wound closure.  On closer 
examination of the wound photographs there was a noticeable "shouldering" effect 
in some of the photos (Figure 6.14), with the wound closing at the lower end 
(nearest the centre of the well), but not at the upper end (nearest the edge of the 
well).  Those cells at the peripheral edge of the well appeared less healthy than 
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those more centrally placed.  The assay was therefore refined so that the parallel 
reference lines for taking photographs of the wound crossed the well more centrally, 
avoiding taking photos towards the periphery and therefore avoiding this peripheral 
edge effect.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13. Dose-finding experiment of the effect of acute EPA supplementation on 
HUVEC wound closure.  This was performed on a single 6 well plate with 2 photos taken 
per well.  Error bars represent mean +- SEM of the two photos taken per well.  
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Figure 6.14. Photograph of the shouldering effect seen in some of the wound scores.  
Note the less healthy cells and absence of wound closure at the well periphery (top edge of 
photo) compared to the healthier cells and wound closure more centrally in the well (middle 
and bottom edge of photo).  The transition is marked with arrows. 
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Two further experiments were performed in triplicate 6-well plates with EPA doses 
10-50µM.  In the first experiment (Figure 6.15 & 6.16) there was no appreciable 
wound closure at 3 hours.  At 6 hours, control cells showed 45.8% wound closure.  
In the cells treated with 20, 30 and 40µM EPA, wound closure was approximately 
24% lower than that in controls, with wound closures of 35.0% (p=0.01), 37.5% 
(p=0.04) and 34.9% (p<0.01) respectively.  Wound closure in cells treated with 
50µM EPA was half of that in controls, with a wound closure of 23.6% (p<0.01).  At 
9 hours, wound closure in the control cells was 75%.  Wound closure was 
approximately 13% lower in cells treated with 10, 20 and 30µM EPA than controls 
(p=0.17 to p=0.29).  Cells treated with EPA 40µM EPA showed almost one third 
less wound closure than controls with a wound closure of 54% (p<0.01), and cells 
treated with 50µM EPA showed two-thirds less wound closure than controls with a 
wound closure of 24.4% (p<0.01).  All statistical comparisons were performed using 
unpaired t-tests.  
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Figure 6.15.  Effect of acute EPA supplementation on HUVEC wound closure: 
Experiment 1.  Wound closure over time is shown as the percentage reduction in the width 
of the wound compared to width at baseline.  Each bar is the mean of 6 photos from 3 
separate wells, except for the EPA 50µM group where two of the wells showed a 
shouldering effect at one of the reference lines.  These photos were discarded and bars in 
the EPA 50µM group are therefore the mean of 4 photos from three wells.  Error bars 
represent mean+- SEM. 
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Figure 6.16.  Photographs of HUVEC wound closure over time: Experiment 1.  Wound 
closure at 0, 3, 6 and 9hrs in control cells and cells acutely supplemented with 40µM and 
50µM EPA.  Note the progressive closure of the wound over time in the control group (left 
column), with less pronounced closure in the EPA supplemented groups (centre and right 
column). 
 
 
 
Control EPA 40µM 
0hrs 
3hrs 
6hrs 
9hrs 
EPA 50µM 
187 
 
 
In the second experiment, supplementation of cells with EPA concentration >20µM 
resulted in cells lifting off the plate and floating in the culture medium within three 
hours.  The reason for this unexpected variability in the dose of EPA which resulted 
in cells lifting off the plate between the two experiments is not clear.  Perhaps the 
technique of wound scoring was too vigorous in the second experiment, resulting in 
more disruption of the HUVEC monolayer.  Alternatively, it could have been due to 
an incorrect concentration of EPA being used in the second experiment, either due 
to an error in the mixing of EPA-supplemented media, or because a new batch of 
EPA capsules was used for this experiment.  Wound closure was only calculable for 
doses of EPA of 10 and 20µM (Figure 6.17 and Figure 6.18).  Supplementation with 
EPA 10µM resulted in a 13.8% reduction in wound closure compared to controls at 
6 hours (p=0.32), and 13.1% reduction at 9hrs (p=0.20).  EPA 20µM resulted in 
37.8% reduction in wound closure compared to controls at 3hrs (p=0.04), 82.5% 
reduction at 6hrs (p<0.01) and 67.8% reduction at 9hrs (p<0.01).      
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Figure 6.17.  Effect of acute EPA supplementation on HUVEC wound closure: 
Experiment 2.  Wound closure over time is shown as the percentage reduction in the width 
of the wound compared to width at baseline.   Each bar is the mean of 6 photos from 3 
separate wells.  Error bars represent mean+- SEM.    
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Figure 6.18.  Photographs of HUVEC wound closure over time: Experiment 2. Wound 
closure at 0, 3, 6 and 9hrs in control cells and cells acutely supplemented with 10µM and 
20µM EPA 
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6.2.3 Chronic EPA supplementation 
In the first experiment of the effect of chronic EPA supplementation (1µM EPA for 2 
weeks) on HUVEC wound closure, the effect of adding 10nM VEGF to the culture 
medium immediately after performing the wound score was also investigated.  The 
results are shown in Figure 6.19.  There was no statistically significant difference in 
wound closure between EPA-supplemented cells and EPA-naive cells, although 
wound closure in the EPA-supplemented cells was 15.2% greater at 6hrs (p=0.15) 
and 20.2% greater at 12hrs (p=0.07) compared to the EPA-naive cells.  Addition of 
VEGF did not increase wound closure in either the EPA-naive or EPA-
supplemented cells.    
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Figure 6.19.  The effect of chronic EPA supplementation on HUVEC wound closure: 
Experiment 1  Wound closure over time is shown as the percentage reduction in the width 
of the wound compared to width at baseline.  In the chequered bars, 10nM VEGF was 
added immediately after creating the wound scores.  Each bar is the mean of 6 photos from 
three separate wells.  Error bars represent mean +- SEM.  
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Two further replicate experiments investigating the effect of chronic EPA 
supplementation on HUVEC wound migration were performed (Experiments 2 and 
3).  In each experiment, triplicate 6 well plates were plated up, with three wells per 
plate containing EPA naive cells and 3 wells per plate containing EPA-
supplemented cells.  In Experiment 2 (Figure 6.20) EPA-supplemented cells 
showed slower wound closure compared to controls.  Wound closure compared to 
controls was 16.2% less at 6hrs (unpaired t-test, p=0.03) and 14.7% less at 9hrs 
(unpaired t-test, p=0.06).  In Experiment 3 (Figure 6.21) there was no significant 
difference in wound closure between the EPA-naive and EPA supplemented cells.  
The variability in these three experiments is difficult to explain, with one showing 
increased wound closure in the EPA group, another showing reduced closure, and 
the third showing no difference in closure compared to the EPA-naiive cells.  
However, on the basis of this limited number of experiments, it appears that chronic 
EPA-supplementation does not affect wound closure.  
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Figure 6.20.  The effect of chronic EPA supplementation on HUVEC wound closure: 
Experiment 2.  Wound closure over time is shown as the percentage reduction in the width 
of the wound compared to width at baseline.  Each bar is the mean of 18 photos from 8 
replicate wells.  Error bars represent mean +- SEM.    
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Figure 6.21.  The effect of chronic EPA supplementation on HUVEC wound closure: 
Experiment 3.  Wound closure over time is shown as the percentage reduction in the width 
of the wound compared to width at baseline.  Each bar is the mean of 18 photos from 8 
replicate wells.  Error bars rep[resent mean +- SEM.    
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6.3 Matrigel tubule formation assay 
6.3.1 Assay optimisation 
Matrigel was thawed and diluted with PBS to give concentrations of Matrigel 
ranging from 1 in 1 to 1 in 20.  Diluted Matrigel was spread evenly in a 6-well plate 
and left for 30 minutes at 37oC until solidified into a consistent gel layer.  HUVECs 
were seeded at 2x105 cells/well in 2ml of culture medium, and tube formation 
assessed at 4hrs and 24hrs.  Matrigel at concentrations of 1 in 15 and 1 in 20 
resulted in an uneven and patchy layer of Matrigel when viewed under the 
microscope at low power, with correspondingly poor HUVEC seeding and no tubule 
formation (photos not shown).  Tubule formation at higher concentrations of 
Matrigel are shown in Figure 6.22.  A Matrigel concentration of 1 in 3 resulted in 
good tubule formation.  Matrigel at a concentration of 1 in 2 gave similar results to 1 
in 3, whereas concentrations less than 1 in 3 resulted in poor to no tubule 
formation.  A Matrigel concentration of 1 in 3 was therefore chosen for use in 
subsequent experiments. 
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Figure 6.22.  Formation of tubules when HUVECs were seeded on different dilutions 
of Matrigel. 
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The Matrigel assay was less consistent and reproducible than either the MTT assay 
of HUVEC proliferation or the wound score assay of HUVEC migration.  Small 
adjustments to the technique of Matrigel dilution and plating into a 6-well plate 
improved the consistency and reproducibility of the Matrigel gel layer, and 
minimised the formation of air bubbles that were noticeable in the 1:2 dilution photo 
in Figure 6.23.  This was primarily achieved by ensuring that all reagents and 
equipment was cooled to 4oC and then kept on ice at all stages until the Matrigel 
had been plated into the 6 well plate.  Even following this, the formation of tubules 
varied between experiments.  In some experiments, at 24hrs only a small number 
of short tubules formed with healthy HUVECs remaining seeded on the Matrigel 
layer, whereas in other experiments almost all HUVECs had formed long branching 
tubules within 6 hours.  In two experiments it was noted that tubules formed only in 
the centre of the well whereas in the periphery HUVECs remained as a typical 
cobbblestone-appearance cell monolayer. 
On the advice of colleagues in another department who were performing Matrigel 
angiogenesis assays with HUVEC and fibroblast co-cultures, Growth Factor 
Reduced BD Matrigel Basement Membrane Matrix (BD Biosciences, Cat no. 
356231) rather than High Concentration BD Matrigel Basement Membrane Matrix 
(BD Biosciences, Cat no. 354248) was ordered and used for subsequent 
experiments.  In an effort to further improve the reproducibility of the assay by 
improving the consistency of the Matrigel layer, for subsequent experiments the 
concentration of Matrigel was increased from 1 in 3 to 1 in 2 dilution with PBS, and 
0.5ml rather than 0.3ml of diluted Matrigel were plated in each well of the 6-well 
plate.  This improved the number of tubules formed, with more even tubule 
formation across the whole well, and improved the reproducibility between 
experiments.  The results of subsequent acute and chronic EPA supplementation 
experiments using these modifications to the protocol are detailed below.   
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6.3.2 Acute EPA supplementation 
One acute EPA supplementation experiment was performed after the modifications 
to the protocol described above.  Two 6-well plates were prepared with a Matrigel 
layer as described above.  HUVECs in culture medium supplemented with EPA 0-
30µM were placed into separate falcon tubes.   A post-doctoral fellow then seeded 
the HUVECs into the two 6 well plates (2 wells for each EPA concentration) so that 
I remained blind to the treatment allocation.  Well allocation was only revealed to 
me when the image-analysis results were returned from Wimasis.  An example of 
the photograph of tubules taken and uploaded to Wimasis for analysis, together 
with an overlay of the image-recognition of tubules performed by Wimasis is shown 
in Figure 6.23. 
The results of tubule formation at 6hrs are shown in Figure 6.24.  There was no 
significant difference in total tubule length between controls and any concentration 
of EPA (control vs. EPA 30µM p=0.32).  There was no significant difference in the 
number of tubule branching points between controls and any concentration of EPA 
(control vs. EPA 20µM p=0.14, control vs. EPA 30µM p=0.11).  EPA was 
associated with a reduction in the number of tubule loops compared to controls, 
with this narrowly missing statistical significance at the highest dose of EPA (control 
vs. EPA 20µM, p=0.11; control vs. EPA 30µM, p=0.06).  All statistical comparisons 
were performed using unpaired t-tests.   
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Figure 6.23.  Example of Wimasis scoring of tubules.  a) Photograph of HUVEC tubules.  
The image was uploaded to Wimasis for automated image recognition and analysis.  b) 
HUVECs were identified by binary thresholding (blue).  Individual tubules were identified by 
a skeletonization algorithm (pink).  Tubule branching points were identified (white dots).  
Total tubule number, branching points and loops were calculated. 
A 
B 
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Figure 6.24.  The effect of EPA on tubule length, branching and loop formation.  Each 
bar is the mean of 8 images (4 representative photos from each of 2 replicate wells).  Error 
bars represent mean +- SEM.  
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6.3.3 Chronic EPA supplementation 
The effect of chronic 1µM EPA supplementation on HUVEC tubule formation was 
performed in three experiments following the protocol modifications described in 
6.3.1.  In the first experiment the effect of 10nM VEGF supplementation at the time 
of plating HUVECs onto the Matrigel was also investigated.  Two wells were plated 
for each experimental condition (naive, naive+VEGF, chronic EPA, chronic 
EPA+VEGF).  Peak tubule formation was observed at 6 hours and a total of 3 
representative photos taken from the two wells of each experimental condition.  
Example photographs are shown in Figure 6.25.  The results are shown in Figure 
6.26.  There was no significant difference between EPA-naive and EPA-
supplemented cells in either tubule number (p=0.41), number of branching points 
(p=0.40) or number of loops formed (p=0.52).  Addition of VEGF had no significant 
effect on any of these three measures of tubule formation in either the EPA-naive 
cells (p=0.77, p=0.75, p=0.73 respectively) or the EPA supplemented cells (p=0.15, 
p=0.13, p=0.19 respectively). 
 
  
 
Figure 6.25. Example photographs of the effect of chronic EPA supplementation on 
HUVEC tubule formation: Experiment 1.  Photographs taken 6 hours after seeding a) 
Naive cells and b)  EPA-supplemented cells onto Matrigel®.  
A B 
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Figure 6.26.  The effect of chronic EPA-supplementation in HUVEC tubule formation: 
Experiment 1.  Tube formation, branching points and total number of loops formed were 
scored 6 hours after seeding cells onto Matrigel.  In the chequered bars, VEGF was added 
at the time of seeding cells onto Matrigel®.  Each bar is the mean of 3 representative photos 
from 2 wells (i.e. n=3).  Error bars represent mean +- SEM.  
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In the second experiment a single 6-well plate was seeded with naive cells (3 wells) 
and EPA supplemented cells (3 wells).  Tubule formation was much poorer than in 
the first experiment (Figure 6.27).  One representative photo from each well was 
analysed and the results shown in Figure 6.28.  Tubule formation was reduced in 
the EPA-supplemented cells compared to the EPA-naive cells across all three 
measures of tubule formation at both time points.  At 6 hours the EPA- 
supplemented cells showed a 45.7% reduction in tubule length (p=0.01, unpaired t-
test) and a 60.5% reduction in tubule branching points (p=0.05, unpaired t-test) 
compared to EPA-naive cells.    
 
 
  
 
Figure 6.27. Example photographs of the effect of chronic EPA supplementation on 
HUVEC tubule formation: Experiment 2.  Photographs taken 6 hours after seeding a) 
Naive cells and b)  EPA-supplemented cells onto Matrigel®. 
 
 
 
 
 
A B 
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Figure 6.28.  The effect of chronic EPA-supplementation in HUVEC tubule formation: 
Experiment 2.  Tube formation, branching points and total number of loops formed were 
scored 6 hours after seeding cells onto Matrigel.  In the chequered bars, VEGF was added 
at the time of seeding cells onto Matrigel®.  Each bar is the mean of 1 representative photo 
from 3 wells (i.e. n=3).  Error bars represent mean +- SEM.  
p=0.01 
 
p=0.05 
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In the third experiment, one six well plate was seeded with naive cells (3 wells) and 
EPA-supplemented cells (3 wells) by a post-doctoral research fellow so that I 
remained blind to the well allocation.  Well allocation was only revealed to me when 
the image-analysis results were returned from Wimasis.  Four representative 
photos were taken from each well and analysed.  Example photos are shown in 
Figure 6.29.  All four photos from each well were analysed and the results are 
shown in Figure 6.30.  At 6 hours the EPA-supplemented cells showed an 18.3% 
reduction in tubule length (p=0.03), a 30.9% reduction in tubule branching points 
(p=0.04) and a 41.9% non-significant reduction in the number of loops formed 
(p=0.11) compared to EPA-naive cells.  All statistical comparisons were performed 
using unpaired t-tests.   
 
   
  
Figure 6.29. Example photographs of the effect of chronic EPA supplementation on 
HUVEC tubule formation: Experiment 3.  Photographs taken 6 hours after seeding a) 
Naive cells and b)  EPA-supplemented cells onto Matrigel®. 
A B 
204 
 
 
E ffe c t  o f c h ro n ic  E P A  s u p p le m e n ta t io n  o n
H U V E C  m a tr ig e l tu b e  fo rm a tio n
T u b u le  le n g t h
T im e  (h rs )
T
o
ta
l 
tu
b
e
 l
e
n
g
th
 (
p
ix
e
ls
)
6
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
N aive
C h ro n ic  E P A  1 u M
p = 0 .0 3
 
E ffe c t  o f c h ro n ic  E P A  s u p p le m e n ta t io n  o n
H U V E C  m a tr ig e l tu b e  fo rm a tio n
T u b u le  b r a n c h in g  p o in t s
T im e  (h rs )
T
o
ta
l 
b
r
a
n
c
h
in
g
 p
o
in
ts
6
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
N aive
C h ro n ic  E P A  1 u Mp = 0 .0 4
 
E ffe c t  o f c h ro n ic  E P A  s u p p le m e n ta t io n  o n
H U V E C  m a tr ig e l tu b e  fo rm a tio n
T u b u le  le n g t h
T im e  (h rs )
T
o
ta
l 
n
u
m
b
e
r
 o
f 
lo
o
p
s
6
0
2 0
4 0
6 0
8 0
1 0 0
N aive
C h ro n ic  E P A  1 u M
p = 0 .1 1
 
Figure 6.30.  The effect of chronic EPA-supplementation in HUVEC tubule formation: 
Experiment 3.  Tube formation, branching points and total number of loops formed were 
scored 6 hours after seeding cells onto Matrigel.  In the chequered bars, VEGF was added 
at the time of seeding cells onto Matrigel®.  Each bar is the mean of 4 representative photos 
from each of 3 wells (i.e. n=12).  Error bars represent mean +- SEM.  
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6.4 Summary of HUVEC data 
A summary of the effects of acute and chronic EPA supplementation on measures 
of angiogenesis in vitro is shown in Table 6.2.  Acute EPA supplementation resulted 
in a dose-dependent inhibition of HUVEC proliferation over concentration ranges 
comparable to other endothelial cell studies,(195, 355, 356) and chronic low dose 
EPA supplementation (1µM for 2 weeks) caused a similar magnitude reduction in 
HUVEC proliferation to that seen with 10-20µM acute supplementation.  HUVEC 
wound migration was inhibited by acute EPA supplementation in the range of 20-
50µM EPA but the results of the chronic EPA supplementation were more 
equivocal, with a trend to reduced wound closure in two out of three experiments, 
but which did not reach statistical significance in either experiment.  HUVEC tubule 
formation in Matrigel® was inconsistently inhibited by chronic EPA supplementation 
but not acute EPA supplementation.   
 
 Acute EPA Chronic EPA 
Proliferation 
Dose dependent inhibition 
with 40-70% ↓ proliferation 
Equivocal effect on 6-keto-
PGF1α in cell-conditioned 
media, with dose dependent 
↑ in one experiment and no 
change in another.   
16-33% ↓ proliferation 
 
Attenuated response to VEGF 
stimulation of proliferation 
 
No convincing PGE2 rescue 
 
↓6-keto-PGF1α in cell-conditioned 
media 
 
Wound closure 
Dose dependent inhibition 
with 24-67% ↓ wound closure 
 
Non-significant ↓ wound closure 
in 2 out of 3 experiments 
 
VEGF did not stimulate closure 
in either EPA-supplemented 
cells or controls 
Tube 
formation 
No effect 
 
↓tubule length and branching 
points in 2 out of 3 experiments 
 
Table 6.2  Summary of the effect of acute and chronic EPA supplementation on  
measures of angiogenesis in HUVECs.  
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Anti-angiogenic activity of ω-3 PUFAs has been demonstrated in previous in vitro 
endothelial cell studies.  Omega-3 PUFA supplementation has been shown to 
reduce expression of VEGFR-2,(195, 196, 356) reduce cell migration,(194, 196) 
and reduce VEGF-stimulated microtubule formation.(193, 194, 196)  Omega-3 
PUFA supplementation has also been associated with reduced tumour vascularity 
in vivo. (186, 204, 205)  However, similar to the findings in my assays, previous in 
vitro studies have also shown mixed results.  HUVEC wound migration was 
arrested by acute supplementation with EPA but not DHA in a study by Tonutti et al, 
(357) and by conjugated EPA but not by EPA in a study by Tsuzuki et al.(194)  In 
alternative types of migration assays which involved measuring the number of cells 
that migrate out of a Matrigel droplet or the number of cells that migrate across a 
Boyen chamber, neither EPA nor DHA reduced the number of migrating cells 
compared to controls whereas AA did significantly increase the number of migrating 
cells.(194, 355)  Some studies have shown that HUVEC tubule formation is 
inhibited by EPA,(193, 194, 356) DHA,(358) and conjugated EPA,(194) whilst 
another study showed that tubule formation was inhibited by 24hr EPA, DHA or 
DPA only when tubule formation was stimulated with 20µM VEGF.(196)  AA, by 
contrast, increased tubule formation compared to controls in both the VEGF-
stimulated and unstimulated experiments.  One further study, without VEGF 
supplementation, showed no effect of 10 μM EPA or DHA on HUVEC tubule 
formation (355).  It may be that EPA exerts anti-angiogenic activity through both 
direct activity on endothelial cells, and indirect activity mediated, for example, by 
effects on VEGFR expression.   
The reasons for the differing effects of EPA on the three angiogenesis assays used 
in my study are unclear.  Compared to the simple MTT assay of cellular 
proliferation, the processes involved in cell migration (e.g. requiring lamellipoia 
extension and actin-myosin complex contraction) and tubule formation (e.g. 
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requiring motility, cytoskeletal rearrangement and interaction with adjacent cells) 
are more complex.  Different pathways are likely to be upregulated in each process.  
The relative contributions of such pathways, for example the COX-PGE2 and VEGF 
pathways, to each of these processes and the relative speed at which EPA 
supplementation affects these pathways might explain some of the conflicting 
results.  These factors might also explain the different effects seen with acute and 
chronic EPA supplementation.  It is conceivable that chronic EPA supplementation 
has different biological effects than acute EPA supplementation.  Chronic 
supplementation might lead to greater EPA incorporation in cell membranes, or 
greater down-regulation of cell surface VEGFR-2 expression.  Acute EPA 
supplementation meanwhile (0-6hrs in the wound migration and Matrigel assays) 
might not have had time to down-regulate the number of VEGFR-2 receptors, and 
instead exert effects in this timeframe predominantly by inhibition of the COX 
pathway and reduction in PGE2 production (and production of 3-series 
prostaglandins).    
PGE2 is known to be a strong stimulant of cell proliferation.  An alternative acute 
supplementation methodology for the wound migration and Matrigel assays would 
have been to pre-condition HUVECs with EPA acutely for 24-48hrs prior to wound 
scoring or prior to plating on Matrigel rather than adding EPA-containing media after 
the scoring or plating of cells.  Whilst this would have more closely mirrored the 
conditions of the MTT proliferation assay, I already knew that EPA inhibited HUVEC 
proliferation, and decided that the addition of EPA to culture medium 24-48hrs prior 
to wound scoring might have affected the HUVEC confluence at time of scoring and 
therefore biased the results.  I did perform a few preliminary experiments 
investigating the effect of PGE2 rescue on the proliferation of HUVECs chronically 
supplemented with EPA.  PGE2 stimulated proliferation in EPA-supplemented cells 
but did not return proliferation to the baseline proliferation of EPA-naive cells.  This 
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might suggest that PGE2 rescue was under-dosed, although PGE2 stimulated an 
even greater proliferation in the EPA-naive cells suggesting that EPA inhibition of 
proliferation was not solely PGE2 dependent.  Interestingly, the concentration of 6-
keto-PGF1α in the cell-conditioned medium of cells chronically supplemented with 
EPA was lower than that of the EPA-naive cells, whilst acute EPA supplementation 
seemed to have no effect on 6-keto-PGF1α levels.  This might suggest that chronic 
supplementation inhibits COX metabolism of 2-series prostaglandins to a greater 
extent than acute supplementation.  However, these assays were only performed 
on culture medium from single MTT assays, and the results would need to be 
reproduced before drawing any conclusions.   
A few studies were also performed supplementing cells with VEGF.  Whilst VEGF 
stimulated proliferation in the EPA-naive cells, cells chronically supplemented with 
EPA showed no response to VEGF stimulation, suggesting either that VEGFR-2 
receptors were down-regulated or that one mechanism of inhibition by EPA occurs 
downstream of the VEGF receptor.  When the same experiment was performed in 
the wound migration model, supplementation with VEGF failed to stimulate 
migration in either the EPA-naive or chronically EPA-supplemented cells, raising 
the possibility that pathways other than the VEGF pathway are more important in 
endothelial cell migration.  
Without more detailed mechanistic analyses, which may include measuring 
mucosal EPA content, cell surface VEGFR-2 expression or further investigation of 
2-series and 3-series prostaglandin levels in cell-conditioned media, any 
explanation for the difference in the effect of acute and chronic supplementation is 
speculative.  Nevertheless, taken together the results from these HUVEC 
experiments do point towards an inhibitory effect of EPA on angiogenesis, which is 
supported by the available literature, and supports the hypothesis that EPA might 
reduce tumour microvessel density by inhibiting angiogenesis.  
209 
 
 
Chapter 7: Discussion 
 
7.1  Safety profile of EPA 
The high rate of uptake of patients into The EMT Trial (96% of eligible patients) 
demonstrates that ω-3 PUFAs are considered by patients to be safe and that 
potential gastrointestinal side effects such as diarrhoea, dyspepsia and nausea do 
not deter patients from accepting ω-3 PUFAs as a potential adjuvant treatment for 
CRCLM.  In The EMT Trial, EPA-FFA 2g/day was demonstrated to be safe and 
well-tolerated.  The rate of compliance with trial medication was over 90%, and the 
rate of gastrointestinal upset was similar to that seen in other ω-3 PUFA trials.(262, 
314, 315)  Importantly, very few patients were withdrawn due to side effects of 
medication (4.7%), further demonstrating the tolerability of study medication.   
Whilst it is easy to identify pre-operative side effects that can be attributable to 
study medication, the effect of pre-operative interventions on post-operative 
morbidity is harder to measure, and harder still to demonstrate causality.  Few 
institutions formally classify the severity of complications according to a recognised 
grading system, such as the Dindo-Clavien classification system.(359)  This makes 
comparison between the often fastidious collection of morbidity data within a clinical 
trial and the morbidity data published in retrospective reviews of institutional 
databases difficult.   Nevertheless, the rate of post-operative morbidity in the EMT 
Trial was comparable to that of other published series,(307, 308) providing further 
reassurance that EPA supplementation is safe in patients undergoing liver 
resection.      
There have been concerns in the literature about the risk of bleeding with ω-3 
PUFA supplementation.(269)  This concern has not been realised clinically, with a 
recent review highlighting that excessive bleeding was virtually non-existent in over 
210 
 
 
4000 patients taking ω-3 PUFAs who underwent coronary artery bypass grafting, 
carotid artery endarterectomy or percutaneous coronary angioplasty.(268)  
Similarly, no excessive bleeding has been seen in studies of patients taking ω-3 
PUFA supplements who are admitted with acute myocardial infarction (typically 
requiring heparinisation or thrombolysis),(360) or in patients having spinal 
surgery.(361)  Nevertheless, liver resection involves parenchymal transection which 
predisposes the patient to bleeding from the cut surface of the liver.  Any small 
increase in bleeding tendency as a result of EPA supplementation might therefore 
be expected to result in a clinically apparent bleed following liver resection.  
However, liver resections are routinely performed on patients who are still taking 
aspirin, which has a well established anti-platelet activity, without any concern 
about bleeding risk and without additional pre-operative or intra-operative measures 
to minimise bleeding.  The clinical risk of bleeding with EPA supplementation in 
patients undergoing liver resection in The EMT Trial was therefore considered to be 
negligible.  This opinion was supported by the finding that EPA supplementation 
had no effect on either laboratory analysis of whole blood platelet aggregation, or 
on clinical bleeding parameters such as the need for packed red cell transfusion 
and the need for drainage of postoperative collections. 
This excellent safety and tolerability profile makes EPA a strong candidate agent for 
the treatment and/or prevention of CRC and CRCLM.  Whilst both aspirin and COX-
2 inhibitors have been shown to have anti-CRC activity,(127-130, 135, 136, 138, 
139) the risk of bleeding and GI ulceration with prolonged aspirin therapy (140)  and 
the risk of myocardial infarction or thrombosis with prolonged COX-2 inhibitor 
therapy (132, 134) has prevented their long-term use for the chemoprevention of 
CRC and CRCLM.  EPA, in contrast, appears to have no such side effects with long 
term use.(314)  
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7.2 Patient characteristics and tumour biology 
Two factors which play an important role in the outcome of CRCLM, and could 
potentially impact on the results of this trial are the "biology" of the disease and the 
use of chemotherapy.  Of all prognostic markers, lymph node status of the primary 
cancer and size of the CRCLM are consistently the most important independent 
predictors of survival following resection of CRCLM.(362-365)  Together with 
factors such as Dukes' stage and synchronicity of disease, these are considered 
surrogate markers for the tumour biology.  The EPA and placebo groups were well 
matched across all of these factors.   Just under half of patients in both groups had 
received chemotherapy at some stage prior to presentation, with no difference 
between the groups in the interval between chemotherapy and enrolment into The 
EMT Trial.  A higher proportion of patients in the placebo group presented with 
recurrent liver metastases (24% vs. 14%).  This could be interpreted as an 
indication of more "aggressive" disease in the placebo group.  However, this was 
not a statistically significant difference, and secondly, it is known that disease-free 
and overall survival after resection of recurrent liver metastases is similar to that 
after the first resection of CRCLM.  The difference in the proportion of patients with 
recurrent disease in this trial is perhaps of limited clinical significance.  Therefore, 
as far as can be determined the tumour characteristics of the two groups at 
baseline were comparable. 
Although the two groups were well matched across all other baseline 
characteristics, two potentially confounding variables were identified.  Firstly, 
approximately 22% of patients in each group were taking aspirin, which as an 
inhibitor of the COX enzyme acts on the same pathway as one of the proposed 
mechanisms of action of EPA.  Aspirin use was deliberately not cited as an 
exclusion criterion for the study because of the interest in the novel anti-
inflammatory compound resolvinE1, which is metabolised from EPA by acetylated 
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COX-2 (see Figure 1.5 and Section 1.7.4) (164).  Inclusion of aspirin-users 
therefore provided the opportunity to look for resolvin E1 in the plasma and tissue of 
patients who were taking both aspirin and EPA.  These analyses were not 
performed as part of this MD project due to cost and time implications, and samples 
have been stored for future analysis.  Sub-analyses were performed excluding 
concurrent aspirin users.  These showed that aspirin use did not affect the results of 
either the tumour immunohistochemistry or the mechanistic analyses.   
Secondly, patient use of fish oil supplements was not cited as an exclusion criterion 
for participation in the trial.  One in five patients in the placebo group and one in 
eight patients in the EPA group were taking an oral fish oil supplement at the time 
of enrolment.  This previous fish oil exposure introduced a potential confounder into 
the study, but did present the opportunity to study those patients with a prolonged 
exposure to fish oil supplementation prior to entering the trial.  In retrospect, the trial 
methodology would have been more robust if patients who were taking fish oil 
supplements at the time of screening for the trial had been excluded.  One possible 
limitation of the trial is not being able to determine whether patients enrolled into the 
trial decided to either purchase their own over-the-counter ω-3 PUFA supplements 
or increase their oily fish consumption after being told about the potential benefits of 
ω-3 PUFAs.  The FFQ attempted to control for this by monitoring patients’ oily fish 
consumption and nutritional supplement use during the trial.  Within the limitations 
of a FFQ, which relies on patients accurately completing the questionnaire, patients 
did not increase their oily fish consumption or start to take over-the-counter 
supplements during the trial.  Measurement of the fatty acid content of red blood 
cells on each study visit by gas chromatography would have been one way of 
monitoring this more objectively, but to perform these analyses on three occasions 
for 88 patients would have been prohibitively expensive, and other mechanistic 
analyses  were instead prioritised. 
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7.3 Choice of primary endpoint 
Immunohistochemistry for tumour Ki-67 proliferation index was chosen as the 
primary endpoint in The EMT Trial, with tumour apoptosis and microvessel density 
also investigated as secondary endpoints.  Ki-67 proliferation index (PI), has been 
widely studied as a prognostic marker of survival in many types of cancer.(366)  
Specifically, the Ki-67 PI has been evaluated as a surrogate for disease-free and 
overall survival in resectable CRC and CRCLM.  In the largest single-centre study 
of Ki-67 PI in patients with resection of CRCLM (n=221), multivariate analysis 
identified Ki-67 PI as the most significant independent prognostic indicator of 
survival, with a 2.8 RR of cancer death in patients with Ki-67 PI >50% compared to 
Ki-67 Pi <50%.(367)  A larger Chinese study of Ki-67 PI in CRC biopsies before 
and after adjuvant regional chemotherapy (n=509) demonstrated a reduction in Ki-
67 PI following chemotherapy from 48.6% to 38.4% (21% reduction, p<0.05).  At 
mean follow up of 42 months the chemotherapy group demonstrated a significant 
improvement in median survival (45 months vs. 40 months; p=0.02), disease free 
survival (74% vs. 62%; p=0.02) and overall survival (81% vs. 60%; p=0.01) 
compared to the surgery alone group.(368)  The association between reduction in 
Ki-67 post-chemotherapy and survival has been most extensively studied in breast 
cancer, where paired pre- and post-chemotherapy tissue is commonly available.  
Many papers have shown that Ki-67 is prognostic for overall and disease-free 
survival in breast cancer, and that the post-treatment PI is more predictive of 
survival than either the baseline PI or the percentage change in PI.(369) 
Although there were no human studies of the effect of EPA on CRC or CRCLM 
proliferation on which to base a power calculation for The EMT Trial, many in vivo 
studies had demonstrated a reduction in PI in colonic mucosa and colorectal 
tumours of rodents supplemented with ω-3 PUFAs.(370)  Only one of these studies 
evaluated tumour vascularity, with a 50% reduction in MVD of HT-29 subcutaneous 
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tumours in nude mice fed 1g/kg EPA versus controls.(186)  Similarly, in nine human 
studies of ω-3 PUFA supplementation, colonic mucosal PI was reduced (13-70% 
reduction) in all but two studies,(370) and apoptosis index increased in all three 
studies that measured AI (50%, 57% and 700% increases, one study did not reach 
statistical significance).(370)  Based on in vitro and in vivo  findings, a 30% 
reduction in PI with EPA supplementation was predicted.(186, 199) This magnitude 
of reduction in PI has been shown to correlate with increased patient survival in 
studies of chemotherapy agents which are now well established treatments for CRC 
and CRCLM.  In a trial of neoadjuvant regional 5-FU therapy for CRC, a 21% 
difference in Ki-67 PI of post-treatment CRC tissue between the control and 
chemotherapy groups was associated with an 18% improved disease-free survival 
and 35% improved overall survival.(368)  Likewise, in a trial of a single intravenous 
5-FU bolus prior to resection of CRCLM, there was a reduction in Ki-67 PI of 48% 
and 30% in patients receiving 5-FU at 2 hours and 46 hours pre-surgery 
respectively compared to no-chemotherapy controls (312).  A 30% reduction in PI 
therefore seemed an appropriate size of treatment effect to use in the power 
calculation for The EMT Trial. 
Because pre-operative biopsy of liver cancers is contraindicated due to the risks of 
biopsy, in particularly the risk of tumour seeding, histological analysis of pre-and 
post-treatment CRCLM tissue was not possible in this study.  
Immunohistochemistry analysis was therefore restricted to the comparison between 
placebo and EPA groups of post-treatment tumour samples only.  
Immunohistochemistry of the original CRC specimen as a baseline for each patient 
was considered, but it would not have been helpful because of the well-documented 
heterogeneity in characteristics between CRCs and their paired CRCLMs.  There is 
no evidence that Ki-67 PI in the original CRC is comparable to the PI in the 
subsequent CRCLM, with some studies showing a reduction in PI in the CRCLM 
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compared to PI in the CRC specimen,(371) some showing an increase,(372) and 
some showing no difference.(313)  
 
7.4 Discrepancy between in vivo data and CRCLM immunohistochemistry 
EPA supplementation had no effect on either tumour PI or AI levels in The EMT 
Trial, although there was a trend towards reduced tumour vascularity in the EPA 
group.  Why then, when there is strong evidence for EPA reducing proliferation and 
increasing apoptosis in rodent models (151, 161, 162, 186, 199, 225, 226, 238, 
244) and in human mucosal biomarker studies,(232, 254-259, 261) did this not 
translate into similar changes in CRCLM tissue in this study?  The limitations of 
animal models as representations of human disease and the difficulties of 
translating in vivo findings into clinical effects are well known.(373)  The use of 
higher doses of study medications in animal models than would be achievable in 
humans is often a factor, with high doses often being given to accentuate 
mechanistic effects.  For example, the study of MC-26 mouse CRC cells in a model 
of CRCLM used the same preparation of EPA as in The EMT Trial, at a dose of 2.5-
5% EPA as a percentage of total dietary intake.(209)  This represents 
approximately 6-12 g/kg mouse body weight and was comparable to the dose used 
in other rodent models of CRC.(370)  This is 200-400 times higher than the 2g/day 
dose of EPA used in The EMT Trial which equates to approximately 30mg/kg 
human body weight.  Even adjusted for the difference in mouse and human body 
surface areas, as recommended when translating animal into human dose 
equivalents,(374) the mouse dose is still 15-30 times higher than that given in The 
EMT Trial.  Tumour proliferation in this mouse study was measured using  5-bromo-
2-deoxyuridine (BrdU) incorporation rather than Ki-67 expression as the marker of 
proliferation.  However, this is unlikely to have had any bearing on the translatability 
of in vivo findings to clinical studies.  Several studies have shown good correlation 
between proliferation indices measured by BrdU and Ki-67 staining in rodent and 
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human tissues.(375-377)  Furthermore, an anti-proliferative effect of EPA has been 
demonstrated using the Ki-67 assay in both rodent models (186) and in human 
mucosal biomarker studies.(257, 261)    
Aside from the difference in dose of study medications, other possible explanations 
for the discrepancy between in vivo findings and the findings in The EMT Trial might 
include the heterogeneity of tumours in The EMT Trial, the duration of EPA 
supplementation, and the timing of EPA supplementation.   Each is discussed in 
more detail below.   
Tumour heterogeneity 
There was significant heterogeneity in morphological appearance between the 
tumours resected in The EMT Trial.  As illustrated in Figure 5.12, some tumours 
were well differentiated with densely packed proliferating cells, whereas other 
tumours were predominantly mucinous with large mucin lakes and very few cells.  
Mucinous CRCs are believed to have distinct genetic profiles and clinico-
pathological characteristics compared to non-mucinous CRCs.(378-380)  They 
have also been associated with poorer outcomes, including higher rates of lymph 
node involvement, more advanced stage of disease, higher rates of metastasis, and 
poorer overall survival.(381, 382)  The morphological differences between 
mucinous and non-mucinous CRCLMs will have impacted on the scoring of PI, AI 
and MVD due to the density of cells and vessels.  Similarly, some tumours had a 
large stromal component or large areas of inflammatory cell infiltrate, whereas other 
tumours contained very little stroma.  It is recognised that the tumour 
microenvironment interacts with metastatic cells and influences the growth of 
tumours, and whilst these interactions are not fully understood they are of 
undoubted importance to the growth and survival of cancers such as through the 
secretion of pro-angiogenic growth factors or the secretion of MMPs.(383)  It is 
difficult to quantify how this tumour heterogeneity might have affected tumour PI, AI 
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and MVD, but it is worth noting that in most in vivo models of CRC and CRCLM, 
well-established and characterised cell lines are used which will produce a more 
homogeneous cohort of tumours, with a more consistent morphology and biology 
for which to investigate the effects of any intervention.  In The EMT Trial tumour 
heterogeneity could not be quantified, suffice to say that the distribution of different 
tumour types seemed to be equally spread between the placebo and EPA groups.  
Sub-analysis of PI after exclusion of mucinous tumours was performed, but this did 
not reveal any difference in the PI between the two groups.     
Duration of supplementation 
Another explanation for the negative PI and AI findings in The EMT Trial is that the 
period of supplementation may have been too short to observe either the maximal 
incorporation of EPA into the tumour, or to begin to see a reduction in tumoural AA 
content.  On the limited evidence available from colonic mucosa studies, a 
reduction in tissue AA content does not seem to occur until around 12 weeks, 
whereas EPA content seems to peak much earlier at around 4 weeks.(254, 255, 
273, 323)  
It remains unclear why mucosal EPA peaks before the AA content starts to fall, but 
this would suggest that EPA incorporation is not simply a direct substitution of EPA 
for AA.   EPA can be converted to DHA, via DPA, in a two-stage process involving 
elongase and desaturase activity.  Limited evidence from clinical trials suggests 
there is no significant EPA to DHA conversion in human colorectal mucosa,(257, 
262)  Interestingly, there was a significant increase in tumoural DPA, but not DHA, 
content in the EPA group in the EMT Trial.  Similar findings of comparable EPA and 
DPA increases, without a rise in DHA, were seen in the equivalent in vivo study of 
MC-26 mouse CRCLMs using the same preparation of EPA as used in the EMT 
Trial.(209)  This suggests that the conversion between EPA and DPA in CRCLM is 
greater than first appreciated, and greater than that seen in human colonic mucosa.  
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If mucosal EPA content reaches a threshold beyond which EPA is converted to 
DPA and DPA levels continue to rise and diplace AA, this may explain why the EPA 
content seems to plateau before a reduction in AA content is seen.  Interestingly, 
DPA has recently been shown to have anti-CRC activity(384) and has previously 
been shown to inhibit endothelial cell migration.(196)  Future work might consider 
testing the following hypotheses: 
 Mucosal incorporation of EPA occurs at the expense of fatty acids other 
than AA 
 Changes in mucosal fatty acid composition stimulate liberation of AA from 
the mucosa, rather than the direct substitution of one fatty acid (EPA) for 
another (AA) 
 There is a threshold for mucosal EPA content beyond which additional EPA 
is converted into other ω-3 PUFAs such as DPA. 
 DPA has anti-CRC activity   
It was also observed that the tumoural AA content in The EMT Trial was higher than 
the baseline levels of AA in previous human mucosal biomarker studies (Table 5.8).  
Perhaps the ratio of AA:EPA is more important than the absolute level of either fatty 
acid.  The ratio of AA:EPA in The EMT Trial was certainly higher than the AA:EPA 
ratios in the human mucosal biomarker studies which demonstrated reduced 
proliferation and increased apoptosis.   Alternatively, perhaps human mucosa has a 
faster rate of proliferation than CRCLMs, and therefore changes in PUFA 
metabolism due to EPA supplementation will manifest in changes in PI and AI more 
rapidly.   
In the only other study of ω-3 PUFA supplementation in patients with CRCLM, 
72hrs of pre-operative parenteral ω-3 PUFA supplementation was associated with 
an increase in plasma EPA and DHA levels immediately following supplementation 
compared to the control group, but no change in plasma AA levels and no 
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significant change in the ω-3 PUFA content of red blood cell membranes.  Surgery 
for CRCLM was performed 5-12 days following ω-3 PUFA supplementation, by 
which time plasma EPA and DHA levels had returned to baseline levels.  There was 
no significant difference in the EPA, DHA or AA content of tumours from the ω-3 
PUFA supplemented group compared to those from the control group.  The authors 
extrapolate their data backwards to suggest that the total ω-3 PUFA content of 
CRCLMs at the end of supplementation would have been approximately 8%, 
compared to a mean of 5.6% at the time of resection.  This data really only provides 
evidence of a transient rise in plasma ω-3 PUFA content following parenteral 
supplementation.  Extrapolating the tumour PUFA data back to estimate tumoural 
ω-3 PUFA at the end of supplementation is of limited clinical relevance.  If the 
increase in tumoural ω-3 PUFA content was so transient as to have returned to 
baseline values within 5-12 days, what is the likelihood of this having had any 
clinically relevant effect on the tumour biology?  By comparison, oral EPA 
supplementation in The EMT Trial was associated with a statistically significant 
increase in tumoural EPA, DPA, and total ω-3 PUFA (6.2%) content.   
The two studies cannot be compared to assess the relative merits of oral or 
parenteral ω-3 PUFA supplementation on the speed of uptake of ω-3 PUFAs by 
CRCLM, or indeed its washout after cessation of therapy,  because neither study 
assessed tumoural ω-3 PUFA content over time.  What can be said by comparing 
the two studies, however, is that 4 weeks of oral supplementation was feasible, 
could be continued up to the day of surgery, was associated with significant 
changes in tumour ω-3 PUFA content, and that such supplementation could readily 
be applied to future clinical trials.  By comparison, 72hrs of parenteral 
supplementation was not associated with significant changes in tumour ω-3 PUFA 
content, and to bring surgery closer to the end of parenteral supplementation on the 
assumption that the tumour ω-3 PUFA content would be higher would not only be 
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based on extrapolated and unproven data, but would also be logistically more 
challenging than oral supplementation in a clinical trial setting.  Furthermore, neither 
trial saw any change in AA content of tumours, or of plasma or RBCs in the 
Leicester study, suggesting that a longer period of supplementation would be 
required for any future trial.  This further commends the oral route as the more 
pragmatic for any future trial.   
Timing of EPA supplementation 
A third explanation for the discrepancy between the findings of pre-clinical studies 
and The EMT Trial is the timing of EPA supplementation in relation to the 
inducement of CRC/CRCLM.    In The EMT Trial, EPA was given to patients with 
well established CRCLMs, which would have seeded in the liver and started 
growing before the original CRC was resected.  EPA supplementation could 
therefore be considered as given late in the "life-cycle" of the CRCLM.  By contrast, 
ω-3 PUFA supplementation in animal CRC treatment models is started either 
before, at the time of, or shortly after the subcutaneous injection of tumour cells.  
This does not accurately reflect the situation in The EMT Trial where 
supplementation is started in the presence of well-established CRCLMs.  Those in 
vivo  models which pre-load animals with ω-3 PUFA prior to chemical inititation of 
carcinogenesis, or prior to the injection of cancer cell lines, may increase EPA in 
the microenvironment before a tumour has even started growing, altering the 
cancer cell - microenvironment interaction and affect the tumour's growth 
characteristics.  In these situations there may not be a clear distinction between 
"chemoprevention" and "chemotherapy".  Similarly, those in vivo models that start 
ω-3 PUFA supplementation at, or shortly after, cancer cell injection are giving ω-3 
PUFA much earlier in the "life-cycle" of the tumour than in The EMT Trial, which 
may therefore have a greater effect on the tumour's growth characteristics.     
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7.5 Tumoural and urinary prostaglandins 
It is widely believed that one of the mechanisms of action of EPA is the inhibition of 
COX metabolism of AA, causing a reduction in the production of 2-series 
prostaglandins, whilst at the same time providing EPA as an alternative substrate 
for COX causing an increase in the production of 3-series prostaglandins.  There is 
convincing evidence that EPA supplementation reduces pro-tumourgenic PGE2 
production in vivo. (151, 186, 209, 227, 236, 241, 244, 327)  A "PGE2 to PGE3 
switch" has been demonstrated in vitro,(145, 327)  and in rodent models of 
CRC,(151)   pancreatic cancer, (327)  and more recently in mouse CRCLMs using 
the same preparation of EPA as used in the EMT Trial.  However, as yet no studies 
have investigated the effect of ω-3 PUFA supplementation on the levels of PGE2 in 
human CRC or CRCLM, and a PGE2 - PGE3 switch has not been demonstrated in 
any human tissue.   
That there was no difference in tumoural PGE2 levels between the two groups is 
perhaps unsurprising given that there was also no difference in tumoural AA 
content between the two groups.  It is difficult to tease out from the literature 
whether it is the reduction in tissue AA, the inhibition of COX metabolism of AA, or a 
combination of both that accounts for the reduction in PGE2 seen in pre-clinical 
studies of EPA therapy.  Again, for the same reasons that the short duration of EPA 
supplementation might explain why there was no change in tumoural AA content 
with EPA supplementation, so too might it explain why EPA was not associated with 
a reduction in PGE2 in this trial, in contrast to the findings of many pre-clinical 
studies.(151, 186, 209, 227, 236, 241, 244, 327)  It is also unsurprising, given the 
low levels of PGE2 in these tumours and the observation that PGE3 tends to be 
present at 10-20 times lower concentration than PGE2, that PGE3 was detectable in 
only one tumour.  PGE2  levels were an order of magnitude lower in this study than 
in previous in vivo studies.  This might be due to the biological characteristics of the 
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cell lines used in these in vivo  studies.  These can be high expressers of COX and 
produce vast quantities of PGE2, unrepresentative of that seen in human tumours.  
These factors could make it difficult for any study to demonstrate a PGE2 - PGE3 
switch in human tissue.     
Interestingly, although EPA supplementation was not associated with a reduction in 
tumoural PGE2, it did seem to cause a reduction in urinary PGE-M.  Over the last 
10 years there has been interest in the measurement of urinary PGE-M as a non-
invasive measure of systemic PGE2 synthesis, and therefore as a potential 
biomarker of CRC activity.  Some studies have shown a correlation between PGE-
M and the presence of colonic adenomas,(83, 385) and between PGE-M and CRC 
risk.(82)  Other studies in non-small cell lung cancer have shown that celecoxib 
treatment is associated with a reduction in PGE-M,(330) and that patients who had 
the greatest reduction in PGE-M demonstrated improved overall survival.(329)  
Looking at the trends in the data in Figure 5.25, urinary PGE-M fell whilst patients 
were taking EPA, and then rose again to baseline levels after they stopped taking 
EPA.  Although the change in the EPA group between baseline and post-treatment 
did not reach statistical significance, urinary PGE-M post-treatment was significantly 
lower in the EPA group than the placebo group.  The small but statisttically 
significant reduction in PGE-M with EPA therapy indicates that EPA 
supplementation has an effect on PGE2 synthesis.  Whether this is tumour-derived 
PGE2 or systemic PGE2 cannot be determined.  It would be expected that CRCLMs 
are the predominant source of PGE2 production and therefore of PGE-M in the 
urine.  However, the absence of any observed effect of EPA on tumour PGE2 levels, 
and the observation that PGE-M did not fall following resection of the tumour would 
suggest that the urinary PGE-M was coming from systemic sources, for example 
endothelial cells.(386)  One possible explanation could be that the systemic 
inflammatory response to surgery and liver regeneration contributed to elevated 
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systemic PGE2 synthesis, and therefore elevated PGE-M levels, at the six week 
follow up.   Future studies would need to monitor serial PGE-M levels in the 
immediate post-operative period and over a longer period of follow-up to investigate 
this.  Given the strength of the preclinical data that EPA reduces tumoural PGE2 
levels, the relatively small changes in PGE-M seen in this study, and the limitations 
to the study which might explain why there was no change in tumoural PGE2, these 
PGE-M results should not be taken as evidence that EPA does not inhibit tumoural 
PGE2, only that there was absence of an effect of EPA on tumoural PGE2 in this 
trial.  The finding that EPA therapy was associated with small but statistically 
significant reversible reductions in both PGE-M and NFκB activation in PBMCs is 
evidence for a systemic anti-inflammatory effect of EPA, even if in this study it 
cannot be attributable to a direct anti-tumoural effect.  Nevertheless, PGE-M may 
still have a role as a biomarker for CRC activity and justifies further investigation, 
either for the detection of CRC, for assessing and monitoring the response to 
treatment, or for the prognostication of outcome.  
 
7.6 Angiogenesis 
Previously published studies support the hypothesis that ω-3 PUFAs have anti-
angiogenic activity,(387, 388) although the evidence is much more limited than that 
for its effects on the COX-PGE2 pathway and on tumour proliferation.  The 
mechanisms by which ω-3 PUFAs might inhibit angiogenesis are multi-factorial and 
remain unclear.  Pro-angiogenic VEGF induces endothelial cell proliferation, 
migration and invasion, and increases vascular permeability.(19, 389)  Production 
of VEGF is stimulated by inflammatory mediators including PGE2.(390)  Its effects 
are mediated by stimulating a variety of pathways including the MAPK, ERK, JNK 
and PIK3/Akt pathways.(389)  VEGF and VEGFR-2 expression have been shown 
to correlate with CRC tumour vascularity, proliferation and metastasis.(391)   
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Omega-3 PUFAs have been shown to reduce endothelial cell expression of 
VEGFR-2 (195, 196, 356) and inhibit VEGF-induced activation of MAPK.(195)   In 
another study, conjugated EPA, but not EPA, reduced VEGF-stimulated MMP-9 
and MMP-2 mRNA expression and protein secretion at the same concentrations 
that inhibited HUVEC wound migration and tubule formation.(194)  In a further 
study, ω-3 PUFAs suppressed VEGF- and bFGF-mediated expression of 
angiopoietin-2 and secretion of MMP-9, whereas ω-6 PUFAs increased 
angiopoietin-2 expression and MMP-9 secretion.  These effects were COX-
mediated, demonstrated by the abbrogation of these effects in the presence of the 
COX-inhibitor indomethacin and the finding that PGE2, but not PGE3, increased 
angiopoietin-2 expression.  EPA and DHA have both been shown in vitro in HT-29 
CRC cells to reduce VEGF and COX-2 expression, reduce PGE2 levels and inhibit 
the ERK and HIF pathways which are associated with the induction of VEGF 
expression by PGE2.(186)  Similarly, when HT-29 cells were transplanted in nude 
mice EPA and DHA supplementation was associated with a reduction in VEGF and 
COX-2 expression in tumours, a reduction in tumoural PGE2 levels and a reduction 
in tumour vascularity.(186)  These studies support a role of the COX pathway as a 
mechanism for the inhibition of VEGF expression and angiogenesis by EPA.  
The EMT Trial demonstrated a trend towards reduced tumour vascularity with EPA 
supplementation.  Perhaps one would not expect any anti-angiogenic effect of EPA 
to manifest as a reduction in tumour vascularity after only 4 weeks of 
supplementation.  The effect of EPA would most likely be on new vessel formation 
rather than causing disruption of existing vessels.  A longer period of 
supplementation with more prolonged inhibition of new vessel formation might 
reveal a more pronounced effect on tumour vascularity.   
Immunohistochemistry for MVD was performed using the well-established 
endothelial cell marker CD31.  This protein is present on both large and small blood 
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vessels in both tumour tissue and normal tissue and is considered to be a pan-
endothelial cell marker.(392, 393)  CD105, by contrast, is thought to be a 
proliferation-associated protein expressed specifically by newly formed 
(neoangiogenic) blood vessels.(394, 395)  CD105 has therefore been proposed as 
a better marker than CD31 for the evaluation of angiogenesis.(394, 395)  Both 
CD31 and CD105 have been shown to be prognostic for metastatic risk and poor 
outcome in colorectal (396-398) and other types of cancers.(399-402)  Despite the 
recent interest in CD105 as a better marker of neoangiogenesis, the specificity of 
CD105 for tumour blood vessels is not universally accepted and may be dependent 
on the type of tissue being studied.(395, 403)  For example, high levels of CD105 
staining of mature blood vessels has been seen in normal lung and brain tissue but 
not in normal breast tissue or gastric mucosa,(403) and high levels of CD105 
staining of non-endothelial cells has been seen in normal liver and kidney tissue 
(35-70% non-specific expression) but not in normal lung, breast or colonic 
tissue.(395)  Similar findings were observed when a batch of 20 tumours sections 
from The EMT Trial were stained for CD105 as a pilot to assess the quality of 
CD105 staining, using colon cancer tissue microarrays (TMA) which had shown 
good CD105 staining in an unrelated study as a positive control.  The specificity of 
CD105 staining for endothelial cells was poor in the CRCLMs, with a high level of 
non-specific background staining compared to either the comparative CD31 
staining of CRCLMs or the CD105 staining of the colon TMAs (data not shown).  
CD105 was therefore not explored further as a marker of MVD in The EMT Trial. 
These seemingly tissue-specific findings, together with variability in the particular 
antibody and staining methodologies used in different studies might explain the 
inconsistency in findings between studies and explain why no single endothelial cell 
marker has established itself as the marker of choice.  
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The trend to reduced tumour vascularity in The EMT Trial after only a short period 
of EPA supplementation is encouraging for an anti-angiogenic effect of EPA and is 
supported by the in vitro data from the HUVEC studies which demonstrated that 
both acute and chronic EPA supplementation inhibited endothelial cell proliferation, 
and also inhibited, less consistently, endothelial cell migration and tubule formation.  
The anti-angiogenic effects of EPA should be investigated further.  Pre-clinical 
studies might focus on further elucidating the differences between acute and 
chronic EPA supplementation and the mechanistic basis underpinning these 
differences.  Clinical studies of tumour vascularity should investigate the effects on 
MVD of longer periods of EPA supplementation, and should consider carefully the 
choice of endothelial cell marker, perhaps using a combination of markers such as 
CD31 and CD105 to differentiate between mature and neo-angiogenic vessels. 
   
7.7 Tumour microenvironment 
The communication between tumour microenvironment and the growth and 
metastasis of cancer cells is well recognised even if not fully understood.  
Inflammation at the site of a tumour is recognised as an important component of the 
tumour microenvironment, and causes a wide variety of cells to accumulate locally 
and infiltrate the tumour.(404) This has been particularly studied in relation to the 
importance of the COX pathway and pro-inflammatory prostaglandins to the 
initiation and promotion of CRC.(405)  An in-depth discussion of the tumour 
microenvironment in CRC carcinogenesis can be found in the review by 
Peddareddigari et al.(383)  Cells that accumulate and infiltrate CRCs include 
tumour associated macrophages (TAMs), mesenchymal stem cells, myeloid-
derived suppressor cells, mast cells, neutrophils and platelets, amongst 
others.(383)  Of these, TAMs are one of the most important components of the 
tumour, secreting a range of chemokines and growth factors which are involved in 
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inflammation, angiogenesis, epithelial-mesenchymal transition and 
immunosuppression.(383, 406, 407) 
There is limited evidence for the effects of ω-3 PUFAs on the tumour 
microenvironment.  In The EMT Trial, a PBMC model of TAMs showed that EPA 
supplementation was associated with inhibition of the transcription factor NFκB.   
NFκB activation is associated with pro-proliferative, anti-apoptotic and pro-
metastatic pathways and its inhibition has been suggested as a potential 
therapeutic target.(176, 408)  Although changes in NFκB activity in PBMCs cannot 
be taken as direct evidence for an effect of EPA on NFκB activity within CRCLM 
tissue, it is feasible that changes in PBMCs reflect changes in TAMs making the 
PBMC model a biologically plausible surrogate marker of changes within the tumour 
microenvironment.  An alternative approach would have been to attempt to 
measure NFκB activation in CRCLM tissue.  This would have required additional 
CRCLM tissue (which for many patients with small tumours would have been 
scarce), would have been subject to the heterogeneity of the tumour, and would 
have only permitted measurement of NFκB activation post-treatment.  The PBMC 
model, by contrast, permitted a more controlled ex vivo analysis of NFκB activation 
and allowed comparison of NFκB activation pre- and post-treatment.  Further 
studies are required to determine whether inhibition of NFκB signalling by EPA 
contributes to a direct anti-CRC cell activity, whether it exerts an indirect anti-CRC 
effect mediated by the tumour microenvironment, PBMCs or other circulating cells 
e.g. platelets, or whether its effects are more broadly due to a reduction in systemic 
inflammation.  The effect of EPA on tumour microenvironment and circulating cells 
is very much understudied.  Future work might investigate the effect of EPA on the 
number and localisation of macrophages within tumours, the effects of EPA on 
other cells within the tumour microenvironment, and the effect of EPA on signalling 
between circulating platelets and tumour cells which was recently described and 
shown to promote metastasis.(27) 
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7.8 Future clinical work 
Now that two years have passed since the last patients recruited into The EMT Trial 
underwent liver resection, it would be an appropriate time to collect data for a 
comparison of disease-free survival and overall survival between the two groups.  
Whilst this was not explicitly stated as an endpoint in the trial, because the trial 
would have been underpowered for this as an endpoint, it was always planned to 
perform this analysis because the data would be readily available from the Leeds 
Hepatobiliary Unit’s internal prospectively maintained database.  The intention to 
perform such an analysis after 2 years of follow-up was included in the original 
application to Cancer Research UK for approval of The EMT Trial by the Clinical 
Trials Awards and Advisory Committee (CTAAC).   
In the Rothwell meta-analyses of patients who participated in studies of the effect of 
aspirin on cardiovascular disease, there was a significant reduction in 20-year CRC 
incidence (138) and a reduction in all-cancer death after 10 years follow-up.(139)  
The protective effect of aspirin was not evident for 10 years because of the lag time 
between carcinogenesis and the development of clinically evident CRC.  If EPA 
supplementation was associated with a similar separation or time-lag of the Kaplan-
Meier curves for DFS or OS in The EMT Trial, this may indicate a biological effect 
of EPA which was not detectable by the short timeframe IHC and mechanistic 
endpoints measured in the trial.    
Rothwell et al. were able to make use of large multi-centre trials of the effects of 
prolonged aspirin therapy on cardiovascular disease to look at CRC incidence in 
these patients many years after they completed participation in their respective 
trials.(138, 139)  In the same way, it might be possible to perform a similar analysis 
of the chemopreventative effects of ω-3 PUFA supplementation using patients who 
participated in large trials of ω-3 PUFAs in cardiovascular disease such as the 
Italian GISSI trial.  This would be dependent on there being accurate national 
cancer registries in the countries that took part in the original trials.  The 
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coordination of ethical approval for this work may also prove an obstacle.  However, 
given the convincing chemoprevention and cancer-mortality benefits that were 
shown in the Rothwell studies, (138, 139) a similar study for ω-3 PUFAs is worthy 
of investigation, especially given the more favourable long-term side effect profile of 
EPA than aspirin. 
Having demonstrated in The EMT Trial that EPA is safe and well tolerated in 
patients with CRCLM, and confirmed for the first time in CRC/CRCLM at least some 
of the anti-neoplastic effects that have been seen in pre-clinical and mucosal 
biomarker studies, the question that remains is what context would EPA find most 
utility in the treatment of CRC and CRCLM.  Potential uses of EPA include primary 
prevention of CRC or secondary prevention of CRCLM, neoadjuvant/adjuvant 
treatment of patients with established CRC and CRCLM who are undergoing 
surgery with curative intent, and management of incurable disease.  The 
encouraging findings from The EMT Trial support progression to a large, multi-
centre Phase III evaluation of EPA in patients with CRC or CRCLM.  Since the 
duration of supplementation in The EMT Trial was perhaps too short to demonstrate 
some of the potential anti-CRC activity of EPA, Phase III evaluation should involve 
supplementation over a longer period of time, of at least 6 months.  This could be a 
study of EPA supplementation following CRC resection, with outcomes of DFS and 
OS at 5 years.  Alternatively, a similar study of EPA supplementation after CRCLM 
resection would perhaps require a shorter period of follow-up of between 2-5yr for 
DFS and OS endpoints since most CRCLM recurs within the first two years.  There 
is also evidence to support a role for the use of ω-3 PUFAs in combination with 
established chemotherapeutic agents or with radiotherapy, and evaluation of this is 
already underway in other cancers including breast and pancreatic cancer.  
Omega-3 PUFAs also have a potential role as immunonutrition to improve cancer-
related cachexia and to improve outcomes following cancer surgery.  There is 
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therefore also scope to evaluate the use of EPA in combination with current 
neoadjuvant and adjuvant chemotherapy regimens for CRC and CRCLM.  Such 
studies could include chemotherapy side effects and quality of life as outcomes in 
addition to DFS and OS endpoints.       
 
 7.9 Conclusions 
The EMT Trial is the first RCT of an oral ω-3 PUFA in patients with CRCLM.  EPA 
was safe and well tolerated in this population of patients, confirming the excellent 
safety and tolerability profile of ω-3 PUFAs which makes them an attractive 
candidate for the treatment and/or prevention of CRC and CRCLM.  Previous 
concerns that ω-3 PUFAs may predispose patients to bleeding were dispelled, with 
no difference in platelet aggregation or in clinical endpoints of bleeding, transfusion 
rate or post-operative complications following liver resection. 
The EMT Trial demonstrated that EPA supplementation was associated with an 
increase in tumour EPA content, and although there was not a reduction in 
tumoural AA or PGE2 levels, it is conceivable that the period of supplementation 
was too short for this to have been observed.  Similarly, although there was no 
reduction in tumour proliferation index or an increase in apoptosis index, the pre-
clinical evidence for this is strong, and is further supported by the recent 
demonstration of chemopreventative efficacy of EPA in a Phase III trial in patients 
with FAP.  Perhaps with a longer period of supplementation these effects may have 
been observed.  There was a trend to a reduction in tumour vascularity,  supported 
by supplementary in vitro angiogenesis experiments, which taken together provide 
encouragement that EPA might indeed reduce tumour angiogenesis.  EPA 
supplementation was associated with a reduction in urinary PGE-M.  Whether this 
simply represents a reduction in systemic inflammation or is representative of 
changes within the tumour cannot be determined based on the results from this 
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Phase II trial, but it does demonstrate a positive systemic effect of EPA 
supplementation and raises the possibility of urinary PGE-M as a non-invasive 
biomarker of disease progression or response to treatment.  Finally, EPA was 
shown to inhibit PBMC NFκB activation, providing further evidence of a systemic 
anti-inflammatory effect of EPA, and raising the possibility of an effect of EPA on 
the tumour microenvironment.   
Although no firm conclusions about the anti-CRC activity of EPA can be drawn from 
this study, the results from such a short period of supplementation are encouraging 
for there being a beneficial effect of EPA supplementation, and support further 
evaluation of EPA for the treatment and/or prevention of CRC and CRCLM.  The 
mechanistic analyses from this trial also support the need for more pre-clinical 
studies to further elucidate the effects of EPA on tumour growth, angiogenesis, and 
on the tumour microenvironment.  When available, it will be interesting to see the 
DFS and OS analysis from this trial, and this data may help to guide the design of 
any subsequent Phase III trial.   
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AA arachidonic acid 
ACF abberant crypt foci 
ADP adenosine diphosphate 
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OR odds ratio 
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PG prostaglandin 
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PI proliferation index 
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Rv resolvin 
RvE1 resolvin E1 
265 
 
 
SAE serious adverse event 
SEM standard error of the mean 
SPE solid phase extraction 
SUSAR suspected unexpected serious adverse reaction 
TAM tumour associated macrophage 
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VEGF vascular endothelial growth factor 
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Appendix A 
 
Pages from the EPIC Food Frequency Questionnaire that concern dietary fat intake 
were selected for use in The EMT Trial and are shown here. 
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